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 Su Yon Jung, PhD 
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Patients with breast cancer metastases have very poor survival. Delays in the initiation of 
breast cancer treatment may adversely affect survival. Comorbid illness is more common 
in older women. Comorbid illness may explain effects of age on metastatic breast cancer 
survival outcomes. Comorbid illness may affect treatment delay. 
The purpose of the present study was to 1) identify factors related to survival 
following metastatic breast cancer diagnosis, 2) assess the impact of delay in treatment on 
survival while controlling for immortal time bias, and 3) evaluate the role of comorbidity 
as a mediator of survival disparity between younger (≤ 51 years) and older (> 51 years) 
patients. 
A total of 557 patients with the initial breast cancer metastasis diagnosis have 
been followed up between January 1, 1999 and June 30, 2008. Prognostic factors and 
outcomes of these patients were analyzed using log-rank test and Cox regression model, 
demonstrating that hypertension, ER/PR, HER2 status, number of metastatic sites, and 
BMI at metastatic breast cancer diagnosis were the most relevant prognostic factors for 
survival. Backward stepwise selection of covariates was conducted among 553 patients 
and showed that treatment delays of > 12 weeks had a marginal impact on poor survival 
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(HR 1.76, 95% CI 0.99-3.13). Moreover, the interval of 12-24 weeks, compared to the 
interval of 4-12 week was a prognostic factor for survival from first treatment (HR 2.39, 
95% CI 1.19-4.77). To assess comorbidity variable as a mediator of age-survival 
relationship among 553 patients, we applied two approaches: 1) Baron Kenny approach, 
and 2) alternative assessment to compute the percentage change in the HRs. Hypertension 
was related to survival (HR 1.45, 95% CI 1.12-1.89) and hypertension augmented 
Charlson comorbidity score (hCCS) explained survival disparity between young and old 
patients by 44% compared to 40 % of hypertension and 14% of the Charlson comorbidity 
score (CCS).  
Looking for opportunities to improve public health, the present study identifies 
modifiable factors associated with variable outcomes after diagnosis of metastatic breast 
cancer. 
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1.0  INTRODUCTION 
Breast cancer is the most commonly diagnosed solid tumor among women in the US and 
in most other industrialized countries, and the second leading cause of death for women 
with cancer.1 Distant metastatic breast cancer is the most advanced stage of breast cancer 
and occurs in less than 10% of breast cancer patients, estimated 90,000 new cases per 
year, and has different prognosis.2-5 The 5-year relative survival for women diagnosed 
with meatstatic breast cancer between 1999 and 2006 was 23%.6 
Despite the improved treatment approaches for the metastatic breast cancer, 
survival time for patients with metastasis varies greatly, ranged from less than 9 months 
to over 3 years of median survival duration.7 Patients diagnosed with metastatic breast 
cancer can be considered a heterogeneous population whose clinical outcomes vary 
depending on a variety of host factors.8 Several prognostic factors influencing survival 
outcomes were reported by the recent consensus paper on medical treatment of metastatic 
breast cancer. These factors include pathological factors such as hormone receptor 
(estrogen receptor (ER) and/or progesterone receptor (PR)) status, human epidermal 
growth factor receptor-2 (HER2/neu) status, and the location and extent of metastases 
(visceral versus non-visceral).9 Other investigators have demonstrated adverse survival 
outcome after diagnosis with metastatic breast cancer in relation to demographic factors 
including being of older age, black race, low socio-economic status (SES), and higher 
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body mass index (BMI).10-23 Other factors which have been associated with worse 
survival include clinical factors such as hypertension and co-morbid illness.24-30 
Finally, treatment-related factor such as delayed treatment interval has been 
increasingly focused for evaluating its association with survival following metastatic 
breast cancer diagnosis. In previous studies, treatment delay has been defined as the time 
between the date of diagnosis of metastatic breast cancer and the date of the initiation of 
the first course of treatment. Several studies have shown that one to three month delay in 
the start of treatment had a reduced likelihood of survival31-33, while others did not 
support the hypothesis that treatment delay may adversely affect survival.34-42  
These inconsistent results may be attributed to differences in the selection of 
study populations, difference in measurement of survival lengths, and availability of 
covariates.43 Although multiple studies examining prognostic factors individually may be 
helpful in predicting survival among patients with metastatic breast cancer, more 
comprehensive information concerning prognosis is needed. 
Incidence and mortality rates for breast cancer increase with advancing age, and 
this increase has occurred predominantly in women over 50 years, who are considered 
menopausal.8, 12, 44-50 The higher prevalence of comorbidity could explain the poor 
survival outcomes among older patients47, 48, 51-54, but the role of comorbidity as a 
mediator which may explain the survival difference between younger and older patients 
has not been clearly documented. 
Furthermore, hypertension is the most prevalent comorbidity among older breast 
cancer patients, and it affects mortality from breast cancer.28, 47, 50, 53, 55, 56 Hypertension 
can potentially be an important risk factor for cancer mortality. For example, cell death 
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by apoptosis can influence the growth of vascular smooth muscle cells (VSMCs) and the 
increased proliferation of VSMCs responds exaggeratedly to growth stimuli, which is 
characterized by shortening of the cell cycle. This mechanism may lead to increased 
cellular proliferation.57 Charlson comorbidity index (CCI), which has been widely 
employed and considered to be a valid and reliable method of assessing comorbidity for 
cancer research58, did not include certain comorbidities such as hypertension that did not 
contribute to a high relative risk in their study population.48, 59 
This study aimed to 1) identify factors related to survival after diagnosis of 
metastatic breast cancer, 2) evaluate the effect of delays in the initiation of treatment on 
survival among metastatic breast cancer patients, and 3) assess the role of comorbidity, 
including hypertension, as a mediator of explaining the difference in survival following 
metastasis between younger and older patients. 
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2.0  SPECIFIC AIMS AND HYPOTHESES 
In this study, the following specific aims and hypotheses are addressed to identify 
predictor variables influencing survival following diagnosis of metastatic breast cancer. 
1) Specific aim 1: To assess factors associated with mortality after breast cancer 
metastasis. 
a. Aim 1.1: To examine the relationship between demographic or 
socioeconomic factors and survival following metastatic breast cancer 
diagnosis. We hypothesize that older age, black race, less than or equal to 
high school education, low income level, higher BMI, and post 
menopausal status are associated with  poorer survival in women with 
metastatic breast cancer. 
b. Aim 1.2: To investigate the association of pathological factors with 
survival. We hypothesize that being ER or PR negative, HER2 negative, 
increasing number of metastatic organs, and brain, bone, and liver 
metastasis are related to adverse survival outcomes. 
c. Aim 1.3: To explore whether clinical factors are related to survival. We 
hypothesize that hypertension, Charlson comorbidity conditions, and 
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Charlson comorbidity score negatively impact survival among women 
metastatic breast cancer. 
2) Specific aim 2: To evaluate the effect of delays in treatment for breast cancer 
metastasis on survival. We hypothesized that delayed treatment is associated 
with decreased survival among women with metastatic breast cancer.  
3) Specific aim 3: To examine comorbidity as a potential mediator of survival 
disparity between younger and older women diagnosed with metastatic 
breast cancer.  
a. Aim 3.1: To assess the relationship between age and survival among 
women with metastatic breast cancer. We hypothesize that older women 
have poorer survival following metastatic breast caner diagnosis than 
younger women. 
b. Aim 3.2: To evaluate the association between age and comorbidity among 
women diagnosed with metastatic breast cancer. We hypothesize that 
higher prevalence of comorbidity is found in older women than younger 
women. 
c. Aim 3.3: To examine whether comorbidity influences survival after 
metastatic breast cancer diagnosis. We hypothesize that comorbidity has 
adverse impact on survival following metastatic breast cancer diagnosis. 
d. Aim 3.4: To measure the extent to which comorbidity mediates the 
association between age and survival after metastatic breast cancer 
diagnosis. We hypothesize that control for comorbidity attenuates the 
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association between age and poor survival following metastatic breast 
cancer diagnosis. 
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3.0  LITERATURE REVIEW 
3.1 EPIDEMIOLOGY OF BREAST CANCER 
Breast cancer is the most commonly diagnosed tumor among women in the US and in 
most other industrialized countries, and the second leading cause of death for women 
with cancer. 1 Incidence of breast cancer from 2000 to 2004 in the US was 125.3 per 
100,000 and after a 6% decrease from 2002 and 2003, the incidence rates from 2003 to 
2006 remains unchanged.1, 60 The new cases of invasive breast cancer were found in the 
estimated 209,060 cases in 2010.60 Breast cancer mortality rate was 25.5/100,000 
between 2002 and 2004, and 40,230 deaths occurred in 2010 in the US.60 
Distant metastatic breast cancer is the most advanced stage of the disease, which 
carries poor diagnosis (Table 1). Metastatic breast cancer occurs in less than 10% of 
breast cancer patients, estimated 90,000 new cases per year, and has different prognosis 
based on extent of metastases. 2-5 Although great improvements have been made in the 
adjuvant treatment of early breast cancer, 20% of patients initially diagnosed with node-
negative early stage breast cancer (N0), and at least 50-60% of patients with positive 
nodes at diagnosis develop metastatic breast cancer. 61-64  
The medical treatment of metastatic breast cancer offers a wide range of options 
including chemotherapy, hormonal therapy, therapy with antibodies against growth 
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factors relevant to the disease, vaccine therapy, immunologic therapy, and other 
supportive measures.9 Even though patients with metastatic breast cancer are treated 
uniformly with standard therapy, the treatment of metastatic breast cancer remains 
palliative. The survival for patients diagnosed with metastasis may range from a few 
months to several years.7 Patients with metastatic breast cancer represent a heterogeneous 
group whose prognosis and clinical course may depend on a wide variety of host factors.8 
Improved evaluation of the profile of prognostic factors can not be overemphasized in 
women with metastatic breast cancer. 
 
Table 1. Stage distribution and 5-year relative survival by stage at diagnosis for 1999-2006, 
all races, females (National Cancer Institute Surveillance, Epidemiology, and End Results 
Programs (SEER) 
Stage Distribution and 5-year Relative Survival by Stage at Diagnosis for  
1999-2006, All Races, Females  
Stage at Diagnosis Stage  Distribution (%)
5-year  
Relative Survival (%) 
Localized (confined to primary site) 60 98.0 
Regional (spread to regional lymph nodes) 33 83.6 
Distant (cancer has metastasized) 5 23.4 
 
A recent consensus paper on medical treatment of metastatic breast cancer reported a 
number of prognostic factors influencing survival (Table 2). These factors included 
hormone receptor status such as estrogen receptor (ER) and/or progesterone receptor 
(PR), human epidermal growth factor receptor-2 (HER2/neu) status, the location and 
extent of metastases (visceral versus non-visceral), performance status, disease-free 
interval, prior adjuvant therapy, and prior therapy for metastatic breast cancer.9 
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Table 2. Prognostic factors in patients with metastatic breast cancer 
Prognostic factor Favorable Unfavorable 
Performance status Good Poor 
Sites of disease Bone, soft tissue Viscera, CNS 
No. of sites of disease Few Multiple 
Hormone receptor status Positive Negative 
Her-2/neu status Negative Positive (significance less clear in Her-2/neu inhibitors era) 
Disease-free interval > 2 years < 2 years 
Prior adjuvant therapy No Yes 
Prior therapy for MBC No Yes 
CNS, central nervous system; MBC, metastatic breast cancer. 
 
3.2 PROGNOSTIC FACTORS FOR BREAST CANCER SURVIVAL 
3.2.1 Demographic or socio-economic factors 
3.2.1.1  Age 
Breast cancer incidence rates increases with advancing age, and breast cancer is a disease 
primarily seen in older women (Table 3).65 The age-incidence rate changes around the 
menopausal period, most likely due to hormonal change ten years earlier, levels off at the 
40-50 years of age (Clemmesen’s hook), and then increases again to a peak at 75 years, 
and declines.44, 65 Incidence rate for female breast cancer rises over time, and this increase 
has been occurred predominantly in women over the age of 50.44, 65 
Older age has negative impact on survival after breast cancer diagnosis.10-12 
Specifically, Cluze et al. reported that excess mortality rate increased with age in stage IV 
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breast cancer.12 It is generally accepted that young age at diagnosis is associated with 
more aggressive breast cancer and relatively poor survival 66, but several studies showed 
that pre menopausal patients had better survival than post menopausal patients.8, 67 Data 
from the Surveillance, Epidemiology, and End Results Program (SEER) showed that 
breast cancer mortality declined significantly from 7.0/100,000 in 1973 to 6.2/100,000 in 
1988 in women younger than 50 years. On the contrary, mortality rate in older women 
increased from 88.4/100,000 in 1973 to 93.0/100,000 in 1988, an increase of 5.2%.44 
Largiller et al. reported that women over the age of 50 had significantly lower survival 
rates, indicating that post menopausal patients have higher risk of mortality than pre 
menopausal patients.8 Postmenopausal patients have been found to have lower response 
rate to chemotherapy. The increase in side-effects of chemotherapy inducing dose 
reduction, and loss of efficiency in older women, as well as more comordid conditions 
may explain this result.7, 8  
 
Table 3. Percent of U.S. women who develop breast cancer over 10-, 20-, and 30-year intervals 
according to their current age, 2005-2007 
Percent of U.S. Women Who Develop Breast Cancer over 10-, 20-, and 30-Year 
Intervals According to Their Current Age, 2005–2007†  
Current Age 10 Years 20 Years 30 Years 
30 0.43 1.86 4.13 
40 1.45 3.75 6.87 
50 2.38 5.60 8.66 
60 3.45 6.71 8.65 
†Source: Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron 
W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, 
Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK (eds). SEER Cancer 
Statistics Review, 1975–2007,  National Cancer Institute. Bethesda, MD, based 
on November 2009 SEER data submission, posted to the SEER Web site, 2010. 
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3.2.1.2  Ethnicity 
Increasing evidence suggests that breast cancer in black women demonstrates unique 
clinical behavior compared to white women. Nationally, black women have an overall 
lower incidence of breast cancer than do white women, but black women are more likely 
to die of invasive breast cancer (34.5 vs. 25.4 death per 100,000 women).68 Despite 
modest overall improvements in breast cancer survival rates over the last two decades, 
the rates for black women have not improved, and the gap in life expectancy between 
white and black women diagnosed with breast cancer continues to widen. From 1975 to 
2002, Surveillance, Epidemiology, & End Result (SEER) data indicate that white women 
had a 29% increase in breast cancer incidence and a 22% decrease in morality while 
black women experienced an identical 29% increase in breast cancer incidence and, 16% 
increase in mortality during the same time period (Figure 1).69 
 
 
Figure 1. Breast cancer mortality by race (based on SEER data) 
 
The 5-year survival for women diagnosed with meatstatic breast cancer between 
1996 and 2002 was 28% for whites and only 16% for blacks. Of particular concern is that 
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this survival disparity is growing compared with the 1975 to 1979 period, when the 5-
year cancer-specific survival was 18% for whites and 15% for blacks.70 Understanding 
this stage-specific survival disparity is challenging and has been rarely explored in 
previous studies. 
3.2.1.3  Obesity 
Previous studies have reported that overweight or obesity, estimated by body mass index 
(BMI) is associated with increased risk of breast cancer morbidity and adverse survival 
outcomes in pre and postmenopausal women with breast cancer.22, 23 Several mechanisms 
could explain these observations: high concentrations of estrogen, estradiol, and 
testosterone in overweight and obese women with breast cancer; lower level of sex 
hormone-binding globulin, resulting in higher levels of free estradiol and free 
testosterone. Estrogen-sensitive tissue in overweight and obese women may be subject to 
higher estrogen stimulation, inducing more rapid growth of malignant cells.19 
 Weight gain post-diagnosis of breast cancer is common and is likely due to 
increases in fat-free mass. However, weight gain in the immediate period after breast 
cancer diagnosis has not adverse impact on prognosis, indicating that overweight or 
obesity over the lifespan has greater magnitude of impact on survival since breast cancer 
diagnosis.20 
On the other hand, the weight loss of over 10% after breast cancer diagnosis 
increased the risk of breast cancer mortality compared to being weight stable 11, 71, and 
this risk was more pronounced among women who were obese (BMI ≥ 30kg/m2) before 
diagnosis.20 
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3.2.1.4  Socio-economic status (SES) 
Women with low SES tend to have lower risk of developing breast cancer, but at higher 
risk of mortality. Differences in reproductive behavior may account for the social 
difference in breast cancer incidence; women of higher SES, in general, have lower 
parity, older age of first birth, greater frequency of childlessness, a shorter duration of 
breast-feeding, and a later age at menopause, which are all known to increase risk of 
breast cancer.15 The etiology of social differences in breast cancer mortality is less 
known, and previous studies did not achieve a consensus on the relationship between the 
SES and breast cancer survival, which may be explained by differences in measurement 
of SES factors. For example, Dalton et al showed that decreasing disposable income with 
less education were reported to be a risk factor for being diagnosed with a high-risk 
breast cancer 16, and family income was only related to survival among SES factors in 
study conducted by Rezaianzadeh et al.17 Low SES based on women’s occupation was 
shown to be a strong prognostic factor 18, but the study to evaluate the effect of the SES 
including occupation as well as education on survival in breast cancer patients found no 
significant association.72  
3.2.2 Pathological factors 
3.2.2.1  HER2 status and ER or PR status 
Previous studies have pointed out differences in survival outcomes among patients with 
breast cancer associated with tumor-related factors such as hormone-receptor status and 
tumor histology. Basal like tumors (“triple negative”) which exhibit low expression of 
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human epidermal growth factor receptor-2 (HER 2) and estrogen (ER), show less 
favorable patient outcomes than ER positive tumors. 73, 74  
Additionally, several studies reported that ER or PR-negative status is related to 
poor response to treatment or worse survival outcomes following metastatic breast cancer 
diagnosis.7, 8, 64, 75-81 Highest mortality rate in ER-positive tumors occurred later than in 
ER-negative tumors. Grasic et al. reported that the difference of breast cancer mortality 
between ER-negative and ER-positive occurred from 5 year on, and the hazard in ER-
positive was higher than ER-negative.82 Adjuvant hormonal treatment with tamoxifen 
diminishes the risk for death in ER-positive tumors, and the relative gain of mortality in 
tamoxifen treated compared to non-treated group increased at 5 years.83 
3.2.2.2  Metastatic location and number of metastatic organ sites 
Prognosis varies according to patterns of metastasis.2 Breast cancer typically spreads 
hematogenously, producing lung and bone metastasis. Bone is the most frequent site of 
metastasis with the occurrence in 40-55% of metastatic patients in previous studies.8, 76 
Women with a single metastasis to cortical bone may live for many years, whereas 
women with metastasis to vital organs (e.g., lungs, liver, bone marrow, brain, heart) face 
a poorer prognosis.61 
Metastatic breast cancer has worse survival outcomes compared to typical breast 
cancer carcinoma, which may be attributed to increasing number of organ sites affected 
by metastasis. Previous work validated that increasing number of metastatic organ sites at 
diagnosis was a major prognostic factor for survival.10, 11, 64, 79, 84 
Considering those issues, the inclusion of metastatic location and number of 
metastatic organ sties at diagnosis as covariates in the study analysis is necessary to 
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evaluate prognostic factors related to survival after diagnosis of metastasis, limiting the 
possible confounding effect on study result. 
3.2.3 Clinical factors 
3.2.3.1  Treatment delay 
Treatment-related factor such as delays in receiving treatment after diagnosis of breast 
cancer has been increasingly investigated as a reason for the poor survival in women 
diagnosed with breast cancer. Treatment delay has been measured as the time from the 
date of diagnosis of breast cancer to the date of the initiation of the first treatment. It is 
generally assumed that the greater the delay in receiving treatment for breast cancer the 
worse the prognosis outcomes.  
Previous studies demonstrated that one to three month delay in the start of the 
treatment has a reduced likelihood of survival. 31-33 Rechards et al conducted a meta 
analysis for evaluating the association of delayed treatment interval with survival 
outcomes, and concluded that patients with a delay of three to six months from the 
symptom recognition to the start of treatment had lower survival rate than patients with a 
delay of less than three months, and that a delay of more than six months was related to 
poorer survival than was a delay of less than six months.85  
However, there is disagreement regarding whether survival after diagnosis of 
breast cancer is related to the lengths of the delay in the initiation of treatment (Table 4). 
Several studies observed that the longer delays was related to lower survival 31, 43, 86-91; 
other studies did not support the hypothesis that delays in treatment after breast cancer 
diagnosis may adversely influence survival.34-42 These conflicting results may be 
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explained by differences in the selection of patients, by difference in the cut-offs used to 
categorize delay interval, by difference in measurement of survival lengths and by 
availability of clinical, socio-economical and biological covariates.43 
 In addition, factors influencing delays in receiving treatment include age, 
ethnicity, socio-economic status including education, income level, and psychosocial 
factors such as anxiety, misconceptions about cancer, and cultural differences.34, 35, 41-43, 89, 
92, 93 Delay period was shorter among older compared to younger women diagnosed with 
breast cancer, assuming that the diagnostic work-up is more difficult in younger women 
due to a higher frequency of dense and lumpy breast tissues in this age-group.89 Further 
studies regarding factors influencing delays in initiation of treatment are needed. 
 
Table 4. Summary of previous work for the effect of treatment delay on survival 
Previous Study Study design and study population Delay interval 
Studies supporting hypothesis 
Gorin et al (2007) Retrospective, Medicare enrollees ≤ 3 months vs. > 3 months 
Gorin et al (2006) Retrospective, Medicare enrollees ≤ 1 month vs. > 1 month 
Kievit et al (2002) Literature review Per month 
Richards et al (1999) Retrospective, the breast unit at Guy’s hospital < 12 weeks vs. 12-26 weeks 
Hermann et al (1985) Prospective, Cleveland clinic ≤ 2 months vs. 2-<6 months vs. ≥ 6 months 
Sheridan et al (1971) Retrospective, St Vincent hospital tumor clinic 1-3 month vs. 3<-6 months 
Studies not supporting hypothesis 
Elmore et al (2005) Retrospective, Yale-New Haven hospital ≤ 1 month vs. > 1 month 
Hershman et al (2005) Retrospective, Henry Ford Health System tumor 
registry 
≤ 1 week vs. 1-2 weeks vs. > 2 weeks 
Machiavelli et al (1989) Retrospective, institutions of GOCS Hospital 
Privado Guemes and Hospital Privado de 
Comunidad 
< 3 months vs. 3-6 months vs. > 6 months 
Charlson et al (1985) Retrospective, Yale-New Haven hospital < 3 months vs. 3-6 months vs. > 6 months 
Dennis et al (1975) Retrospective, State University Hospital-King 
County hospital center 
< 1 month vs. 1 month vs. > 1 month 
3.2.3.2 Comorbidity 
Cmorbidity, defined as the coexistence of various chronic illnesses in addition to the 
index disease (i.e., breast cancer), is an increasing problem due to its adverse effect on 
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the prognosis in breast cancer patients.55 Breast cancer patients with comorbidity are 
likely to have a lower survival compared to patients without comorbidity, regardless of 
other prognostic factors such as age, and breast cancer stage at diagnosis.24-30, 53 
Satarioano et al reported that comorbidity is a major prognostic factor in patients 
diagnosed with breast cancer.94 
 The adverse impact of comorbidity on survival may be due to the physical burden 
of chronic illnesses and its interaction with the cancer and its treatment. Comorbidity 
conditions can increase the toxicity of specific treatments for cancer, and substantially 
reduce remaining life expectancy by canceling gains with therapy. Thus, patients with 
severe medical comorbid diseases do not receive appropriate therapy for breast cancer, 
which may lead to lower survival.95 
 Previous studies found that prevalence of comorbid conditions increased with 
age.47, 48, 56, 96 Four out of five patients aged 65 years or older have one or more comorbid 
conditions.56 The presence of comorbidity and its treatment for their control could place 
older patients at greater risk of adverse impact on certain treatment (e.g., chemotherapy, 
or surgery), resulting in detrimental prognosis after breast cancer diagnosis.56 Yancik et al 
demonstrated that women older than 75 years diagnosed with breast cancer were more 
likely to die from comorbid diseases than from other prognostic factors.97 
 Hypertension is the most prevalent comorbid disease among older breast cancer 
patients, and its presence is related to negative outcomes from breast cancer.28, 47, 50, 53, 55, 
56 Several studies suggest a link between hypertension and risk of breast caner morbidity 
and mortality. For example, cell death by apoptosis can influence the growth of vascular 
smooth muscle cells (VSMCs) and the increased proliferation of VSMCs responds 
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exaggeratedly to growth stimuli, which is characterized by shortening of the cell cycle. 
This mechanism may lead to increased cellular proliferation.57 Studies of the relationship 
between antihypertensive drugs and risk of cancer demonstrated significant association 
between antihypertensive drugs such as diuretics or calcium channel blockers and breast 
cancer risk 98 99, but biologic explanation for these association has not been elucidated. 
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4.1 ABSTRACT 
 
 
Background: It is generally accepted that patients with breast cancer metastases have 
very poor survival. Metastatic breast cancer patients can be considered a heterogeneous 
population with a varied clinical course, which underscores the need for accurate 
prediction of survival based on prognostic factors. The purpose of the present study was 
to identify factors related to survival in breast cancer patients after diagnosis with 
metastatic disease. 
Populations and Methods: A total of 557 patients with the first breast cancer metastasis 
diagnosis seen at one large urban practice have been retrospectively followed up between 
January 1, 1999 and June 30, 2008. Demographic, tumor characteristics, clinical factors, 
and outcomes of these patients were analyzed by using log-rank test and Cox regression 
model. 
Results: The median survival length was 40 months (range 1-114 months) with 269 
(48.3%) alive and 288 (51.7%) dead. This study demonstrated that a history of 
hypertension, ER/PR status, HER2 status, number of metastatic sites, and BMI at 
diagnosis with metastatic breast cancer were the most relevant prognostic factors for 
survival after metastasis. 
Conclusion: The present study findings may form a foundation for the growing corpus of 
knowledge explaining the outcome differences in treatment of patients with metastatic 
breast cancer, potentially helping to create more personalized treatment approaches for 
this vulnerable group. 
 
Key words: advanced breast cancer, prognostic factors, comorbidity 
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4.2 INTRODUCTION 
 
 
Breast cancer is the most common cancer in women in the United States and in other 
industrialized countries, and the second leading cause of death for women with cancer.100 
Despite improved techniques for breast cancer screening, as many as 7% of women 
present with metastatic disease at the time of diagnosis.101 While most women are 
diagnosed at an early stage, 20% to 80% of these patients, depending on the initial stage 
and the treatment strategy followed, will develop distant metastasis within 5 years of their 
initial diagnosis.102  
Treatment of metastatic breast cancer remains palliative despite recent advances 
in the treatment of this disease. Survival time for patients with metastasis varies greatly; 
median survival duration may range from less than 9 months to over 3 years.7 Patients 
with metastatic breast cancer represent a heterogeneous group whose prognosis and 
clinical course may depend on a wide variety of host factors.8 These observations 
emphasize the importance of defining prognostic factors in women with metastatic breast 
cancer.  
A recent consensus paper on medical treatment of metastatic breast cancer 
reported several factors influencing clinical outcomes. These factors included hormone 
receptor, human epidermal growth factor receptor-2 (HER2/neu) status, the location and 
extent of metastases (visceral versus non-visceral), performance status, disease-free 
interval, prior adjuvant therapy, and prior therapy for metastatic breast cancer.9 Other 
investigators observed poor survival after diagnosis with metastatic breast cancer in 
relation to older age, black-race, low socio-economic status (SES), and higher body mass 
index (BMI).10-23 Other important factors which have been correlated with worse survival 
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include a history of hypertension and co-morbidities.24-30 Interestingly, not every study 
identifies the same set of risk factors explaining variation in prognosis following breast 
cancer metastasis. Although multiple studies examining factors individually may be 
helpful in predicting survival among patients with metastatic breast cancer, more 
comprehensive information concerning prognosis are needed.  
This study aimed to identify factors related to survival in patients with metastatic 
breast cancer. The study used data from 557 patients with metastatic breast cancer seen at 
one large urban practice between January 1, 1999 and June 30, 2008.  
 
4.3 POPULATIONS AND METHODS 
 
4.3.1 Patients Selection 
 
The study included 557 patients with the first breast cancer metastasis seen at two urban 
hospitals (Montefiore and Magee) of the University of Pittsburgh Medical Center 
(UPMC) and by the University of Pittsburgh Cancer Institute (UPCI) Breast Cancer 
Program physicians. Patients with metastatic breast cancer were identified from daily 
hospital clinic lists and confirmed with medical records through clinical, radiological, or 
pathologic exams. Inclusion criteria included female patients aged eighteen or older with 
metastatic breast cancer diagnosed between January 1, 1999 and June 30, 2008. Of 671 
patients diagnosed with metastatic breast cancer during this period, 114 patients were 
excluded because their medical records were unavailable for the secondary review. This 
study was approved by the University of Pittsburgh Institutional Review Board. 
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4.3.2 Data Collection 
 
The medical record abstraction protocol was developed. See Figure 2. Retrospective 
review of medical records according to study protocol was utilized. Chart abstraction 
form was summarized monthly by trained registered nurse. The primary data sources for 
abstraction were hand written medical records, usually completed at the monthly patient 
visit. 
Age, race, estrogen receptor (ER) and/or progesterone receptor (PR) status, HER2 
status, number of metastatic sites and metastatic location were assessed using the chart 
abstraction form completed by primary reviewer. Quality guaranteed protocol for the 
secondary chart review was established. The weighted kappa coefficients of secondary 
chart abstraction with n = 23, and of repeated chart abstraction with n = 23 for Charlson 
comorbidity score were 0.88 (95% CI 0.64-1.00) and 0.88 (95% CI 0.66-1.00), 
respectively; secondary and repeated chart abstraction for hypertension were 0.93 (95% 
CI 0.79-1.00) and 1.00 (95% CI 1.00-1.00), respectively.  
The secondary chart retrieval procedure was performed to evaluate marital status, 
socioeconomic status (SES) including insurance, education, residential zip code, BMI at 
breast cancer diagnosis and at study entry, weight change (difference weight between at 
metastasis and weight at breast cancer diagnosis), menopausal status, and comorbidities 
according to the protocol. All independent variables were measured at the time of 
metastatic breast cancer. 
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Variables with more than 40% missing data such as marital status, insurance, BMI 
at breast cancer diagnosis and weight change were excluded for purposes of the analysis. 
Missing data imputation procedure was accomplished on education, median household 
income, BMI (at study entry), menopausal status and hypertension having missing values 
ranged 5% to 35% (hypertension 5%, menopause 11%, education 13%, BMI 20%, 
income 35%). 
 
4.3.3 Independent variables 
 
Demographic or socioeconomic variables included age, race, education, median 
household income, BMI, and menopausal status. The median household income was 
linked to residential zip code matched to U.S. 2000 census summary file 3.103 The BMI 
was calculated as a weight in kilogram (kg) divided by a height in meters squared and 
classified into four groups: less than 20kg/m2 (underweight), 20-24.9kg/m2 (normal), 25-
29.9kg/m2 (overweight), 30kg/m2 or higher (obese).  
Pathological factors that were selected for analysis included ER/PR status, HER2 
status, number of metastatic sites, and metastatic location. Determination of ER/PR and 
HER2 status used the pathologic report following the first metastatic site biopsy, if 
available, and the initial breast cancer site biopsy, otherwise. Metastatic locations were 
categorized into four groups: brain, bone, liver, and other.  Lung, adrenal gland, lymph 
node, soft tissue and other visceral sites were combined in other group due to a small 
sample size or non significant effect on survival according to univariate and multivariate 
analysis. 
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Clinical variables included a history of hypertension, Charlson comorbidity 
conditions and Charlson comorbidity score. Hypertension was defined as a blood 
pressure greater than or equal to 140 mmHg systolic pressure or greater than or equal to 
90 mmHg diastolic pressure (American Heart Association) 104, at least twice presented at 
different visits. Hypertension included controlled hypertensives. The Charlson 
comorbidity score, a composite of 19 comorbidity conditions was constructed using 18 
comorbidity conditions (without metastatic solid tumor) which were weighted by 1,2,3, 
or 6. The sum of the weighted comorbidity conditions has a theoretical range between 0 
and 31. Final Charlson comorbidity score was obtained by adding the age-comorbidity 
combined risk score.58, 105  
 
4.3.4 Outcome variable 
 
The outcome variable was an overall survival in months (defined as interval between 
metastatic breast cancer diagnosis and death or study end point). The study ascertained 
the occurrence of death in two ways. For in-hospital deaths, the hospital record was 
reviewed. For out of hospital deaths, the data were confirmed utilizing U.S. social 
security death index. Analyses censored all followed on June 30, 2008. 
 
4.3.5 Statistical analysis 
 
Simple imputation procedure for missing data used SPSS implementation of the 
Expectation Maximization (EM) algorithm of Dempster, Laird and Rubin (1977).106 The 
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frequency distribution of complete data of variables which were imputed was compared 
to the available data of corresponding variables prior to imputation using appropriate two 
sample t-tests for continuous variables and chi-squared statistics for categorical variables.  
Log rank test and Kaplan-Meier’s curve for categorical variables were conducted 
to evaluate the relationship between independent variables and outcome of interest. Cox 
proportional hazards regression model was performed for univariate and multivariate 
analysis to produce hazard ratios (HRs) and 95% confidence interval (95% CI).  
Multicollinearity was assessed by using coefficient of multiple determination (R2), 
tolerance, and variance-inflation factor (VIF) for each independent variable using 
remaining covariates as its predictors; no serious multicollinearity was identified. Two 
tailed p-value less than 0.05 was considered significant. SAS (version 9.2) and SPSS 
(version 17.0) were used. 
 
4.4 RESULTS 
 
Analysis included 557 patients with metastatic breast cancer diagnosed between January 
1, 1999 and June 30, 2008. The median survival length was 40 months (range 1-114 
months), with 269 (48.3%) alive and 288 (51.7%) dead. The characteristics of 557 
patients are summarized in table 5. The median age was 55 years (range 26-88 years). 
The majority of patients was non-black (93.5%), post menopausal (74.5%), Charlson 
comorbidity condition-free (79.5%), ER/PR positive (73.2%), HER2 negative (65.5%), 
and metastatic at only one site (61.8%). The median household income was $41,335 
(range $18,473-$85,102) and 287 (51.5%) patients had more than high school education. 
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Half of the patients (n = 237, 42.5%) had a history of hypertension. Most patients 
(73.2%) were overweight (n = 257, 46.1%) or obese (n = 151, 27.1%), while other 
patients were of normal  weight range (n = 118, 21.2%) or underweight group (n = 31, 
5.6%). 114 (20.5%) patients had one or more of the Charlson comorbidity conditions: 
mainly diabetes (6.6%), mild liver disease (4.3%), chronic pulmonary disease (CPD, 
4.1%) and congestive heart failure (CHF, 2.3%). Bone, liver, brain metastasis were 
diagnosed in 301 (54.0%), 116 (20.8%), and 34 (6.1%) patients, respectively.  
 
4.4.1 Univariate analysis 
 
Table 6 and Figure 3-9 showed results for univariate analyses of survival after breast 
cancer metastasis. Patients with metastatic breast cancer had significantly unfavorable 
outcomes when they were older (P = 0.003), having less than or equal high school 
education (P = 0.034). A history of hypertension (P < 0.0001), ER/PR negative (P = 
0.001) and HER2 negative (P = 0.048), were significantly associated with poor survival 
after breast cancer metastasis. In addition, patients diagnosed with greater number of 
metastatic sites (P < 0.0001), brain metastasis (P = 0.009) or liver metastasis (P = 0.005) 
had significantly worse prognoses. Charlson comorbidity score (P = 0.059) for one unit 
increase and the normal body weight group (P = 0.068) compared to the underweight 
group had a marginal negative effect on survival. Race, menopausal status, CHF, CPD, 
mild liver disease, diabetes, metastasis at bone or other site did not significantly impact 
survival. 
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4.4.2 Multivariate analysis 
 
A multivariate analysis was performed including all variables in univariate analysis 
(Table 7). In multivariate analysis, the normal body weight group (HR 1.86, 95% CI 
1.03-3.35) had significantly poorer survival outcomes than the underweight group. 
History of hypertension (HR 1.53, 95% CI 1.14-2.07), ER/PR negative status (HR 1.84, 
95% CI 1.40-2.41), HER2 negative status (HR 1.45, 95% CI 1.09-1.93), and greater 
number of metastatic sites (HR 1.27, 95% CI 1.01-1.59) were found to be unfavorable 
factors on survival. Age, education and brain or liver metastasis, which were significant 
prognostic factors on survival in univariate analysis, were not strongly associated with 
survival after adjustment for other covariates in multivariate analysis.  
There was a synergistic interaction (P = 0.019) between brain and liver metastasis 
negatively influencing survival. We performed the univariate and multivariate analysis 
with independent variables using the parametric, accelerated failure-time models 
assuming a Weibull distribution 107 and results were comparable to those in univariate 
and multivariate analysis using Cox regression models (data not shown).  
 
4.5 DISCUSSION 
 
The present study was a hospital clinic-based retrospective study evaluating potential 
factors including socioeconomic, clinical, and pathological factors related to survival 
among 557 women with metastatic breast cancer. The study found that a history of 
hypertension, ER/PR status, HER2 status, number of metastatic sites, and BMI at the 
time of diagnosis with metastatic breast cancer had significant impact on survival in 
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multivariate analysis, while age, education, brain or liver metastasis were strong 
predictors on survival in univariate analysis only. 
The majority of the breast cancer literature suggests that higher BMI (obese or 
overweight) at diagnosis is associated with a poor prognosis 19-23, which is consistent with 
the present study showing that over weight and obese patients had worse survival than 
underweight patients in univariate analysis. In the present study, the normal body weight 
at metastatic diagnosis was found to have almost double risk of dying after metastatic 
breast cancer than a patients’ underweight status. The weight loss of over 10% after 
breast cancer diagnosis increased the risk of breast cancer mortality compared to being 
weight stable 11, 71, and this risk was more pronounced among women who were obese 
(BMI ≥ 30kg/m2) before diagnosis.20 We attempted to evaluate the effect of weight 
change from breast cancer to metastatic diagnosis on survival, however, weight change 
was not included in the data analysis due to the high level of missing data. It is reasonable 
to assume that patients who lose weight between initial breast cancer diagnosis and 
metastasis have poor survival. 
The number of metastatic sites was a major prognostic factor for survival after 
adjustment for other covariates. This finding validates previous work that found more 
metastatic sites at diagnosis a poor prognosis.10, 11, 64, 79, 84 Bone metastasis was associated 
with a relatively better survival 71, 75, 78, 108 and bone is the most frequent site of metastasis 
with 54% in our study and 40-55% in other studies.8, 76 As previously reported, the 
association between brain or liver metastases and low survival rate was observed 
significantly in only univariate analysis in consistency with other studies.11, 17, 64 When 
lung, liver and other visceral sites were all combined in the variable “visceral dominant 
  30
site”, they have been reported to be influential factors on poor breast cancer survival.7, 8, 
75, 77, 81, 84 
This study demonstrated that patients with positive HER2 status had better 
survival which is in concordance with other studies.9, 75 Several studies showed that ER 
and/or PR negative increased the risk of poor response to treatment or mortality among 
metastatic breast cancer patients.7, 8, 64, 75-81 The peak hazard of mortality in ER-positive 
tumors occurred later than in ER-negative tumors. Grasic et al. reported that the 
difference of breast cancer mortality risk between ER-negative and ER-positive occurred 
from 5 year on, and the hazard in ER-positive was higher than ER-negative.82 Adjuvant 
hormonal treatment with tamoxifen diminishes the risk for relapse and death in ER-
positive tumors, and the relative gain of mortality in tamoxifen treated compared to non-
treated group increased at 5 years.83 Our findings are similar to the previous study results 
by reporting that ER/PR positive had better impact on 5 year survival after breast cancer 
metastasis, afterwards the risk of ER/PR-positive increased on survival.  
Comorbidity affects medical decision-making, outcomes in terms of treatment 
complications, recurrence, and survival in breast cancer patients. Unlike other reports 24-30, 
our study did not observe a significant association between comorbidity and survival. Our 
chart abstraction procedure detected Charlson comorbidity in only 21% of cases. Most 
other studies reported a higher prevalence of Charlson comorbidity (37-65%).24, 28-30 
Consistent with another study 28, we observed an association between history of 
hypertension and survival after diagnosis of metastatic breast cancer even after 
adjustments for other comorbidities. Hypertension can be an important risk factor for 
cancer. For example, cell death by apoptosis can influence the growth of vascular smooth 
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muscle cells (VSMCs) and the increased proliferation of VSMCs responds exaggeratedly 
to growth stimuli, which is characterized by shortening of the cell cycle. This mechanism 
may lead to increased cellular proliferation.57 The Charlson list of comorbidities excludes 
hypertension. Future studies of clinical predictors of survival after breast cancer diagnosis 
should not rely only on Charlson comorbidities, but also include, at minimum, a history 
of hypertension. 
This study had limitations. We did not consider specific treatment regimens in the 
analysis to preserve the power due to high degree of variation in treatment regimens 
among metastatic breast cancer women. However, it is reasonable to assume that 
treatments were selected in accordance with acceptable criteria and were carried out by 
competent physicians at this university affiliated, National Cancer Institute (NCI) 
designated site.  
Given that the median survival length (18 months) of patients with unavailable 
charts was significantly shorter than that (40 months) of patients having complete data, 
the possible sources of selection bias can not be excluded. We can assume that paper-
version medical records for patients who died earlier have higher chance of being lost 
than those for patients who died recently. The exclusion of patients whose charts were 
not found from the analysis did not appear to make significantly different changes in 
study results in terms of analyses of age, race, number of metastatic sites, metastatic 
location, ER/PR status and HER2 status.  
Our data collection procedure extracted comorbidity information from multiple 
medical record sources (Figure 2), including clinic intake forms, progress notes, 
laboratory results, and physician summaries. Medical record documentation was not 
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strictly uniform over the period of time (January 1, 1999 through June 30, 2008) covering 
first diagnosis of metastatic breast cancer. For example, medical records for women with 
breast cancer metastasis diagnosed during an early time period more often lacked a clinic 
intake form than medical records for women diagnosed during a later time period (data 
not shown). This type of calendar time-related variability in medical record completeness 
or quality may have introduced a systemic error leading to 1) the underestimation of 
Charlson comorbidity during early time periods and 2) the failure to detect association 
between Charlson comorbidity and survival because of concurrent improvements in the 
effectiveness of medical treatment for metastatic breast cancer. In our study, however, 
Charlson comorbidity score values were independent of the year of first diagnosis of 
metastatic breast cancer (data not shown). Assuming similarly ill women were diagnosed 
with metastatic breast cancer in earlier and later time periods, this result suggests that 
variable medical record quality did not adversely affect our results associating the 
Charlson comorbidity measurements with survival. 
We did the sensitivity test using available data of variables prior to imputation 
procedure compared to complete data of corresponding variables which were imputed, 
and there was no apparent difference in the frequency distribution and in the univariate 
analysis. In addition, our study findings are fairly robust since similar results using semi-
parametric, Cox regression and parametric, accelerated failure-time models were 
obtained.  
In conclusion, studies of prognostic factors in metastatic breast cancer patients 
vary considerably in terms of the patients’ selection, availability of clinical, socio-
economical, biological covariates, patients’ lost follow-up, and statistical method for 
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analysis.8 Many studies have considered individual risk factor, one at a time, but few 
studies have considered a comprehensive range of risk factors together. 
Utilizing a large database reflective of current metastatic breast cancer treatment 
this study employed a uniform protocol for data collection and examined prognostic 
factors in a comprehensive fashion. The present study findings may form a foundation for 
the growing corpus of knowledge explaining the outcome differences in treatment of 
patients with metastatic breast cancer, potentially helping to create more personalized 
treatment approaches for this vulnerable group. 
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4.7 TABLES AND FIGURES 
 
Table 5. Characteristics of patients with metastatic breast cancer identified at two sites of the UPMC, 
UPCI Breast Cancer Program 
Variable* Number of patients Percentage 
Age (Median age in years 55years) 
26-88 years 557 100 
Ethnicity 
Non-Black 521 93.5 
Black 36 6.5 
Education 
≤ High School 270  48.5 
> High School 287 51.5 
Median Household Income (Median of Median Household Income $ 41,335 ) 
$18,473-$85,102 557 100 
BMI 
<20 kg/m2 31  5.6 
20-24.9 kg/m2 118  21.2 
25-29.9 kg/m2 257  46.1 
≥30 kg/m2 151  27.1 
Menopausal status 
Pre menopause 142 25.5 
Post menopause 415 74.5 
History of hypertension 
No 320 57.5 
Yes 237 42.5 
Charlson comorbidity score 
0 443 79.5 
1 15 2.7 
2 32 5.7 
3+ 67 12.1 
Charlson Comorbidity Condition 
Congestive heart failure  13 2.3 
Chronic pulmonary disease  23 4.1 
Mild liver disease  24 4.3 
Diabetes  37 6.6 
ER/PR status 
ER/PR positive 408 73.2 
ER/PR negative 149 26.8 
HER2 status 
HER2 positive 192 34.5 
HER2 negative 365 65.5 
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Table 5 (Continued)   
Variable Number of patients Percentage 
Number of metastatic sites 
1 344 61.8 
2 137 24.6 
3+ 76 13.6 
Metastatic location  
Brain 34 6.1 
Bone 301 54.0 
Liver 116 20.8 
Other 309 55.5 
Abbreviation: BMI, body mass index; ER/PR, estrogen receptor and/or progesterone 
receptor; HER2, human epidermal growth factor receptor-2. 
* Variables with < 1% of frequency were excluded from analysis. 
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Table 6. Univariate analysis with Cox regression in patients with metastatic breast cancer identified 
at two sites of the UPMC, UPCI Breast Cancer Program 
Variable** Patients no (%) Hazard ratio 95% CI P-value 
Age 557 (100) 1.01 1.01-1.02 0.003 
Ethnicity 
Non-Black 521 (93.5) 1.00 referent 
Black 36 (6.5) 1.46 0.88-2.43 
 
0.144 
Education* 
≤ High School 270 (48.5) 1.00 referent 
> High School 287 (51.5) 0.78 0.62-0.98 
 
0.034 
BMI* 0.012† 
<20 kg/m2 31 (5.6) 1.00 referent  
20-24.9 kg/m2 118 (21.2) 1.71 0.96-3.03 0.068 
25-29.9 kg/m2 257 (46.1) 1.10 0.63-1.91 0.736 
≥30 kg/m2 151 (27.1) 1.46 0.82-2.57 0.196 
Menopausal status* 
Pre menopause 142 (25.5) 1.00 referent 
Post menopause 415 (74.5) 1.17 0.89-1.52 
 
0.256 
History of hypertension* 
No 320 (57.5) 1.00 referent 
Yes 237 (42.5) 1.62 1.28-2.06 
 
<0.0001 
Charlson comorbidity 
score 
557 (100) 1.09 1.00-1.18 0.059 
Congestive heart failure 
No 544 (97.7) 1.00 referent 
Yes 13 (2.3) 1.86 0.88-3.96 
 
0.105 
Chronic pulmonary disease 
No 534 (95.9) 1.00 referent 
Yes 23 (4.1) 1.30 0.77-2.19 
 
0.319 
Mild liver disease 
No 533 (95.7) 1.00 referent 
Yes 24 (4.3) 1.35 0.75-2.41 
 
0.315 
Diabetes 
No 520 (93.4) 1.00 referent 
Yes 37 (6.6) 1.34 0.84-2.13 
 
0.223 
ER/PR status 
ER/PR positive 408 (73.2) 1.00 referent 
ER/PR negative 149 (26.8) 1.54 1.20-1.98 
 
0.001 
HER2 status 
HER2 positive 192 (34.5) 1.00 referent 
HER2 negative 365 (65.5) 1.28 1.00-1.64 
 
0.048 
Number of metastatic sites 557 (100) 1.37 1.21-1.56 <0.0001 
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Table 6 (Continued) 
Variable** Patients no (%) Hazard ratio 95% CI P-value 
Metastatic location 
Brain 
No 523 (93.9) 1.00 referent 
Yes 34 (6.1) 1.77 1.16-2.72 
 
0.009 
Bone 
No 256 (46.0) 1.00 referent 
Yes 301 (54.0) 1.20 0.95-1.51 
 
0.136 
Liver 
No 441 (79.2) 1.00 referent 
Yes 116 (20.8) 1.47 1.13-1.93 
 
0.005 
Other 
No 248 (44.5) 1.00 referent 
Yes 309 (55.5) 1.02 0.81-1.29 
 
0.847 
Abbreviation: 95% CI, 95% Confidence Interval; BMI, body mass index; ER/PR, 
estrogen receptor and/or progesterone receptor; HER2, human epidermal growth factor 
receptor-2. 
* Missing data were replaced with imputed data using simple imputation procedure of 
EM algorithm.106 
** Variables with P value≈1.0 or with < 1% of frequency were excluded from analysis. 
† P-value for omnibus test. 
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Table 7. Multivariate analysis with Cox regression in patients with metastatic breast cancer 
identified at two sites of the UPMC, UPCI Breast Cancer Program 
Variable Patients no 
(%) 
Hazard ratio 95% CI P-value 
Age 557 (100) 1.01 1.00-1.03 0.134 
Ethnicity 
Non-Black 521 (93.5) 1.00 referent 
Black 36 (6.5) 1.20 0.69-2.08 
 
0.528 
Education* 
≤ High School 270 (48.5) 1.00 Referent 
> High School 287 (51.5) 0.87 0.68-1.12 
 
0.282 
BMI* 0.025† 
<20 kg/m2 31 (5.6) 1.00 referent  
20-24.9 kg/m2 118 (21.2) 1.86 1.03-3.35 0.040 
25-29.9 kg/m2 257 (46.1) 1.20 0.67-2.15 0.544 
≥30 kg/m2 151 (27.1) 1.35 0.74-2.46 0.335 
Menopausal status* 
Pre menopause 142 (25.5) 1.00 referent 
Post menopause 415 (74.5) 0.82 0.57-1.17 
 
0.277 
History of Hypertension* 
No 320 (57.5) 1.00 referent 
Yes 237 (42.5) 1.53 1.14-2.07 
 
0.005 
Charlson comorbidity 
score 
557 (100) 0.97 0.84-1.12 0.699 
Congestive heart failure 
No 544 (97.7) 1.00 referent 
Yes 13(2.3) 1.20 0.49-2.91 
 
0.694 
Chronic pulmonary disease 
No 534 (95.9) 1.00 referent 
Yes 23 (4.1) 1.37 0.73-2.58 
 
0.323 
Mild liver disease 
No 533 (95.7) 1.00 referent 
Yes 24 (4.3) 1.28 0.66-2.48 
 
0.459 
Diabetes 
No 520 (93.4) 1.00 referent 
Yes 37 (6.6) 1.25 0.67-2.34 
 
0.490 
ER/PR status 
ER/PR positive 408 (73.2) 1.00 referent 
ER/PR negative 149 (26.8) 1.84 1.40-2.41 
 
<0.0001 
HER2 status 
HER2 positive 192 (34.5) 1.00 referent 
HER2 negative 365 (65.5) 1.45 1.09-1.93 
 
0.010 
Number of metastatic sites 557 (100) 1.27 1.01-1.59 0.043 
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Table 7 (Continued) 
Variable Patients no 
(%) 
Hazard ratio 95% CI P-value 
Metastatic location 
Brain 
No 523 (93.9) 1.00 referent 
Yes 34 (6.1) 1.54 0.91-2.62 
 
0.109 
Bone 
No 256 (46.0) 1.00 referent 
Yes 301 (54.0) 1.32 0.91-1.90 
 
0.146 
Liver 
No 441 (79.2) 1.00 referent 
Yes 116 (20.8) 1.37 0.94-1.99 
 
0.100 
Other 
No 248 (44.5) 1.00 referent 
Yes 309 (55.5) 1.01 0.66-1.53 
 
0.983 
Abbreviation: 95% CI, 95% Confidence Interval; BMI, body mass index; ER/PR, 
estrogen receptor and/or progesterone receptor; HER2, human epidermal growth factor 
receptor-2. 
* Missing data were replaced with imputed data using simple imputation procedure of 
EM algorithm.106 
† P-value for omnibus test. 
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Figure 2. Medical record abstraction procedure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  44
Education 
 
Figure 3. Kaplan-Meier’s curve of survival by education with log-rank test in patients with 
metastatic breast cancer identified at two sites of the UPMC, UPCI Breast Cancer Program 
(Categorical covariates significantly influencing on survival in univariate analysis were presented.) 
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BMI 
 
Figure 4. Kaplan-Meier’s curve of survival by BMI with log-rank test in patients with metastatic 
breast cancer identified at two sites of the UPMC, UPCI Breast Cancer Program (Categorical 
covariates significantly influencing on survival in univariate analysis were presented.) 
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History of hypertension 
 
Figure 5. Kaplan-Meier’s curve of survival by history of hypertension with log-rank test in patients 
with metastatic breast cancer identified at two sites of the UPMC, UPCI Breast Cancer Program 
(Categorical covariates significantly influencing on survival in univariate analysis were presented.) 
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ER/PR status 
 
Figure 6. Kaplan-Meier’s curve of survival by ER/PR status with log-rank test in patients with 
metastatic breast cancer identified at two sites of the UPMC, UPCI Breast Cancer Program 
(Categorical covariates significantly influencing on survival in univariate analysis were presented.) 
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Her2 status 
 
Figure 7. Kaplan-Meier’s curve of survival by HER2 status with log-rank test in patients with 
metastatic breast cancer identified at two sites of the UPMC, UPCI Breast Cancer Program 
(Categorical covariates significantly influencing on survival in univariate analysis were presented.) 
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Brain metastasis 
 
Figure 8. Kaplan-Meier’s curve of survival by brain metastasis with log-rank test in patients with 
metastatic breast cancer identified at two sites of the UPMC, UPCI Breast Cancer Program 
(Categorical covariates significantly influencing on survival in univariate analysis were presented.) 
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Liver metastasis 
 
Figure 9. Kaplan-Meier’s curve of survival by Liver metastasis with log-rank test in patients with 
metastatic breast cancer identified at two sites of the UPMC, UPCI Breast Cancer Program 
(Categorical covariates significantly influencing on survival in univariate analysis were presented.) 
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5.1 ABSTRACT 
Background: It is generally accepted that delay in receiving treatment for breast cancer 
results in adverse prognostic outcomes. The purpose of the present study was to evaluate 
the impact of delay in treatment after the diagnosis of metastatic disease on survival 
measured from metastatic breast cancer diagnosis and from first treatment while 
controlling for immortal time effect among patients with metastatic breast cancer. 
Populations and Methods: A total of 553 patients with the initial breast cancer 
metastasis diagnosis from one large urban practice have been followed up between 
January 1, 1999 and June 30, 2008. Prognostic factors and outcomes of these patients 
were analyzed by using log-rank test and Cox regression model. Backward stepwise 
selection of covariates was conducted to assess the association of treatment delay with 
survival. 
Results: The median survival was 40 months (range 1-114 months), with 265 (47.9%) 
alive and 288 (52.1%) dead at the end of the follow-up period. Treatment delays of > 12 
week had worse survival from first treatment than the delays of 4-12 week in univariate 
analysis (HR 2.02, 95% CI 1.16-3.54), and had a marginal impact on poor survival in 
multivariate analysis (HR 1.76, 95% CI 0.99-3.13). Moreover, the interval of 12-24 week, 
compared to the interval of 4-12 week was a prognostic factor for survival from first 
treatment in multivariate analysis (HR 2.39, 95% CI 1.19-4.77). 
Conclusion: This study demonstrated that delay of over 12 weeks in receiving treatment 
for metastatic breast cancer results in adverse survival outcomes. Findings of this study 
suggest the usefulness of targeted efforts to ensure prompt treatment initiation in patients 
diagnosed with metastatic breast cancer. 
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Key words: advanced breast cancer, treatment delay 
5.2 INTRODUCTION 
Breast cancer is the most common cancer in women in the United States and in other 
industrialized countries, and the second leading cause of death for women with cancer.100 
Despite improved techniques for breast cancer screening, as many as 7% of women 
present with metastatic disease at the time of diagnosis.101 While most women are 
diagnosed at an early stage, 20% to 80% of these patients, depending on the initial stage 
and the treatment strategy followed, will develop distant metastasis within 5 years of their 
initial diagnosis.102 Survival time for patients with metastasis varies greatly with median 
survival duration ranging from less than 9 months to over 3 years.7  
Delays in the initiation of breast cancer treatment may adversely affect survival. 
The influence of delays on survival between breast cancer diagnosis and treatment 
remains controversial. Several studies observed that survival was worse among patients 
with longer treatment delays 31, 43, 86-91; others did not show that survival was affected by 
treatment delay interval.34-42 These conflicting results may be explained by differences in 
the patients’ selection, by difference in the cut-offs used to define delay, and by 
availability of clinical, socio-economical and biological covariates.43 One of the major 
limitations with the majority of previous studies on the effect of delays on survival is that 
no account has been taken of immortal time effect. Immortal time refers to a span of time 
in the follow-up period of a cohort during which an outcome of interest could not 
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possibly occur.109-111 Measurement of survival from the date of treatment for the effect of 
treatment delays on survival can overcome immortal time bias. 
This study aimed to evaluate the impact of delays in the initiation of treatment on 
survival from metastatic breast cancer diagnosis and from first treatment in patients with 
metastatic breast cancer. To our knowledge, this is the first study to analyze the effect of 
treatment delays on survival among metastatic breast cancer patients. Moreover, this 
study controlled for immortal time bias by measuring survival from the initiation of 
treatment. The study used data from 553 patients with metastatic breast cancer seen at 
one large urban practice between January 1, 1999 and June 30, 2008.  
5.3 POPULATIONS AND METHODS 
5.3.1 Patients Selection 
The study included 553 patients with the first breast cancer metastasis seen at two urban 
hospitals (Montefiore and Magee) of the University of Pittsburgh Medical Center 
(UPMC) and by the University of Pittsburgh Cancer Institute (UPCI) Breast Cancer 
Program physicians. Patients with metastatic breast cancer were identified from daily 
hospital clinic lists and confirmed with medical records through clinical, radiological, or 
pathologic exams. Inclusion criteria included female patients aged eighteen or older with 
metastatic breast cancer diagnosed between January 1, 1999 and June 30, 2008. Of 671 
patients diagnosed with metastatic breast cancer during this period, 114 patients were 
excluded because their medical records were unavailable for the secondary review. 
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Additionally, 4 patients were excluded because they did not have history of clinic follow-
up (i.e., missing information for treatment) prior to the first treatment or until study end 
point. This study was approved by the University of Pittsburgh Institutional Review 
Board. 
 
5.3.2 Data Collection 
The medical record abstraction protocol was developed (Figure 10). Retrospective review 
of medical records according to study protocol was utilized. Chart abstraction form was 
summarized monthly by trained registered nurse. The primary data sources for 
abstraction were hand written medical records, usually completed at the monthly patient 
visit. 
Age, race, estrogen receptor (ER) and/or progesterone receptor (PR) status, 
human epidermal growth factor receptor-2 (HER2) status, number of metastatic sites and 
metastatic location were assessed using the chart abstraction form completed by primary 
reviewer. Quality guaranteed protocol for the secondary chart review was established. 
The weighted kappa coefficients of secondary chart abstraction with n = 23, and of 
repeated chart abstraction with n = 23 for Charlson comorbidity score were 0.88 (95% CI 
0.64-1.00) and 0.88 (95% CI 0.66-1.00), respectively; secondary and repeated chart 
abstraction for hypertension were 0.93 (95% CI 0.79-1.00) and 1.00 (95% CI 1.00-1.00), 
respectively.  
The secondary chart retrieval procedure was performed to evaluate marital status, 
socioeconomic status (SES) including insurance, education, residential zip code, BMI at 
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breast cancer diagnosis and at study entry, weight change (difference weight between at 
metastasis and weight at breast cancer diagnosis), menopausal status, and comorbidities 
according to the protocol. All predictor variables were measured at the time of metastatic 
breast cancer. 
Variables with more than 40% missing data such as marital status, insurance, BMI 
at breast cancer diagnosis and weight change were excluded for purposes of the analysis. 
Missing data imputation procedure was accomplished on education, median household 
income, BMI (at study entry), menopausal status and hypertension having missing values 
ranged 5% to 35% (hypertension 5%, menopause 11%, education 13%, BMI 20%, 
income 35%). 
 
5.3.3 Definition of treatment delay 
Treatment delay was defined as the time in days between the date of initial breast cancer 
metastasis and the date of the initiation of first treatment. The date of first metastatic 
breast cancer diagnosis was identified as the date of first metastatic biopsy or CT scan, 
whichever came first. The date of first treatment initiation was considered as the date of 
the start of first treatment obtained from paper-version medical records. Treatment types 
included systematic therapy such as chemotherapy, hormonal therapy, immunologic 
therapy, vaccine therapy, and other biologic therapy. Fourteen patients did not have a 
history of treatment until death or end of study period. Their treatment delay interval was 
censored at the date of death, or study end point.  
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Week (7 days) was chosen as a unit of time in this study. Period lasting for less 
than 7 days was recorded as “0 week”. Treatment delay interval was categorized in two 
ways: 1) categorization into 3 groups (less than or equal to 4 weeks, more than 4 weeks to 
less than or equal to 12 weeks, and more than 12 weeks); 2) categorization into 4 groups 
(less than or equal to 4 weeks, more than 4 weeks to less than or equal to 12 weeks, more 
than 12 weeks to less than or equal to 24 weeks, and more than 24 weeks) to keep lead 
time effect to a minimum.85 Lead time bias can be kept to a minimum by excluding 
patients having delays of >24 weeks, and by comparing the effect of delays between 4-12 
week and 12-24 week on survival.85 The categorizations of treatment delay interval were 
similar to the ones previously used in other similar studies 34, 43, 88, especially the meta-
analysis conducted by Richards et al.85 
 
5.3.4 Predictor variables 
Demographic or socioeconomic variables included age, race, education, median 
household income, BMI, and menopausal status. The median household income was 
linked to residential zip code matched to U.S. 2000 census summary file 3.103 The BMI 
was calculated as a weight in kilogram (kg) divided by a height in meters squared and 
classified into four groups: less than 20kg/m2 (underweight), 20-24.9kg/m2 (normal), 25-
29.9kg/m2 (overweight), 30kg/m2 or higher (obese).  
Pathological factors that were selected for analysis included ER/PR status, HER2 
status, number of metastatic sites, and metastatic location. Determination of ER/PR and 
HER2 status used the pathologic report following the first metastatic site biopsy, if 
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available, and the initial breast cancer site biopsy, otherwise. Metastatic locations were 
categorized into four groups: brain, bone, liver, and other.  Lung, adrenal gland, lymph 
node, soft tissue and other visceral sites were combined in other group due to a small 
sample size or non significant effect on survival according to univariate and multivariate 
analysis. 
Clinical variables included a history of hypertension, Charlson comorbidity 
conditions, and Charlson comorbidity score. Hypertension was defined as a blood 
pressure greater than or equal to 140 mmHg systolic pressure or greater than or equal to 
90 mmHg diastolic pressure (American Heart Association) 104, at least twice presented at 
different visits. Hypertension included controlled hypertension. The Charlson 
comorbidity score, a composite of 19 comorbidity conditions was constructed using 18 
comorbidity conditions (without metastatic solid tumor) which were weighted by 1, 2, 3, 
or 6. The sum of the weighted comorbidity conditions has a theoretical range between 0 
and 31. Final Charlson comorbidity score was obtained by adding the age-comorbidity 
combined risk score.58, 105  
 
5.3.5 Outcome variable 
The outcome variable was an overall survival in months defined into two ways: interval 
between metastatic breast cancer diagnosis and death or study end point; interval from 
the date of first treatment to the date of death or the end of follow-up period. Fourteen 
patients who were either censored or died before first treatment were excluded from 
analysis for the effect of treatment delays on survival from first treatment. The study 
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ascertained the occurrence of death in two ways. For in-hospital deaths, the hospital 
record was reviewed. For out of hospital deaths, the data were confirmed utilizing U.S. 
social security death index. Analyses censored all followed on June 30, 2008. 
 
5.3.6 Statistical analysis 
Simple imputation procedure for missing data used SPSS implementation of the 
Expectation Maximization (EM) algorithm of Dempster, Laird and Rubin (1977).106 The 
frequency distribution of complete data of variables which were imputed was compared 
to the available data of corresponding variables prior to imputation using appropriate two 
sample t-tests for continuous variables and chi-squared statistics for categorical variables. 
Multicollinearity was assessed by using coefficient of multiple determination (R2), 
tolerance, and variance-inflation factor (VIF) for each predictor variable using remaining 
covariates as its predictors; no serious multicollinearity was identified. 
Demographic, pathological, and clinical characteristics according to the length of 
treatment delays were tested using F-test from Analysis of Variance for continuous 
variables and chi-squared statistics for categorical variables. If continuous variables were 
skewed or had outliers, Kruskal-Wallis test was implemented. 
Log rank test for categorical variables was conducted to evaluate the relationship 
between predictor variables and survival. Kaplan-Meier estimation was used to generate 
group-specific survival curves for treatment delay categories. Cox proportional hazards 
regression model was performed for univariate analysis for both categorical and 
continuous variables to produce hazard ratios (HRs) and 95% confidence interval (95% 
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CI). Cox regression using backward stepwise selection of covariates was accomplished to 
assess the association of treatment delays with survival, accounting for covariates. 
Two tailed p-value of less than 0.05 was considered significant. SAS (version 9.2) 
and SPSS (version 17.0) were used. 
5.4 RESULTS 
Analysis included 553 patients with metastatic breast cancer diagnosed between January 
1, 1999 and June 30, 2008. The median survival was 40 months (range 1-114 months), 
with 265 (47.9%) women having survived and 288 (52.1%) having died. Of the 553 
patients included in the analysis, majority of patients was non-black (93.5%), post 
menopausal (74.9%), Charlson comorbidity condition-free (79.4%), ER/PR positive 
(73.1%), HER2 negative (65.5%), and had metastasis at only one site (61.5%). The 
median age was 55 years (range 26-88 years). The median household income was 
$41,190 (range $18,473-$85,102) and 283 (51.2%) patients had more than high school 
education. Most patients (73.1%) were overweight (n = 253, 45.8%) or obese (n = 151, 
27.3%), while other patients were of normal weight or underweight group (n = 149, 
26.9%). Half of the patients (n = 237, 42.9%) had a history of hypertension, and 114 
(20.6%) patients had one or more of the Charlson comorbidity conditions. Bone, liver, 
and brain metastasis were diagnosed in 298 (53.9%), 116 (21.0%), and 34 (6.1%) patients, 
respectively.  
The characteristics of 553 patients by the length of treatment delays (≤ 4 week, 4-
12 week, and > 12 week) are summarized in table 8. The median treatment delay interval 
  61
was 13 days (25 percentile 0 day and 75 percentile 32 days). Patients having treatment 
delays more than 4 weeks were more likely to have brain metastasis (P = 0.0006) and 
ER/PR negative status (P < 0.0001). More than two site metastases (P = 0.013), and other 
metastasis (i.e., including soft tissue, lymph node, and visceral site) (P = 0.002) were 
more likely to be found in patients having treatment delays with 4-12 week. Age was 
related to the increase of treatment delays (P = 0.047). No other differences of 
characteristics by treatment delays were noted. 
 
5.4.1 Univariate Analysis 
Table 9 outlines results for univariate analyses of survival after breast cancer metastasis. 
Patients with metastatic breast cancer had significantly unfavorable outcomes when they 
were older (P = 0.004), having less than or equal to high school education (P = 0.0495), 
history of hypertension (P = 0.0001), ER/PR negative (P = 0.002), and HER2 negative (P 
= 0.047). In addition, patients diagnosed with greater number of metastatic sites (P < 
0.0001), brain metastasis (P = 0.014) or liver metastasis (P = 0.006) had significantly 
worse prognoses. Charlson comorbidity score (P = 0.067) for one unit increase and the 
normal body weight group (P = 0.069) compared to the underweight group had a 
marginal negative effect on survival. Race, menopausal status, congestive heart failure 
(CHF), chronic pulmonary disease (CPD), mild liver disease, diabetes, metastasis at bone 
or other site did not significantly impact survival. 
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5.4.2 The effect of treatment delays on survival 
Survival graphs of treatment delays (≤ 4 week, 4-12 week, and > 12 week) related to 
survival since metastatic breast cancer diagnosis and since first treatment were presented 
in Figure 11 and Figure 12, respectively. 
Table 10 showed results for univariate and multivariate analyses of treatment 
delays (≤ 4 week, 4-12 week, and > 12 week) on survival after breast cancer metastasis. 
The treatment delay interval of > 12 week was not associated with survival relative to 
metastatic breast cancer diagnosis, compared to the 4-12 week of treatment delays in 
univariate and multivariate analysis. 
Cox regression analyses of treatment delays (≤ 4 week, 4-12 week, and > 12 
week) on survival after first treatment were conducted (Table 11). Treatment delays of > 
12 week had worse survival from first treatment than the interval of 4-12 week in 
univariate analysis (HR 2.02, 95% CI 1.16-3.54), and had a marginal impact on poor 
survival in multivariate analysis (HR 1.76, 95% CI 0.99-3.13). The treatment interval of 
≤ 4 week was not significantly related to survival relative to first treatment using 4-12 
week of treatment delays as a referent group in univariate and multivariate analysis. 
Additionally, history of hypertension (HR 1.64, 95% CI 1.26-2.13), ER/PR 
negative status (HR 1.70, 95% CI 1.27-2.27), HER2 negative status (HR 1.63, 95% CI 
1.24-2.15), greater number of metastatic sites (HR 1.32, 95% CI 1.15-1.51), were found 
to be unfavorable factors on survival from first treatment. Liver metastasis was associated 
with survival on borderline (HR 1.32, 95% CI 0.98-1.79). The normal body weight group 
(HR 2.12, 95% CI 1.16-3.90) was related to poorer survival than the underweight group 
(data not shown). There were no significant interaction terms between predictor variables 
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and treatment delays on survival relative first treatment. Similar results for multivariate 
analyses of covariates related to survival from breast cancer metastasis were observed 
(date not shown). 
Furthermore, treatment delay interval (classified as ≤ 4 week, 4-12 week, 12-24 
week, and > 24 week) was assessed for the effect of delays of 12-24 week, compared to 
4-12 week on survival. The interval of 12-24 week had poor survival measured from first 
treatment than the interval of 4-12 week in univariate analysis (HR 2.74, 95% CI 1.39-
5.39) and multivariate analysis (HR 2.39, 95% CI 1.19-4.77) (data not shown).  
5.5 DISCUSSION 
The present study was a hospital clinic-based retrospective study evaluating the 
relationship between treatment delays and survival, adjusting for socioeconomic, clinical, 
and pathological factors among 553 women with metastatic breast cancer. Survival was 
measured from metastatic breast cancer diagnosis, and from first treatment to control for 
immortal time bias. To our knowledge, no study has examined the connection between 
delayed treatment interval and survival among patients diagnosed with metastatic breast 
cancer with survival measured in two ways: survival from metastasis and from first 
treatment.  
The study found that treatment delays of > 12 week, compared to 4-12 week had a 
marginal negative effect on survival from first treatment. Our study finding validates 
previous studies 41, 43, 88, as summarized in a systemic review performed by Richards el 
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al.85 Investigators reported that patients experiencing delays of ≥ 3 months (which is 
considered as 12 weeks) had lower 5-year survival than patients with shorter delay.85 
Only few studies have measured survival after first treatment related to the impact 
of treatment delays.39, 41, 89, 112 As with the current study, researchers found that longer 
delays in treatment affected negatively on survival from first treatment.41, 89 This finding 
is important as it shows that the impact of treatment delays on survival was accounted for 
immortal time effect.109-111 
In the current study, treatment delay interval was reclassified into 4 groups (≤ 4 
week, 4-12 week, 12-24 week, and > 24 week) and examined for the difference in 
survival between patients with delays of 4-12 week and patients with delays of 12-24 
week to keep lead time effect to a minimum.85 Considering the median survival measured 
from first treatment among 539 patients as 41 months (164 weeks), 8 weeks (difference 
median week between 4-12 week and 12-24 week) could compensate for lead time effect. 
In agreement with other studies 41, 43, 85, 90, 12-24 week of delays compared to 4-12 week 
of delays, was found to be a significant factor on survival from first treatment in 
multivariate analysis (HR 2.39, 95% CI 1.19-4.77) (data not shown). 
Adverse survival outcomes were significantly associated with history of 
hypertension, ER/PR negative status, HER2 negative status, increasing number of 
metastasis, and liver metastasis, corroborating previous literatures.9, 17, 28, 64, 75, 79, 82 
Longer delays in treatment were related to two or more metastatic sites, and brain 
metastasis in this study, suggesting that patients having multiple metastatic sites at 
diagnosis spent more time on pre treatment workup. Additionally, if patients received 
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local cranial radiation and/or surgery for brain metastasis, the systemic therapy may have 
been delayed. 
This study had limitations. We did not consider specific treatment regimens in the 
analysis, as study population was heterogeneous with respect to treatment regimen. 
However, it is reasonable to assume that treatments were selected in accordance with 
acceptable criteria and were carried out by competent physicians at this university 
affiliated, National Cancer Institute (NCI) designated site. 
The study did not include 114 patients because medical records were unavailable 
for the secondary review, which could induce the possible sources of selection bias. The 
exclusion of patients whose charts were not found from the analysis did not appear to 
make significantly different changes in study results in terms of analyses of age, race, 
number of metastatic sites, metastatic location, ER/PR status and HER2 status. 
We did the sensitivity test using available data of variables prior to imputation 
procedure compared to complete data of corresponding variables which were imputed, 
and there was no apparent difference in the frequency distribution and in the univariate 
analysis. 
Seventy percent of patients in our study started treatments within 4 weeks of 
diagnosis of metastatic breast cancer (Table 10). National Breast and Cervical Cancer 
Early Detection Program (1991-1995) reported similar distribution (78.2%) of 30 days 
interval to diagnosis of any breast cancer and initiation of treatment.113 
In conclusion, this is the first study, to our knowledge, to analyze the association 
between delays in treatment and survival among patients with metastatic breast cancer. 
Moreover, this study controlled for immortal time bias by measuring survival from the 
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initiation of treatment. The study demonstrated that delay of over 12 week in receiving 
treatment for metastatic breast cancer results in adverse survival outcomes: delays of > 12 
week compared to 4-12 week had a marginal negative effect on survival from first 
treatment; furthermore, patients with delays of 12-24 week had significantly worse 
survival from first treatment than those with delays of 4-12 week. Utilizing a large 
database reflective of current metastatic breast cancer treatment this study employed a 
uniform protocol for data collection and examined prognostic factors in a comprehensive 
fashion. Findings of this study suggest the usefulness of targeted efforts to ensure prompt 
treatment initiation in patients diagnosed with metastatic breast cancer. Additionally, our 
findings highlight the need for future research into factors influencing delays in treatment 
and better understanding of these associations may lead to interventions that can improve 
breast cancer outcomes. 
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5.7 TABLES AND FIGURES 
 
Table 8. Characteristics of patients with metastatic breast cancer by the length of treatment delay 
(≤4 week, 4–12 week, >12 week), identified at two sites of the UPMC, UPCI Breast Cancer Program 
Treatment delay 
≤4 week 
(n=390) 
4–12 week 
(n=129) 
>12 week 
(n=34) 
 
 
 
Variable* No. (%) No. (%) No. (%) 
Age (range 26-88 years), 
Median** 
54.0 54.0 65.5 
Median Household income  
(range $18,473-$85,102), Median 
 
41367.0 
 
41044.2 
 
39843.2 
Race 
Non-Black 365 (70.6) 122 (23.6) 30 (5.8) 
Black 25 (69.4) 7 (19.4) 4 (11.1) 
Education 
≤High School 189 (70.0) 64 (23.7) 17 (6.3) 
> High School 201 (71.0) 65 (23.0) 17 (6.0) 
BMI 
<20 kg/m2 16 (51.6) 13 (41.9) 2 (6.5) 
20-24.9 kg/m2 88 (74.6) 25 (21.2) 5 (4.2) 
25-29.9 kg/m2 172 (68.0) 65 (25.7) 16 (6.3) 
≥30 kg/m2 114 (75.5) 26 (17.2) 11 (7.3) 
Menopausal status 
Pre menopause 99 (71.2) 35 (25.2) 5 (3.6) 
Post menopause 291 (70.3) 94 (22.7) 29 (7.0) 
History of hypertension 
No 224 (70.9) 77 (24.4) 15 (4.8) 
Yes 166 (70.1) 52 (21.9) 19 (8.0) 
Charlson comorbidity score 
0 318 (72.4) 94 (21.4) 27 (6.2) 
1 9 (60.0) 5 (33.3) 1 (6.7) 
2 20 (62.5) 12 (37.5) 0 (0.0) 
3+ 43 (64.1) 18 (26.9) 6 (9.0) 
Charlson Comorbidity Condition 
Congestive heart failure 
No 384 (71.0) 124 (23.0) 32 (5.9) 
Yes 6 (46.1) 5 (38.5) 2 (15.4) 
Chronic pulmonary disease 
No 376 (70.9) 123 (23.2) 31 (5.9) 
Yes 14 (60.9) 6 (26.1) 3 (13.0) 
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Table 8 (Continued) 
 
 
 
Variable* 
Treatment delay 
Mild liver disease 
No 376 (71.1) 121 (22.9) 32 (6.1) 
Yes 14 (58.3) 8 (33.3) 2 (8.3) 
Diabetes 
No 365 (70.7) 119 (23.1) 32 (6.2) 
Yes 25 (67.6) 10 (27.0) 2 (5.4) 
ER/PR status** 
ER/PR positive 309 (76.5) 83 (20.5) 12 (3.0) 
ER/PR negative 81 (54.4) 46 (30.9) 22 (14.8) 
HER2 status 
HER2 positive 138 (72.3) 44 (23.0) 9 (4.7) 
HER2 negative 252 (69.6) 85 (23.5) 25 (6.9) 
Number of metastatic sites** 
1 253 (74.4) 65 (19.1) 22 (6.5) 
2+ 137 (64.3) 64 (30.0) 12 (5.6) 
Metastatic location 
Brain** 
No 375 (72.2) 116 (22.4) 28 (5.4) 
Yes 15 (44.1) 13 (38.2) 6 (17.7) 
Bone 
No 173 (67.8) 64 (25.1) 18 (7.1) 
Yes 217 (72.8) 65 (21.8) 16 (5.4) 
Liver 
No 300 (68.6) 106 (24.3) 31 (7.1) 
Yes 90 (77.6) 23 (19.8) 3 (2.6) 
Other** 
No 189 (77.1) 40 (16.3) 16 (6.5) 
Yes 201 (65.3) 89 (28.9) 18 (5.8) 
Abbreviation: BMI, body mass index; ER/PR, estrogen receptor and/or progesterone 
receptor; HER2, human epidermal growth factor receptor-2. 
* Variables with < 1% of frequency were excluded from analysis. 
** P < 0.05. 
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Table 9. Univariate analysis of survival relative to metastatic breast cancer diagnosis in patients (n = 
553) with metastatic breast cancer identified at two sites of the UPMC, UPCI Breast Cancer 
Program 
Variable** Patients No. (%) Hazard ratio 95% CI P-value 
Age 553 (100) 1.01 1.00-1.02 0.004 
Race 
Non-Black 517 (93.5) 1.00 referent 
Black 36 (6.5) 1.46 0.88-2.42 
 
0.148 
Education* 
≤ High School 270 (48.8) 1.00 referent 
> High School 283 (51.2) 0.79 0.63-1.00 
 
0.0495 
BMI* 0.022† 
<20 kg/m2 31 (5.6) 1.00  referent  
20-24.9 kg/m2 118 (21.3) 1.70 0.96-3.02 0.069 
25-29.9 kg/m2 253 (45.8) 1.13 0.65-1.97 0.666 
≥30 kg/m2 151 (27.3) 1.46 0.83-2.58 0.191 
Menopausal status* 
Pre menopause 139 (25.1) 1.00 referent 
Post menopause 414 (74.9) 1.14 0.87-1.49 
 
0.337 
History of hypertension* 
No 316 (57.1) 1.00 referent 
Yes 237 (42.9) 1.60 1.26-2.03 
 
0.0001 
Charlson comorbidity 
score 
553 (100) 1.08 0.99-1.18 0.067 
Congestive heart failure 
No 540 (97.6) 1.00 referent 
Yes 13 (2.4) 1.85 0.87-3.94 
 
0.108 
Chronic pulmonary disease 
No 530 (95.8) 1.00 referent 
Yes 23 (4.2) 1.28 0.76-2.16 
 
0.347 
Mild liver disease 
No 529 (95.7) 1.00 referent 
Yes 24 (4.3) 1.34 0.75-2.39 
 
0.325 
Diabetes 
No 516 (93.3) 1.00 referent 
Yes 37 (6.7) 1.33 0.83-2.12 
 
0.233 
ER/PR status 
ER/PR positive 404 (73.1) 1.00 referent 
ER/PR negative 149 (26.9) 1.50 1.17-1.93 
 
0.002 
HER2 status 
HER2 positive 191 (34.5) 1.00 referent 
HER2 negative 362 (65.5) 1.28 1.00-1.64 
 
0.047 
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Table 9 (Continued) 
Variable** Patients No. (%) Hazard ratio 95% CI P-value 
Number of metastatic sites 553 (100) 1.36 1.20-1.55 <0.0001 
Metastatic location 
Brain 
No 519 (93.9) 1.00 referent 
Yes 34 (6.1) 1.71 1.12-2.62 
 
0.014 
Bone 
No 255 (46.1) 1.00 referent 
Yes 298 (53.9) 1.21 0.95-1.52 
 
0.1117 
Liver 
No 437 (79.0) 1.00 referent 
Yes 116 (21.0) 1.46 1.11-1.91 
 
0.006 
Other 
No 245 (44.3) 1.00 referent 
Yes 308 (55.7) 1.02 0.81-1.28 
 
0.891 
Abbreviation: 95% CI, 95% Confidence Interval; BMI, body mass index; ER/PR, 
estrogen receptor and/or progesterone receptor; HER2, human epidermal growth factor 
receptor-2. 
* Missing data were replaced with imputed data using simple imputation procedure of 
EM algorithm.106  
** Variables with P value≈1.0 or with < 1% of frequency were excluded from analysis. 
† P-value for omnibus test. 
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Table 10. Cox regression analysis between treatment delay (≤4 week, 4–12 week, >12 week) and 
survival from metastatic breast in patients (n = 553) with metastatic breast cancer identified at two 
sites of the UPMC, UPCI Breast Cancer Program 
Survival measured from metastatic breast cancer diagnosis 
Univariate analysis  Multivariate analysis¶  
Variable 
 
Patients No. (%) Hazard ratio 95% CI P-
value 
 Hazard 
ratio 
95% CI P-
value 
Treatment delay 553 (100.0)   0.194†    0.761† 
≤4 week* 390 (70.5) 1.11 0.83-1.48 0.483  1.09 0.81-1.47 0.578 
4–12 week** 129 (23.3) 1.00 referent   1.00 referent  
>12 week*** 34 (6.2) 1.56 0.96-2.56 0.075  1.20 0.71-2.01 0.499 
Abbreviation: 95% CI, 95% Confidence Interval. 
¶ Cox regression was performed for examining the effect of treatment delay on survival, 
adjusted by covariates (BMI, history of hypertension, ER/PR status, HER2 status, 
number of metastatic sites, and liver metastasis), selected to be significant with P-value 
<0.05 by backward stepwise selection. 
* Patients (n = 2) who were either censored or died within 4 weeks after metastatic 
diagnosis without receiving treatment were included in analysis. 
** Patients (n = 4) who were either censored or died between 4 weeks and 12 weeks after 
metastatic diagnosis without receiving treatment were included in analysis. 
*** Patients (n = 8) who were either censored or died more than 12 weeks after 
metastatic diagnosis without receiving treatment were included in analysis. 
† P-value for omnibus test. 
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Table 11. Cox regression analysis between treatment delay (≤4 week, 4–12 week, >12 week) and 
survival from first treatment in patients* (n = 539) with metastatic breast cancer identified at two 
sites of the UPMC, UPCI Breast Cancer Program 
Survival measured from first treatment 
Univariate analysis  Multivariate analysis**  
Variable 
 
Patients No. (%) Hazard ratio 95% CI P-
value 
 Hazard 
ratio 
95% CI P-
value 
Treatment delay 539 (100.0)   0.037†    0.148† 
≤4 week 388 (72.0) 1.10 0.82-1.47 0.537  1.05 0.78-1.43 0.741 
4–12 week 125 (23.2) 1.00 referent   1.00 referent  
>12 week 26 (4.8) 2.02 1.16-3.54 0.014  1.76 0.99-3.13 0.056 
Abbreviation: 95% CI, 95% Confidence Interval. 
* Patients (n=14 among 553) who were either censored or died before first treatment 
were excluded from analysis. 
** Cox regression was performed for examining the effect of treatment delay on survival, 
adjusted by covariates (BMI, history of hypertension, ER/PR status, HER2 status, 
number of metastatic sites, and liver metastasis), selected to be significant with P-value 
<0.05 by backward stepwise selection. 
† P-value for omnibus test. 
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Figure 10. Medical record abstraction procedure 
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Figure 11. Kaplan-Meier’s curve of survival since metastatic breast cancer diagnosis by treatment 
delay (≤4 week, 4–12 week, >12 week) in patients (n = 553) with metastatic breast cancer identified at 
two sites of the UPMC, UPCI Breast Cancer Program 
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Figure 12. Kaplan-Meier’s curve of survival since first treatment by treatment delay (≤4 week, 4–12 
week, >12 week) in patients (n = 539) with metastatic breast cancer identified at two sites of the 
UPMC, UPCI Breast Cancer Program 
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6.1 ABSTRACT 
Background: The presence of comorbidity becomes increasingly important for its 
prognostic effect on survival in breast cancer patients with advancing age. The purpose of 
the present study was to evaluate the role of comorbidities including hypertension as a 
mediator of disparity in survival following metastasis between younger (≤ 51 years) and 
older (> 51 years) patients. 
Populations and Methods: A total of 553 patients aged 26 to 88 years with the initial 
breast cancer metastasis diagnosis from one large urban practice have been followed up 
between January 1, 1999 and June 30, 2008. Comorbidity variables and outcomes of 
these patients were analyzed using Cox regression model. To assess comorbidity 
variables as a mediator of age-survival relationship, we applied two approaches: 1) Baron 
Kenny approach, and 2) alternative assessment to compute the percentage change in the 
HRs. 
Results: The median survival was 40 months (range 1-114 months), with 265 (47.9%) 
alive and 288 (52.1%) dead at the end of the follow-up period. Older patients had worse 
survival than younger patients (HR 1.43, 95% CI 1.11-1.84) after adjustment of 
covariates. Hypertension was related to survival (HR 1.45, 95% CI 1.12-1.89) when age 
and other covariates were controlled. Hypertension augmented Charlson comorbidity 
score (hCCS) was a significant prognostic factor of survival (1 vs. 0 score, HR 1.40, 95% 
CI 1.07-1.83; 2 vs. 0 score, HR 1.88, 95% CI 1.22-2.89) in mutivariate analysis, 
explaining survival disparity between younger and older patients by 44% compared to 
40 % of hypertension and 14% of the Charlson comorbidity score (CCS). 
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Conclusion: The study demonstrated that hypertension/hCCS was a prognostic factor for 
metastatic breast cancer survival. HCCS explained the age-survival relationship better 
than hypertension or CCS. Additionally, hypertension and hCCS were found to be strong 
mediators of the relationship between age and survival among patients with breast cancer 
metastasis. Findings of this study suggest that hypertension should be included in the 
comorbidity information for decision making support programs to aid patient consultation. 
 
Key words: advanced breast cancer, comorbidity, hypertension, mediation 
6.2 INTRODUCTION 
Breast cancer is the most common cancer in women in the United States and in other 
industrialized countries, and the second leading cause of death for women with cancer.110 
Despite improved techniques for breast cancer screening, as many as 7% of women 
present with metastatic disease at the time of diagnosis.101 While most women are 
diagnosed at an early stage, 20% to 80% of these patients, depending on the initial stage 
and the treatment strategy followed, will develop distant metastasis within five years of 
their initial diagnosis.63 
Incidence rates of breast cancer increased with advancing age and this increase 
has occurred predominantly in women over 50 years.44, 45 Mortality from breast cancer 
also increases with age.8, 12, 44, 46-50 Large number of older women with breast cancer have 
coexistent diseases (comorbidities) at the time of diagnosis, which may influence their 
treatment options and survival.26, 47, 49, 55, 56, 96 
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Comorbidity at diagnosis can have an adverse impact on survival. Specially, 
Braithwaite et al reported that hypertension was related to survival since breast cancer 
diagnosis even after adjustment of age, race, and other covariates.28 The presence of 
comorbid conditions and its treatment could place older patients at a greater risk of dying 
from breast cancer. Several studies examined the prediction of the comorbidity on 
survival in elderly breast cancer patients aged over 65 or 75 years 47, 48, 51-54, but the role 
of comorbidity as a mediator which accounts for relationship between age and survival 
has not been clearly documented. 
While several comorbidity measurement systems exist, the Charlson comorbidity 
index (CCI) has been most popularly studied and considered to be a valid and reliable 
method of assessing comorbidity for cancer research.58 Recent reports suggest that the 
CCI did not include certain comorbidities such as hypertension that did not contribute to 
a high relative risk in their study population.48, 59 Hypertension is the most prevalent 
comorbidity among older breast cancer patients, and it affects mortality from breast 
cancer.28, 47, 50, 53, 55, 56  
This study aimed to evaluate the role of comorbidities including hypertension as a 
mediator of disparity in survival following metastasis between younger (≤ 51 years) and 
older (> 51 years) patients. The age variable was classified using 51 as a cut point of 
old/young group because women in the U.S. undergo menopause at the mean age of 51 
114, 115, and women of > 51 years could be different from women of  ≤ 51 years 
biologically, and clinically in term of the breast cancer influencing cancer treatment, and 
survival.45, 116 To our knowledge, no study has examined the mediation effect of 
comorbidity between age and survival among metastatic breast cancer patients. 
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Furthermore, we created hypertension augmented Charslon comorbidity score (hCCS) 
adding hypertension as a comorbid condition to the Charlson comorbid index, examined 
the prognostic effect on survival, and compared the magnitude to which survival disparity 
between younger and older group may be explained by hCCS relative to CCS or 
hypertension alone.   
6.3 POPULATIONS AND METHOD 
6.3.1 Patients Selection 
The study included 553 patients with the first breast cancer metastasis seen at two urban 
hospitals (Montefiore and Magee) of the University of Pittsburgh Medical Center 
(UPMC) and by the University of Pittsburgh Cancer Institute (UPCI) Breast Cancer 
Program physicians. Patients with metastatic breast cancer were identified from daily 
hospital clinic lists and confirmed with medical records through clinical, radiological, or 
pathologic exams. Inclusion criteria included female patients aged eighteen or older with 
metastatic breast cancer diagnosed between January 1, 1999 and June 30, 2008. Of 671 
patients diagnosed with metastatic breast cancer during this period, 114 patients were 
excluded because their medical records were unavailable for the secondary review. 
Additionally, 4 patients were excluded because they did not have history of clinic follow-
up (i.e., missing information for treatment) prior to the first treatment or until study end 
point. This study was approved by the University of Pittsburgh Institutional Review 
Board. 
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6.3.2 Data Collection 
The medical record abstraction protocol was developed (Figure 13). Retrospective review 
of medical records according to study protocol was utilized. The chart abstraction form 
was summarized monthly by trained registered nurses. The primary data sources for 
abstraction were hand written medical records, usually completed at the monthly patient 
visit. 
Age, race, estrogen receptor (ER) and/or progesterone receptor (PR) status, 
human epidermal growth factor receptor-2 (HER2) status, number of metastatic sites and 
metastatic location were assessed using the chart abstraction form completed by primary 
reviewer. Quality guaranteed protocol for the secondary chart review was established. 
The weighted kappa coefficients of secondary chart abstraction with n = 23, and of 
repeated chart abstraction with n = 23 for Charlson comorbidity score were 0.88 (95% CI 
0.64-1.00) and 0.88 (95% CI 0.66-1.00), respectively; secondary and repeated chart 
abstraction for hypertension were 0.93 (95% CI 0.79-1.00) and 1.00 (95% CI 1.00-1.00), 
respectively.  
Secondary chart retrieval procedure was performed to evaluate marital status, 
socioeconomic status (SES) including insurance, education, residential zip code, BMI at 
breast cancer diagnosis and at study entry, weight change (difference weight between at 
metastasis and weight at breast cancer diagnosis), menopausal status, delays in treatment 
for breast cancer metastasis, and comorbidities according to the protocol. All predictor 
variables were measured at the time of metastatic breast cancer diagnosis. 
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Variables with more than 40% missing data such as marital status, insurance, BMI 
at breast cancer diagnosis and weight change were excluded for purposes of the analysis. 
Missing data imputation procedure was accomplished on education, median household 
income, BMI (at study entry), menopausal status and hypertension having missing values 
ranged 5% to 35% (hypertension 5%, menopause 11%, education 13%, BMI 20%, 
income 35%). 
6.3.3 Predictor variables 
Demographic or socioeconomic variables included age, race, education, median 
household income, BMI, and menopausal status. The median household income was 
linked to residential zip code matched to U.S. 2000 census summary file 3.103 The BMI 
was calculated as a weight in kilogram (kg) divided by a height in meters squared and 
classified into four groups: less than 20kg/m2 (underweight), 20-24.9kg/m2 (normal), 25-
29.9kg/m2 (overweight), 30kg/m2 or higher (obese).  
Pathological factors that were selected for analysis included ER/PR status, HER2 
status, number of metastatic sites, and metastatic location. Determination of ER/PR and 
HER2 status used the pathologic report following the first metastatic site biopsy, if 
available, and the initial breast cancer site biopsy, otherwise. Metastatic locations were 
categorized into four groups: brain, bone, liver, and other.  Lung, adrenal gland, lymph 
node, soft tissue and other visceral sites were combined in other group due to a small 
sample size or non significant effect on survival according to univariate and multivariate 
analysis. 
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Treatment delay was defined as the time in days between the date of initial breast 
cancer metastasis and the date of the initiation of first treatment. The date of first 
treatment initiation was considered as the date of the start of first treatment obtained from 
paper-version medical records. Treatment types included systematic therapy such as 
chemotherapy, hormonal therapy, immunologic therapy, vaccine therapy, and other 
biologic therapy. Treatment delay interval was categorized into 3 groups: less than or 
equal to 4 weeks, more than 4 weeks to less than or equal to 12 weeks, and more than 12 
weeks. 
Comorbidity variables included hypertension, Charlson comorbidity conditions, 
Charlson comorbidity score, and hypertension augmented Charlson comorbidity score. 
The comorbidity conditions were assessed from medical records at the time of metastasis 
including the previous history. Hypertension was defined as a blood pressure greater than 
or equal to 140 mmHg systolic pressure or greater than or equal to 90 mmHg diastolic 
pressure (American Heart Association) 104, at least twice presented at different visits. 
Hypertension included controlled hypertension. The Charlson comorbidity score (CCS), a 
composite of 19 comorbidity conditions was constructed using 18 comorbidity conditions 
(without metastatic solid tumor) which were weighted by 1 point for 10 conditions, 2 
points for 6 conditions, 3 points for 1 condition and 6 points for 1 condition.58, 105 We 
used Deyo’s clinical comorbidity index which adapted the Charlson comorbidity index 
for research relying on International Classification of Diseases (ICD-9-CM) codes.105 The 
sum of the weighted comorbidity conditions has a theoretical range between 0 and 31. 
Charlson comorbidity score did not add the age-comorbidity combined risk score for the 
purposes of analyses. Hypertension-augmented Charlson comorbidity score (hCCS) was 
  86
constructed by assigning the weight of 1 point to hypertension and adding to the CCS 
(Table 12).28 The difference between CCS and hCCS was that hCCS included 
hypertension by 1 point with CCS conditions. 
6.3.4 Outcome variable 
The outcome variable was an overall survival in months (defined as interval between 
metastatic breast cancer diagnosis and death or study end point). The study ascertained 
the occurrence of death in two ways. For in-hospital deaths, the hospital record was 
reviewed. For out of hospital deaths, the data were confirmed utilizing U.S. social 
security death index. Analyses censored all followed on June 30, 2008. 
6.3.5 Statistical analysis 
Simple imputation procedure for missing data used SPSS implementation of the 
Expectation Maximization (EM) algorithm of Dempster, Laird and Rubin (1977).106 The 
frequency distribution of complete data of variables which were imputed was compared 
to the available data of corresponding variables prior to imputation using appropriate two 
sample t-tests for continuous variables and chi-squared statistics for categorical variables. 
Multicollinearity was assessed by using coefficient of multiple determination (R2), 
tolerance, and variance-inflation factor (VIF) for each predictor variable using remaining 
covariates as its predictors. 
Wilcoxon rank sum test and chi-squared statistics were used to identify 
statistically significant differences between younger and older group for continuous and 
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categorical variables, respectively. Log rank test was conducted to evaluate the 
relationship between predictor variables and survival. Kaplan-Meier estimation was used 
to generate survival curve for age variable. Odds ratios (ORs) and 95% confidence 
interval (95% CI) of younger vs. older group were obtained from binary logistic 
regression for hypertension, and ordinal logistic regression (assuming proportional odds) 
for CCS, and hCCS. Cox proportional hazards regression model was performed for 
univariate and multivariate analysis for categorical predictor variables (age and 
comorbidity variables), and both categorical and continuous covariates to produce hazard 
ratios (HRs) and 95% confidence interval (95% CI). A similar modeling approach was 
also applied using accelerated, failure-time model assuming a Weibull error 
distribution.107 
To assess the comorbidity variables (hypertension, CCS, and hCCS) as a mediator 
of age-survival relationship, we applied two approaches: 1) Baron Kenny approach 117-120, 
and 2) alternative assessment to compute the percentage change in the HRs.59, 117, 120-126 
The formal analysis to detect the mediation effect proposed by Baron and Kenny, follows 
from the definition of a mediator: Variable M is considered a mediator if (1) X 
(independent variable, i.e., age in this study) significantly predicts Y (outcome of interest, 
i.e., survival in this study), 2) X significantly predicts M, 3) M significantly predicts Y 
controlling for X.117-120 These criteria are assessed by estimating the following equations:  
                              Y = ί1 + cX                            (1) 
                              M= ί2 + aX                            (2) 
                              Y = ί3 + c’X + bM                (3) 
where ί is an intercept coefficient.118, 119 
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An additional approach for assessing the extent to which comorbidity variables 
explain the young-old group difference on survival is to compare a model that include all 
covariates and age with a model that include all covariates and age and comorbidity 
variables, and examine percentage changes in the HRs for the age-survival relationship. 
The percentage change in the HRs was computed as: 
((HRwithout comorbidity – HRcomorbidity) / (HRwithout comorbidity-1.0)) X 100 
where HRcomorbidity denotes the HR for the effect of age on survival after adjustment of 
comorbidity.59, 117, 120-126  
Two tailed p-value of less than 0.05 was considered significant. SAS (version 9.2) 
and SPSS (version 17.0) were used. 
6.4 RESULTS 
Analysis included 553 patients with metastatic breast cancer diagnosed between January 
1, 1999 and June 30, 2008. The median survival was 40 months (range 1-114 months), 
with 265 (47.9%) women having survived and 288 (52.1%) having died. Of the 553 
patients included in the analysis, the majority of patients were non-black (93.5%), post 
menopausal (74.9%), Charlson comorbidity condition-free (79.4%), ER/PR positive 
(73.1%), HER2 negative (65.5%), and had metastasis at only one site (61.5%). The 
median household income was $41,190 (range $18,473-$85,102) and 283 (51.2%) 
patients had more than high school education. Most patients (73.1%) were overweight (n 
= 253, 45.8%) or obese (n = 151, 27.3%), while other patients were of normal weight or 
underweight group (n = 149, 26.9%). The median treatment delay interval was 13 days 
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(25 percentile 0 day and 75 percentile 32 days). Half of the patients (n = 237, 42.9%) had 
hypertension, and 114 (20.6%) patients had one or more of Charlson comorbidity 
conditions. Bone, liver, and brain metastasis were diagnosed in 298 (53.9%), 116 (21.0%), 
and 34 (6.1%) patients, respectively.  
The distributions of patient characteristics by age group (≤ 51 years vs. > 51 
years) are displayed in Table 13. The median age was 55 years (range 26-88 years) and 
107 patients in the younger group (≤ 51 years) relative to 181 patients in older group (> 
51 years) died. Patients of > 51 years were more likely to have lower income level (P = 
0.0007), less than or equal to high school education (P < 0.0001), and present with post 
menopausal (P < 0.0001) and HER2 negative (P = 0.018) status compared to patients of ≤ 
51 years. Hypertension (P < 0.0001) and more than or equal to one score of hCCS (P < 
0.0001) were more likely to be found in older group. 
6.4.1 Univariate analysis 
Patients with metastatic breast cancer had significantly unfavorable outcomes when they 
were in the older group (P = 0.008) (Figure 14), having less than or equal to high school 
education (P = 0.0495), hypertension (P = 0.0001), one or two score of hCCS (0 vs. 1, P 
= 0.001; 0 vs. 2, P = 0.011), ER/PR negative (P = 0.002), and HER2 negative (P = 0.047). 
In addition, patients diagnosed with greater number of metastatic sites (P < 0.0001), brain 
metastasis (P = 0.014) or liver metastasis (P = 0.006) had significantly worse prognoses. 
The CCS (P = 0.067) for one unit increase and the normal body weight group (P = 0.069) 
compared to the underweight group had a marginal negative effect on survival (data not 
shown). 
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6.4.2 Comorbidity variables (hypertension, CCS, and hCCS) and age 
Multivariate logistic regression was conducted for the relationship between age and three 
comorbidity variables (Table 14). Patients aged > 51 years were more than four times as 
likely as patients aged ≤ 51 years to have hypertension (OR 4.66, 95% CI 3.11-6.99). 
Older patients ( > 51 years) had 2.58 times the odds of one or more CCS relative to zero 
CCS, two or more CCS relative to zero or one CCS, and three or more CCS relative to 
zero, one, or two CCS (OR 2.59, 95% CI 1.58-4.24) compared to younger patients ( ≤ 51 
years); the odds of older patients was about four times higher to have hCCS (1+ vs. 0; 2+ 
vs. 0, 1; 3+ vs. 0, 1, 2) than younger patients (OR 3.94, 95% CI 2.73-5.69). 
6.4.3 Comorbidity variables and outcome of interest 
Table 15 showed results for Cox regression analysis of three comorbidity variables on 
survival. In multivariate analysis, hypertension was found to be a significant prognostic 
factor (HR 1.45, 95% CI 1.12-1.89). The hCCS of one or two score was associated with 
survival compared to the zero score of hCCS (1 vs. 0, HR 1.40, 95% CI 1.07-1.83; 2 vs. 0, 
HR 1.88, 95% CI 1.22-2.89). The each score of CCS was not significantly related to 
survival using the zero score of CCS as a referent group in multivariate analysis. There 
were no significant interaction terms between age and each comorbidity variable on 
survival, suggesting that the relationship between age and survival was not modified by 
comorbidity. Additionally, the terms for the interaction among age, HER2 and each 
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comorbidity variable were not significant, indicating that the effect of each comorbidity 
variable on survival in HER2 positive and in HER2 negative status was not modified by 
age group.  
6.4.4 Comorbidity variables explaining the age-survival relationship 
Comparing a model that included all covariates and age on survival with a model that 
included all covariates and age and each comorbidity variables, introduction of 
hypertension, CCS, and hCCS into a model that included covariates and age, reduced the 
HR of age on survival by 40%, 14%, and 44%, respectively (Table 16). Furthermore, the 
effect of age on survival was no longer significant after adjustment of hypertension (HR 
1.26, 95% CI 0.97-1.65) or hCCS (HR 1.24, 95% CI 0.95-1.63), suggesting that 
hypertension and hCCS strongly mediate the age-survival relationship.117, 118 When using 
accelerated failure-time models assuming a Weibull distribution 107, results were 
comparable to those in multivariate analysis using Cox regression models (data not 
shown). The menopausal status was excluded for adjustment in multivariate model 
because its collinearity with age on survival and it’s standing in the causal pathway 
between age and survival, the association of age and survival can be underestimated. 
6.5 DISCUSSION 
The present study was a hospital clinic-based study evaluating the role of comorbidity as 
a mediator of survival disparity between younger and older group and comparing the 
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magnitudes to which each comorbidity variable (hypertension, CCS, and hCCS) mediated 
the age-survival relationship. To our knowledge, this is the first study to assess the role of 
comorbidity as a mediator between age and survival among metastatic breast cancer 
patients. Furthermore, we added hypertension as a comorbid condition to the Charlson 
comorbid index, creating hypertension augmented Charlson comorbidity score (hCCS) 
and compared the extent to which hCCS explained the poor survival of older than 
younger group, relative to other comorbidity variables (hypertension, and CCS).  
The study found that hypertension/hCCS was a strong predictor of survival 
following breast cancer metastasis, and hCCS was better than CCS (14%) or 
hypertension alone (40%) to explain disparity between the younger and older group in 
survival by 44% after accounting for all covariates. Moreover, hypertension and hCCS 
were found to be a strong mediator because the effect of age on survival was not 
significant after adjustment of hypertension or hCCS (Table 16).117, 118 
 Consistently with previous studies 8, 12, 44, 49, 65, our study found that older age (> 
51 years) had an adverse impact on survival than younger group (≤ 51 years). 
Specifically, Largillier et al reported that excess mortality rate increased with patients 
more than 50 years relative to patients of less than 50 years in stage IV breast cancer.8 
Several studies showed that younger patients had better survival than older patients 8, 12, 
46-49, and this difference in survival between age groups does not seem to be the result of 
the difference of treatment, but suggests the influence of age-related factors such as 
comorbid conditions which place the older group at greater risk of poor prognosis on the 
course of metastatic disease.46 
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In agreement with previous studies 47, 48, 56, 96, the current study found that 
comorbid conditions increased with age (hypertension, OR 4.66, 95% CI 3.11-6.99; CCS, 
OR 2.59, 95% CI 1.58-4.24; hCCS, OR 3.94, 95% CI 2.73-5.69). Hypertension was the 
most prevalent comorbid condition among breast cancer patients 47, 48, 50, 53, 56, 96, 98, and 
was more likely to be found in older patient group.56 Hypertension can potentially be an 
important risk factor for cancer morbidity and mortality. For example, cell death by 
apoptosis can influence the growth of vascular smooth muscle cells (VSMCs) and the 
increased proliferation of VSMCs responds exaggeratedly to growth stimuli, which is 
characterized by shortening of the cell cycle. This mechanism may lead to increased 
cellular proliferation.57  
We observed an association between hypertension and survival after diagnosis of 
metastatic breast cancer even after adjustments of age and other covariates (Table 15), 
corroborating previous literature.28 
Our chart abstraction procedure detected Charlson comorbidity in 21% of cases 
which is in concordance with other studies.26, 49, 52, 95 In this study, we found that 
Charlson comorbidity score (CCS) for one unit increase had a marginal adverse effect on 
survival in univariate analysis, but was not significant after accounting for age and other 
covariates in consistent with another study.47 Additionally, CCS by itself was not a strong 
mediator of age-survival relationship, however, hCCS, combining hypertension with CCS 
explained the survival disparity between younger and older age group by 44% relative to 
14% of CCS and 40% of hypertension alone, indicating that hCCS was a better than CCS 
or hypertension to describe the age-survival relationship.  
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Standard Charlson list of comorbidities excludes hypertension. Based on the study 
results, we recommend that future studies of clinical predictors of survival after breast 
cancer metastasis should not rely only on Charlson comorbidities, but also include, at 
minimum, a hypertension. 
This study had limitations. We did not consider specific treatment regimens in the 
analysis, as study population was heterogeneous with respect to treatment regimen. 
However, it is reasonable to assume that treatments were selected in accordance with 
acceptable criteria and were carried out by competent physicians at this university 
affiliated, National Cancer Institute (NCI) designated site. 
The study did not include 114 patients because medical records were unavailable 
for the secondary review, which could induce the possible sources of selection bias. 
Exclusion of patients whose charts were not found from the analysis did not appear to 
make significantly different changes in study results in terms of analyses of age, race, 
number of metastatic sites, metastatic location, ER/PR status and HER2 status (data not 
shown). 
We performed sensitivity test using available data of variables prior to imputation 
procedure compared to complete data of corresponding variables which were imputed, 
and there was no apparent difference in the frequency distribution and in the univariate 
analysis. In addition, our study findings were fairly robust since similar results using 
semi-parametric, Cox regression and parametric, accelerated failure-time models were 
obtained (data not shown). 
Our data collection procedure extracted comorbidity information from multiple 
medical record sources (Figure 13), including clinic intake forms, progress notes, 
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laboratory results, and physician summaries. Medical record documentation was not 
strictly uniform over the period of time (January 1, 1999 through June 30, 2008) covering 
first diagnosis of metastatic breast cancer. For example, medical records for women with 
breast cancer metastasis diagnosed during an early time period were missing a clinic 
intake form more frequently than medical records for women diagnosed during a later 
time period (data not shown). This type of calendar time-related variability in medical 
record completeness or quality may have introduced a systemic error leading to 1) the 
underestimation of Charlson comorbidity during early time periods and 2) the failure to 
detect association between Charlson comorbidity and survival because of concurrent 
improvements in the effectiveness of medical treatment for metastatic breast cancer. In 
our study, however, Charlson comorbidity score values were independent of the year of 
first diagnosis of metastatic breast cancer (data not shown). Assuming similarly ill 
women were diagnosed with metastatic breast cancer in earlier and later time periods, this 
result suggests that variable medical record quality did not adversely affect our results 
associating the Charlson comorbidity measurements with survival. 
In conclusion, this is the first study, to our knowledge, to assess the role of 
comorbidity as a mediator of the age-survival relationship among patients with metastatic 
breast cancer. Moreover, we created hCCS variable combining Charlson comorbidity 
score with hypertension and compared the extent to which survival difference between 
younger and older age group may be explained by hCCS relative to other comorbidity 
variables (hypertension, and CCS). The study demonstrated that hypertension/hCCS was 
a prognostic factor on survival following metastasis, and hCCS explained better than 
hypertension or CCS for age-survival relationship. Additionally, hypertension and hCCS 
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were found to be a strong mediator of the relationship between age and survival among 
patients with breast cancer metastasis. 
Utilizing a large database reflective of current metastatic breast cancer treatment, 
this study employed a uniform protocol for data collection and examined prognostic 
factors in a comprehensive fashion. Findings of this study suggest that hypertension 
should be included in the comorbidity information for decision making support programs 
to aid in the consultation for patient care, and physicians should balance the benefit of 
anti-cancer treatment against current health condition and the possible decrease of quality 
of life that may occur during cancer treatment. 
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6.7 TABLES AND FIGURES 
 
Table 12. Comorbidity conditions utilized for the construction of CCS and hCCS at the UPMC, 
UPCI Breast Cancer Program 
  
Comorbidity conditions 
Assigned 
weight 
Myocardial infarct 1 
Congestive heart failure 1 
Peripheral vascular disease 1 
Cerebrovascular disease 1 
Dementia 1 
Chronic pulmonary disease 1 
Connective tissue disease 1 
Ulcer disease 1 
Mild liver disease 1 
Diabetes 1 
Hemiplegia 2 
Moderate or severe renal disease 2 
Diabetes with end organ damage 2 
Any tumor 2 
Leukemia 2 
Lymphoma 2 
Moderate or severe liver disease 3 
Charlson comorbidity condition 58 
AIDS 6 
Non-Charlson comorbidity 
condition 
Hypertension 1 
Abbreviation: CCS, Charlson comorbidity score; hCCS, hypertension augmented 
Charlson comorbidity score. 
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Table 13. Characteristics of patients with metastatic breast cancer by age (≤51 years, >51 years), 
identified at two sites of the UPMC, UPCI Breast Cancer Program 
≤ 51 years  
(n = 223) 
> 51 years  
(n = 330) 
 
 
Variable* No. (%) No. (%) 
Median Household income  
(range $18,473-$85,102), Median** 
$42,136.1 $40,680.3 
Race 
Non-Black 213 (41.2) 304 (58.8) 
Black 10 (27.8) 26 (72.2) 
Education** 
≤High School 81 (30.0) 189 (70.0) 
> High School 142 (50.2) 141 (49.8) 
BMI 
<20 kg/m2 16 (51.6) 15 (48.4) 
20-24.9 kg/m2 57 (48.3) 61 (51.7) 
25-29.9 kg/m2 94 (37.2) 159 (62.8) 
≥30 kg/m2 56 (37.1) 95 (62.9) 
Menopausal status** 
Pre menopause 134 (96.4) 5 (3.6) 
Post menopause 89 (21.5) 325 (78.5) 
ER/PR status 
ER/PR positive 159 (39.4) 245 (60.6) 
ER/PR negative 64 (42.9) 85 (57.1) 
HER2 status** 
HER2 positive 90 (47.1) 101 (52.9) 
HER2 negative 133 (36.7) 229 (63.3) 
Number of metastatic sites 
1 130 (38.2) 210 (61.8) 
2+ 93 (43.7) 120 (56.3) 
Metastatic location 
Brain 
No 204 (39.3) 315 (60.7) 
Yes 19 (55.9) 15 (44.1) 
Bone 
No 102 (40.0) 153 (60.0) 
Yes 121 (40.6) 177 (59.4) 
Liver 
No 170 (38.9) 267 (61.1) 
Yes 53 (45.7) 63 (54.3) 
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Table 13 (Continued) 
≤ 51 years  
(n = 223) 
> 51 years  
(n = 330) 
 
 
Variable* No. (%) No. (%) 
Other 
No 92 (37.5) 153 (62.5) 
Yes 131 (42.5) 177 (57.5) 
Charlson Comorbidity Condition 
Congestive heart failure** 
No 222 (41.1) 318 (58.9) 
Yes 1 (7.7) 12 (92.3) 
Chronic pulmonary disease 
No 217 (40.9) 313 (59.1) 
Yes 6 (26.1) 17 (73.9) 
Mild liver disease 
No 215 (40.6) 314 (59.4) 
Yes 8 (33.3) 16 (66.7) 
Diabetes** 
No 219 (42.4) 297 (57.6) 
Yes 4 (10.8) 33 (89.2) 
Treatment delay 
≤4 week 159 (40.8) 231 (59.2) 
4–12 week 55 (42.6) 74 (57.4) 
>12 week 9 (26.5) 25 (73.5) 
CCS 
0 197 (44.9) 242 (55.1) 
1 18 (22.5) 62 (77.5) 
2 7 (24.1) 22 (75.9) 
3+ 1 (20.0) 4 (80.0) 
hCCS** 
0 155 (56.8) 118 (43.2) 
1 58 (29.3) 140 (70.7) 
2 7 (12.1) 51 (87.9) 
3+ 3 (12.5) 21 (87.5) 
Hypertension** 
No 176 (55.7) 140 (44.3) 
Yes 47 (19.8) 190 (80.2) 
Abbreviation: BMI, body mass index; ER/PR, estrogen receptor and/or progesterone 
receptor; HER2, human epidermal growth factor receptor-2; CCS, Charlson comorbidity 
score; hCCS, hypertension augmented Charlson comorbidity score. 
* Variables with < 1% of frequency were excluded from analysis. 
** P < 0.05. 
 
 
  103
Table 14. Logistic regression odds ratios of age (≤51years vs. >51 years) predicting comorbidity 
variables (hypertension, CCS, and hCCS) among patients with metastatic breast cancer, identified at 
two sites of the UPMC, UPCI Breast Cancer Program 
≤51 years 
(n = 223) 
>51 years 
(n = 330) 
  
 
Outcome variable Odds ratio 95% CI Odds 
ratio† 
95% CI P-value 
Hypertension* 1.00 referent 4.66 3.11-6.99 <0.0001 
CCS** 1.00 referent 2.59 1.58-4.24 0.0002 
hCCS*** 1.00 referent 3.94 2.73-5.69 <0.0001 
Abbreviation: 95% CI, 95% Confidence Interval; CCS, Charlson comorbidity score; 
hCCS, hypertension augmented Charlson comorbidity score. 
† Multivariate regression was adjusted by covariates (race, education, treatment delay, 
ER/PR status, HER2 status, number of metastatic sites, brain, bone, and liver metastasis); 
further adjustment including BMI did not significantly change the estimates. 
* Hypertension was dichotomous (no vs. yes) as an outcome variable. 
** CCS (0 vs. 1 vs. 2 vs. 3+) was analyzed as an outcome variable using ordinal logistic 
regression. 
*** hCCS (0 vs. 1 vs. 2 vs. 3+) was analyzed as an outcome variable using ordinal 
logistic regression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  104
Table 15. Cox regression analysis between comorbidity (hypertension, CCS, and hCCS) and survival 
among patients with metastatic breast cancer, identified at two sites of the UPMC, UPCI Breast 
Cancer Program 
Variable No. (%) Hazard ratio* 95% CI P-value 
Hypertension  
No 316 (57.1) 1.00 referent  
Yes 237 (42.9) 1.45 1.12-1.89 0.005 
CCS 0.283† 
0 439 (79.4) 1.00 referent  
1 80 (14.5) 1.35 0.96-1.91 0.088 
2 29 (5.2) 1.34 0.80-2.25 0.266 
3+ 5 (0.9) 0.88 0.21-3.66 0.862 
hCCS 0.013† 
0 273 (49.4) 1.00 referent  
1 198 (35.8) 1.40 1.07-1.83 0.015 
2 58 (10.5) 1.88 1.22-2.89 0.004 
3+ 24 (4.3) 1.42 0.78-2.56 0.248 
Abbreviation: 95% CI, 95% Confidence Interval; CCS, Charlson comorbidity score; 
hCCS, hypertension augmented Charlson comorbidity score. 
* Multivariate regression was adjusted by age and other covariates (race, education, 
treatment delay, ER/PR status, HER2 status, number of metastatic sites, brain, bone, and 
liver metastasis); further adjustment including BMI did not significantly change the 
estimates. 
† P-value for omnibus test. 
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Table 16. Comorbidity (hypertension, CCS, and hCCS) as a mediator of the relationship between age 
and survival among patients with metastatic breast cancer, identified at two sites of the UPMC, 
UPCI Breast Cancer Program 
Variable Hazard ratio 95% CI P-value 
Hypertension 
Hazard ratio for age on survival adjusted by covariates* 1.43 1.11-1.84 0.005 
Hazard ratio for age on survival adjusted by hypertension and covariates* 1.26 0.97-1.65 0.086 
Proportion explained by hypertension for the effect of age on survival 40% 
CCS 
Hazard ratio for age on survival adjusted by covariates* 1.43 1.11-1.84 0.005 
Hazard ratio for age on survival adjusted by CCS and covariates* 1.37 1.06-1.77 0.016 
Proportion explained by CCS for the effect of age on survival 14% 
hCCS 
Hazard ratio for age on survival adjusted by covariates* 1.43 1.11-1.84 0.005 
Hazard ratio for age on survival adjusted by hCCS and covariates* 1.24 0.95-1.63 0.110 
Proportion explained by hCCS for the effect of age on survival 44% 
Abbreviation: 95% CI, 95% Confidence Interval; CCS, Charlson comorbidity score; 
hCCS, hypertension augmented Charlson comorbidity score. 
* Multivariate regression was adjusted by covariates (race, education, treatment delay, 
ER/PR status, HER2 status, number of metastatic sites, brain, bone, and liver metastasis); 
further adjustment including BMI did not significantly change the estimates. 
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Figure 13. Medical record abstraction procedure 
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Figure 14. Kaplan-Meier’s curve of survival by age in patients with metastatic breast cancer 
identified at two sites of the UPMC, UPCI Breast Cancer Program 
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7.0  GENERAL DISCUSSION 
Breast cancer is the most common cancer and the second leading cause of cancer 
mortality in women in the United States.1 Distant metastasis of breast cancer is found 
among 7% of women with initial breast cancer diagnosis. Most of these women have 
poor survival outcomes.7, 101  
 Metastatic breast cancer patients represent a heterogeneous population with a 
varied clinical course, and different clinical outcomes underline the need for accurate 
prediction of survival based on prognostic factors. Many studies have considered 
individual risk factors, one at a time, but few studies have considered a comprehensive 
range of risk factors collectively. 
Delay in receiving treatment for breast cancer may result in adverse prognostic 
outcomes among breast cancer patients. Epidemiologic studies examining the effect of 
treatment delay on survival after breast cancer diagnosis have yielded inconsistent results. 
For example, Gorin et al conducted a population based study with SEER database 
enrolling Medicare recipients 65 years and older women in breast cancer. Investigators 
observed that a delay of more than three months had less favorable outcomes than less 
than or equal to three months.33 This contrasts with the findings of Charlson et al who 
investigated a hospital based retrospective study using 685 women diagnosed with breast 
cancer at Yale-New Haven Hospital, demonstrating that there were no significant 
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differences in survival with treatment delay less than three months vs. 3-6 months vs. 
more than six months of delays.39 
The 5-year relative survival rate is remarkably higher among women diagnosed 
with breast cancer before age 50 compared to women diagnosed at ages 50 and older.44 
The higher prevalence of comorbid conditions in older women may influence their 
treatment options and survival 26, 47, 49, 55, 56, 96, but the role of comorbidity as a mediator 
which may explain the poorer survival in older women than younger women has not been 
clearly documented. 
This study was designed to undertake the investigation of factors influencing 
survival following metastastic breast cancer diagnosis, to examine relationship between 
treatment delay and survival, and to evaluate the role of comorbidity as a mediator of 
age-survival relationship in women with metastatic breast cancer. 
 In this study, we investigated the effect of predictor variables on survival from the 
time of diagnosis of metastatic breast cancer: outcome of interest was overall survival 
(i.e., all causes of death). There is a need to analyze the effect of predictor variables on 
specific outcomes of interest by measuring breast cancer specific survival or evaluating 
competing cause survival (non-breast cancer cause) as an outcome of interest, and by 
assessing quality of life as an outcome variable.  
In study aim 3, we applied Baron-Kenny approach to assess the role of 
comorbidity as a mediator of age-survival relationship. Baron-Kenny approach is 
considered a traditional method to evaluate mediation between indicator and outcome of 
interest, but this approach tends to miss a true mediation effect (Type II error), or lead to 
erroneously present mediation effect (Type I error) suffering from low statistical 
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power.120 One of the statistically rigorous methods by which mediation hypotheses may 
be assessed is bootstrapping method which provides a direct significant test of the 
mediation effect.127, 128 The bootstrapping approach (i.e., bootstrapping the sampling 
distribution of indirect effect) derives a confidence interval with effect size estimation of 
mediation effect in a wide variety of situations. This method does not require many 
assumptions as other tests, which is likely to make test findings more accurate than 
traditional mediation analysis. 119, 120 
 Additionally, we evaluated comorbidity at the time of diagnosis of metastasis to 
assess this effect on survival following metastatic breast cancer, and to investigate this 
effect as a mediator between age and survival. More studies are needed to fully 
understand these associations by measuring comorbidity variables as time-varying 
covariates (i.e., comorbidity acquired after metastasis). We used comorbidity variable 
with the summary measures (i.e., Charlson comorbidity score) in the study analysis to 
assess this variable as a mediator of age-survival relationship; evaluating individual 
comorbid conditions such as diabetes, CHF, and CVD in the causal pathway between age 
and survival could extend knowledge explaining the different clinic outcomes between 
younger and older women with metastatic breast cancer, focusing on the role of specific 
co-morbid conditions. 
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7.1 ARTICLE 1: FACTORS ASSOCIATED WITH MORTALITY AFTER 
BREAST CANCER METASTASIS 
In the study, we used a hospital clinic-based study evaluating factors such as 
demographic or socioeconomic, clinical, and pathological factors related to survival 
following metastatic breast cancer diagnosis among 557 women. We found that most 
relevant factors on survival were ER or PR status (HR 1.84, 95% CI 1.40-2.41), HER2 
status (HR 1.45, 95% CI 1.09-1.93), hypertension (HR 1.53, 95% CI 1.14-2.07), and 
number of metastatic sites (HR 1.27, 95% CI 1.01-1.59). Our findings are similar to the 
previous study results reporting that ER or PR negative, HER2 negative had worse 
impact on survival, and demonstrating the significant associations between hypertension, 
or more than one organ site affected by metastasis, and survival. 7-11, 64, 75-81, 84 28 In 
contrast with other published reports 24-30, our study did not observe a significant 
association between comorbidity and survival. The comparability of our study result with 
other studies is limited due to the methodological limitation in our study: the variability 
in medical record completeness (i.e., lack of clinic intake form). Even though more 
medical records in women diagnosed in early time period lacked the clinic intake form 
than those in women diagnosed during a later time period, Charlson comorbidity score 
was independent of the year of diagnosis of metastasis, indicating that the variable 
medical record quality did not affect negatively our study results related to the 
assessment of Charlson comorbidity score with survival. 
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7.2 ARTICLE 2: THE EFFECT OF DELAYS IN TREATMENT FOR BREAST 
CANCER METASTASIS ON SURVIVAL 
In this study, we measured survival in two ways: interval between metastatic breast 
cancer diagnosis and death or study end point, and interval from the date of the first 
treatment to the date of death or the end of follow-up period. We assessed the relationship 
between treatment delay and survival measured after diagnosis of metastasis of breast 
cancer, and after first treatment. We eliminated immortal time effect by measuring 
observation time on date of first treatment and reduced lead time bias by excluding 
women with very long treatment (>24 weeks) delay from the group of women exposed to 
treatment delay (>12 weeks). This exclusion may limit, but not completely eliminate, 
lead time bias as a source of concern. Before making strong etiologic conclusions about 
the effects of treatment delay on metastatic breast cancer outcomes, we looked for a 
consistent pattern of association, across all these analyses.  
We found that delays more than 12 weeks in receiving treatment for metastatic 
breast cancer resulted in adverse survival outcomes after first treatment: compared to 4-
12 weeks, delays of > 12 weeks had a negative effect on survival and furthermore, 
patients with delays of 12-24 weeks had worse survival than those with delays of 4-12 
weeks. This study provided the first results of exploring the relationship between delays 
in treatment and survival among metastatic breast cancer patients by accounting for 
metastatic locations and number of organ sites affected by metastasis. 
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7.3 ARTICLE 3: COMORBIDITY AS A POTENTIAL MEDIATOR OF 
SURVIVAL DISPARITY BETWEEN YOUNGER AND OLDER WOMEN 
DIAGNOSED WITH METASTATIC BREAST CANCER 
In this study, we assessed the role of each comorbidity variable including hypertension, 
Charlson comorbidity score (CCS), and hypertension augmented Charlson comorbidity 
score (hCCS) as a mediator which may explain survival difference (disparity) between 
older and younger women with metastatic breast cancer. To evaluate the comorbidity as a 
mediator of the age-survival relationship, we employed two approaches: 1) Baron Kenny 
approach and 2) alternative assessment to measure the amount to which comorbidity 
explains the age-survival relationship by computing the percentage change in the hazard 
ratios (i.e, indirect effect of comorbidity variable among total effect of age on survival, 
(c-c’)/c). The computation of the result ((c-c’)/c) using Cox regression model was 
comparable to the computation of the result using accelerated, failure-time model. 
The study demonstrated 1) older patients had worse survival than younger 
patients, 2) hypertension or hCCS was related to survival since metastasis, and 3) hCCS 
explained the poorer survival of older than younger women by 44%, compared to 40% of 
hypertension, and 14% of CCS. Furthermore, hypertension and hCCS were found to be 
strong mediators between age and survival following metastasis.  
As of December 2010, Charlson list of comorbidities does not include 
hypertension. The study findings suggest that future studies of clinical predictors of 
survival after metastatic breast cancer diagnosis should not rely only on Charlson 
comorbidities, but also include, at minimum, a history of hypertension. 
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7.4 STUDY STRENGTHS 
We utilized a large clinical database reflecting current metastatic breast cancer treatment 
and treatment patterns for metastasis for up to ten years of follow-up. We employed a 
uniform protocol for data collection, and defined two brand new exposure variables such 
as treatment delay, and co-morbidity including individual and summary measures. We 
evaluated prognostic factors from several domains, including demographic, clinical, and 
pathological factors. 
7.5 STUDY LIMITATIONS 
This study had several limitations. We excluded 114 patients without available paper 
version medical records for the secondary review. Given that excluded patients had lower 
survival than patients included in the study analysis, the possible source of selection bias 
could not be excluded even though the analyses of age, race, number of metastatic sites, 
metastatic location, ER or PR status, and HER2 status on survival were not different 
between excluded and remaining patients in the study.  
 The calendar time-related variability in medical record completeness, resulting in 
missing data ranged up to 35% may have introduced a systemic error to our study 
findings. However, we did sensitivity test by using available data of variables before 
imputation procedure compared to complete data of corresponding variables after 
imputation, and there was no significant difference in the frequency distribution and in 
the results of the univariate analyses. Moreover, we obtained the similar results using 
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Cox regression and accelerated, failure-time models, indicating that our study findings 
are fairly robust. 
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8.0  PUBLIC HEALTH SIGNIFICANCE 
Despite impressive advances of breast cancer treatment strategies, treatment of metastatic 
breast cancer remains palliative. Overall, metastatic breast cancer is a medical outcome 
associated with progressive life limiting illness. However, it is possible to distinguish 
between groups of women with outcomes better and worse than average, based on 
patients’ comorbidities and other prognostic factors. This knowledge creates opportunity 
to tailor treatment approaches according to prognosis.  
We found that hypertension at the time of metastatic breast cancer had an adverse 
impact on survival. Discovering the biologic explanation for the association between 
hypertension and adverse prognosis might provide new prevention or treatment 
opportunities.  
Women who began systemic treatment late (i.e., more than 12 weeks after 
diagnosis of metastatic breast cancer) experienced reduced survival compared to women 
who began treatment early (i.e., 12 or fewer weeks after diagnosis of metastasis). 
Improved treatment outcomes may be achieved by efforts designed to avoid unnecessary 
delays in starting systematic treatment. Additionally, our study findings emphasize the 
need for future study to examine factors related to treatment delays and better 
understanding of these associations may induce the improvement of treatment outcomes. 
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 In addition, older women experience worse survival than younger women. A 
higher prevalence of co-morbid illness may explain a substantial portion of this poor 
survival outcome in older women. Efforts that aim to manage co-morbid illness in older 
women may reduce the survival difference between older and younger women. 
 Finally, these study findings may form a foundation for the growing corpus of 
knowledge explaining the differences in treatment outcomes among patients diagnosed 
metastatic breast cancer, helping to support clinical initiatives that provide emotional and 
physical support for patients in order to ensure appropriate and timely treatment for 
metastatic breast cancer. 
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APPENDIX A 
SUPPLEMENTAL TABLES AND FIGURES FOR SPECIFIC AIM 1 
A.1 SAMPLE SIZE AND POWER ESTIMATION 
We estimated the power by using the formula for the Cox regression model established 
by Hsieh, F.Y. et al and Schoenfeld D.A.129, 130  
The 663 sample size and 0.6 event rate were used to calculate the power of 
evaluating factors related to mortality after breast cancer metastasis based on the MBC 
Study followed till June 30, 2008. 
The power for racial disparity (i.e., black vs. non-black) in mortality after breast 
cancer metastasis was assessed by using 0.25 as a standard deviation (STD) of race, 
0.0029 as a correlation coefficient (R-squared) of race with covariates, and several 
hazards ratios (HRs) ranged from 1.44 to 2.0 based on the upper 95% Confidence Interval 
(95% CI) according to the database of the MBC Study from January 1, 1999 to June 30, 
2008 (Table 17).  
The power for assessing the relationship between age as either continuous or 
binary (>= 55, < 55) variable and mortality outcome, was calculated from 0.5 as a STD of 
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age, 0.008 as a R-squared of age with covariates, and several HRs between 1.23 and 1.5 
according to the upper 95% CI based on the MBC data base (Table 18). 
We assessed the power for evaluating the association between ER/PR status 
(positive vs. non-positive) and mortality after breast cancer metastasis by choosing 0.46 
as a STD of ER/PR status, 0.0054 as a R-squared of ER/PR status with covariates, and 
several HRs ranged from 1.3 to 1.74 using the upper 95% CI (Table 19). 
The power of examining the relationship between HER2 status (positive vs. non-
positive) and mortality outcome was calculated with 0.48 as a STD of HER2 status, 
0.0558 as a R-squared of HER2 status with covariates, and several HRs (1.226 to 1.5) 
based on the upper 95% CI (Table 20). All calculations were conducted with the PASS 
software (NCSS, Kaysville, Utah) with a two sided test, 0.05 Type I error. 
 
 
Table 17. Power calculation for racial disparity (i.e., black vs. non-black) related mortality after 
breast cancer metastasis 
HR Power 
1.44 43.3 % 
1.7 75.2 % 
1.9 89.2 % 
2.0 93.2 % 
Type 1 Error = 0.05 
Event rate = 0.6, R-squared = 0.0029, STD = 0.25 
Sample size = 663 (Black=43, Non-Black=620) 
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Table 18. Power calculation for relationship between age (continuous or binary (>= 55, < 55) 
variable) and mortality 
HR Power 
1.23 54.6 % 
1.3 74.1 % 
1.4 91.6 % 
1.5 98.1 % 
Type 1 Error = 0.05 
Event rate = 0.6, R-squared = 0.008, STD = 0.5 
Sample size = 663 (Black=43, Non-Black=620) 
 
Table 19. Power calculation for association between ER/PR status (positive vs. non-positive) and 
mortality after breast cancer metastasis 
HR Power 
1.3 67.0 % 
1.4 86.8 % 
1.74 99.9 % 
Type 1 Error = 0.05 
Event rate = 0.6, R-squared = 0.0054, STD = 0.46 
Sample size = 663 (Black=43, Non-Black=620) 
 
Table 20. Power calculation of relationship between HER2 status (positive vs. non-positive) and 
mortality 
HR Power 
1.226 47.4 % 
1.4 87.9 % 
1.5 96.5 % 
Type 1 Error = 0.05 
Event rate = 0.6, R-squared = 0.0558, STD = 0.48 
Sample size = 663 (Black=43, Non-Black=620) 
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A.2 SELECTION OF STUDY POPULATION 
MBC data base between Jan 
1, 1999 and June 30, 2008: 
671 patients
557 patients
553 patients
553 patients 539 patients
Excluded 114 patients 
without available paper 
version chart
Excluded 4 patients who 
had missing information 
for treatment
Survival measured from 
first treatment
Survival measured from 
metastatic diagnosis
Excluded 14 patients who 
died or censored before 
first treatment
Aim 1
Aim 2
Aim 3
 
Figure 15. Selections of study population for each aim 
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A.3 MULTICOLLINEARITY 
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Table 21. Assessment of multicollinearity for each independent variable using remaining covariates 
as its predictors 
Coefficientsa 
Unstandardized 
Coefficients 
Standardized 
Coefficients  Collinearity Statistics 
Model  B  Std. Error  Beta  t  Sig.  Tolerance  VIF 
(Constant)  .855 .172   4.974 .000     
ImpIncome  4.712E‐6 .000 .111 2.577 .010  .912 1.096
M1M4  ‐.015 .197 ‐.004 ‐.076 .940  .545 1.836
CHF  .047 .147 .015 .322 .747  .751 1.331
DiabetesMild  ‐.005 .097 ‐.003 ‐.055 .956  .631 1.585
LiverMild  .130 .104 .057 1.253 .211  .831 1.204
COPD  ‐.028 .108 ‐.012 ‐.260 .795  .800 1.249
M1M2M7  .141 .233 .031 .606 .545  .642 1.557
ImpHer2  ‐.028 .043 ‐.028 ‐.641 .522  .883 1.133
Liver  .016 .065 .014 .245 .806  .534 1.873
Bone  ‐.021 .061 ‐.023 ‐.350 .727  .396 2.527
Brain  ‐.011 .110 ‐.006 ‐.104 .917  .536 1.867
ImpER  ‐.031 .046 ‐.029 ‐.671 .502  .908 1.102
MetSite  ‐.008 .037 ‐.015 ‐.210 .834  .348 2.876
Cimpcat4stageIIBMI  ‐.060 .046 ‐.057 ‐1.323 .186  .907 1.102
Black  .113 .085 .059 1.334 .183  .851 1.176
age  ‐.005 .002 ‐.141 ‐2.321 .021  .458 2.185
ImpCharlson_Index  .000 .022 ‐.002 ‐.035 .972  .385 2.595
ImpHypertension  ‐.117 .046 ‐.122 ‐2.541 .011  .737 1.357
Other (Other, Adreanal, 
Lymphnode, Lung, Softtissue) 
‐.068 .070 ‐.072 ‐.977 .329  .309 3.237
1 
Impmeno  ‐.033 .057 ‐.031 ‐.579 .563  .600 1.666
a. Dependent Variable: ImpGths 
 
  124
 
Pearson Correlation Coefficient assessment of collinearity for Charlson comorbidity 
score and four Charlson comorbidity 
 
proc corr data=collinearity;var impcharlson_index chf copd 
livermild diabetesmild;run; 
 
The CORR Procedure 
 
   5  Variables:    ImpCharlson_Index CHF               COPD              LiverMild 
                    DiabetesMild 
 
 
                                       Simple Statistics 
 
 Variable                   N         Mean      Std Dev          Sum      Minimum      
Maximum 
 
 ImpCharlson_Index        557      0.63555      1.41740    354.00000            0      
7.00000 
 CHF                      557      0.02334      0.15111     13.00000            0      
1.00000 
 COPD                     557      0.04129      0.19915     23.00000            0      
1.00000 
 LiverMild                557      0.04309      0.20324     24.00000            0      
1.00000 
 DiabetesMild             557      0.06643      0.24925     37.00000            0      
1.00000 
 
                                       Simple Statistics 
 
                                Variable            Label 
 
                                ImpCharlson_Index 
                                CHF                 CHF 
                                COPD                COPD 
                                LiverMild           LiverMild 
                                DiabetesMild        DiabetesMild 
 
 
                           Pearson Correlation Coefficients, N = 557 
                                   Prob > |r| under H0: Rho=0 
 
                                 Imp 
                           Charlson_                                     Liver      Diabetes 
                               Index           CHF          COPD          Mild          Mild 
 
    ImpCharlson_Index        1.00000       0.42605       0.34651       0.25440       0.53192 
                                            <.0001        <.0001        <.0001        <.0001 
 
    CHF                      0.42605       1.00000       0.08745      -0.03280       0.14977 
    CHF                       <.0001                      0.0391        0.4397        0.0004 
 
    COPD                     0.34651       0.08745       1.00000       0.08927       0.01711 
    COPD                      <.0001        0.0391                      0.0352        0.6870 
 
    LiverMild                0.25440      -0.03280       0.08927       1.00000       0.01441 
    LiverMild                 <.0001        0.4397        0.0352                      0.7344 
 
    DiabetesMild             0.53192       0.14977       0.01711       0.01441       1.00000 
    DiabetesMild              <.0001        0.0004        0.6870        0.7344 
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Assessment of collinearity for Charlson comorbidity score using four Charlson 
comorbidity conditions as its predictors 
 
proc reg;model impcharlson_index=chf copd livermild 
diabetesmild;run; 
The REG Procedure 
                                         Model: MODEL1 
                             Dependent Variable: ImpCharlson_Index 
 
                     Number of Observations Read                        671 
                     Number of Observations Used                        557 
                     Number of Observations with Missing Values         114 
 
 
                                      Analysis of Variance 
 
                                             Sum of           Mean 
         Source                   DF        Squares         Square    F Value    Pr > F 
 
         Model                     4      619.47657      154.86914     171.82    <.0001 
         Error                   552      497.53959        0.90134 
         Corrected Total         556     1117.01616 
 
 
                      Root MSE              0.94939    R-Square     0.5546 
                      Dependent Mean        0.63555    Adj R-Sq     0.5514 
                      Coeff Var           149.38129 
 
 
                                      Parameter Estimates 
 
                                               Parameter       Standard 
  Variable             Label           DF       Estimate          Error    t Value    Pr > |t| 
 
  Intercept            Intercept        1        0.22826        0.04333       5.27      <.0001 
  CHF                  CHF              1        3.16699        0.27073      11.70      <.0001 
  COPD                 COPD             1        2.05052        0.20383      10.06      <.0001 
  LiverMild            LiverMild        1        1.62458        0.19911       8.16      <.0001 
DiabetesMild         DiabetesMild     1        2.69017        0.16341      16.46      <.0001 
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A.4 CHARLSON COMORBIDITY CONDITIONS 
Table 22. Frequency and Cox regression analysis for Charlson comorbidity conditions 
  Frequency (%)  Univariate_HRs (P‐value)  Multivariate_HRs (P‐value) 
MI    6 / 557 (1.1)  1.15 (.78)  1.18 (.75) 
CHF  13 / 557 (2.3)  1.86 (.10)  1.67 (.22) 
PVD    2 / 557 (0.4)  0 .00 (.97)  0.00 (.98) 
CVD    8 / 557 (1.4)  1.30 (.65)  1.56 (.46) 
Dementia    1 / 557 (0.2)  0.00 (.98)  0.00 (.985) 
COPD  23 / 557 (4.1)  1.30 (.32)  1.29 (.35) 
Connectivetissue    4 / 557 (0.7)  1.84 (.39)  1.69 (.47) 
Ulcer    4 / 557 (0.7)  1.00 (1.00)  0.88 (.86) 
Livermild  24 / 557 (4.3)  1.35 (.31)  1.28 (.43) 
Diabetesmild  37 / 557 (6.6)  1.34 (.22)  1.31 (.29) 
Renal    2 / 557 (0.4)  2.50 (.36)  1.21 (.86) 
Diabetessevere    2 / 557 (0.4)  0.55 (.55)  0.58 (.58) 
Anytumor    9 / 557 (1.6)  0.73 (.58)  0.75 (.62) 
Leukemia    1 / 557 (0.2)  2.48 (.37)  2.00 (.50) 
Lymphoma    3 / 557 (0.5)  1.31 (.71)  1.37 (.66) 
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Table 23. Interactions between each comorbidity and age/race on survival using Cox regression 
Interaction of variables‐CHF, COPD, LiverMild, DiabetesMild with Age, Race 
Charlson_comorbidity with 
Univ_P‐value<3.0 
Multi interaction with Age/Race  HRs (P‐value) 
Age,CHF,AGE*CHF  0.99 (.72) 
Black,CHF,Black*CHF  0.38 (.38) 
CHF 
Age,Black,CHF,Age*Black*CHF  0.99 (.38) 
Age,COPD,Age*COPD  1.02 (.33) 
Black, COPD,Black*COPD  2.39 (.22) 
COPD 
Age,Black,COPD,Age*Black*COPD  1.01 (.41) 
Age,LiverMild,Age*LiverMild  1.01 (.85) 
Black,LiverMild,Black*LiverMild  0.00 (.97) 
LiverMild 
Age,Black,LiverMild,Age*Black*LiverMild  0.84 (.97) 
Age,DiabetesMild,Age* DiabetesMild  1.00 (.82) 
Black,DiabetesMild,Black* DiabetesMild  1.12 (.85) 
DiabetesMild 
Age,Black,DiabetesMild,Age*Black* DiabetesMild  1.00 (.94) 
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Table 24. Frequency and analysis using accelerated failure-time model for Charlson comorbidity 
conditions 
  Frequency (%)  Univariate_Estimates (P‐value)  Multivariate_Estimates (P‐value) 
MI    6 / 557 (1.1)  ‐.11 (.77)  ‐.12(.76) 
CHF  13 / 557 (2.3)  ‐.51 (.09)  ‐.41(.21) 
PVD    2 / 557 (0.4)  16.36(1.0)  16.88(1.0) 
CVD    8 / 557 (1.4)  ‐.25 (.59)  ‐.38 (.42) 
Dementia    1 / 557 (0.2)  15.57(1.0)  16.30(1.0) 
COPD  23 / 557 (4.1)  ‐.21 (.31)  ‐.21 (.32) 
Connectivetissue    4 / 557 (0.7)  ‐.54 (.34)  ‐.48 (.40) 
Ulcer    4 / 557 (0.7)  ‐.03 (.95)  .07(.90) 
Livermild  24 / 557 (4.3)  ‐.22 (.35)  ‐.17 (.48) 
Diabetesmild  37 / 557 (6.6)  ‐.26 (.16)  ‐.24 (.22) 
Renal  2 / 557 (0.4)  ‐.77 (.33)  ‐.16 (.85) 
Diabetessevere    2 / 557 (0.4)  .48(.55)  .43(.58) 
Anytumor    9 / 557 (1.6)  .25(.59)  .22(.63) 
Leukemia    1 / 557 (0.2)  ‐.75 (.35)  ‐.54 (.51) 
Lymphoma  3 / 557 (0.5)  ‐.19 (.73)  ‐.23 (.68) 
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Table 25. Interactions between each comorbidity and age/race on survival using accelerated failure-
time model 
Interaction of variables‐CHF, COPD, LiverMild, DiabetesMild with Age, Race 
Charlson_comorbidity 
with Univ_P‐value<3.0 
Multi interaction with Age/Race  Estimates (P‐value) 
Age,CHF,AGE*CHF  .01(.77) 
Black,CHF,Black*CHF  .74(.40) 
CHF 
1.85(.11) 
Age,Black,CHF,Age*Black*CHF  .01(.39) 
Age,COPD,Age*COPD  ‐.02 (.34) 
Black, COPD,Black*COPD  ‐.69 (.21) 
COPD 
1.325(.29) 
Age,Black,COPD,Age*Black*COPD  ‐.01 (.41) 
Age,LiverMild,Age*LiverMild  ‐.01 (.82) 
Black,LiverMild,Black*LiverMild  15.83(1.0) 
LiverMild 
1.34(.32) 
Age,Black,LiverMild,Age*Black*LiverMild  .26(1.0) 
Age,DiabetesMild,Age* DiabetesMild  ‐.00 (.87) 
Black,DiabetesMild,Black* DiabetesMild  ‐.08 (.87) 
DiabetesMild 
1.35(.20) 
Age,Black,DiabetesMild,Age*Black* DiabetesMild  ‐.00 (.95) 
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A.5 UNIVARIATE ANALYSIS 
Table 26. Univariate analyses by Cox  regression of missing variables  (Gths,  Income, Catincome, StageIIBMI, CatStageIIBMI, Cat4StageIIBMI, Menopause, 
Chalson_Index,  Hypertension)  and  corresponding  imputed  variables  (ImpGths,  ImpIncome,  ImpCatIncome,  ImpStageIIBMI,  ImpCatStageIIBMI, 
ImpCat4StageIIBMI, ImpMeno, impCharlson_index, impHypertension) for survival 
  Observed value  Missing(1) vs. NonMissing(0)  
among Non‐systemic Missing 
Systemic Missing (1) vs. Complete Variables among 
Non‐SystemicMissing(0) 
Variable  Value  N  Med  Mean 
(SE) 
HR 
(P‐value) 
Value  N  Med  Mean 
(SE) 
HR 
(P‐value) 
Value  N  Med  Mean 
(SE) 
HR 
(P‐value) 
0  238  33.0  41.9 
(2.32) 
0  486  38.0  46.3 
(1.76) 
0  486  38.0  46.3 
(1.76) 
Gths 
1  248  45.0  46.6 
(2.08) 
.74 
(.02) 
Long‐rank test, 
P=.02 
1  71  45.0  45.1 
(3.185) 
.90 
(.53) 
Long‐rank 
test, 
P=.53 
1  114  18.0  22.3 
(1.63) 
2.74 
(<.00) 
Long‐rank 
test, 
P=<.00 
  Missing  185        Missing  0        Missing  71       
  Total  671        Total  557        Total  671       
0  360  43.0  47.0 
(2.025) 
0  360  43.0  47.0 
(2.025) 
Income  Dollars  360  43.0  47.0 
(2.025) 
1.00 
(.57) 
1  197  36.0  44.2 
(2.52) 
1.08 
(.51) 
Long‐rank 
test, 
P=.50 
1  114  18.0  22.3 
(1.63) 
2.92 
(<.00) 
Long‐rank 
test, 
P=<.00 
  Missing  311        Missing  0        Missing  197       
  Total  671        Total  557        Total  671       
1  67  34.0  48.8 
(5.56) 
1.00  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
2  133  45.0  45.8 
(2.77) 
.92 
(.69) 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
CatIncome 
3  160  40.0  43.8 
(2.375) 
.98 
(.92) 
Long‐
rank 
test, 
P=.89 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Missing  311        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
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Table 26 (Continued) 
  Observed value  Missing(1) vs. NonMissing(0)  
among Non‐systemic Missing 
Systemic Missing (1) vs. Complete Variables among 
Non‐SystemicMissing(0) 
  Total  671        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
0  443  38.0  44.3 
(1.78) 
0  443  38.0  44.3 
(1.78) 
StageIIBMI  Kg/m2  443  38.0  44.3 
(1.78) 
1.01 
(.52) 
1  114  58.0  53.7 
(3.47) 
.67 
(.01) 
Long‐rank 
test, 
P=.01 
1  114  18.0  22.3 
(1.63) 
2.585 
(<.00) 
Long‐rank 
test, 
P=<.00 
  Missing  228        Missing  0        Missing  114       
  Total  671        Total  557        Total  671       
0  31  58.0  42.3 
(4.84) 
1.00  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
1  118  32.0  37.6 
(2.64) 
1.73 
(.06) 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
CatStageIIBMI 
2  294  40.0  45.6 
(2.25) 
1.36 
(.27) 
Long‐
rank 
test, 
P=.08 
N/A  N/A  N/A  N/A 
N/A 
 
N/A  N/A  N/A  N/A 
N/A 
  Missing  228        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Total  671        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
0  31  58.0  42.3 
(4.84) 
1.00  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
1  118  32.0  37.6 
(2.64) 
1.73 
(.06) 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
2  150  41.0  47.2 
(3.16) 
1.27 
(.41) 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
Cat4StageIIBMI 
3  144  39.0  39.1 
(2.185) 
1.45 
(.20) 
Long‐
rank 
test, 
P=.13 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Missing  228        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Total  671        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
0  101  58.0  53.2 
(3.63) 
0  498  43.0  47.2 
(1.73) 
0  498  43.0  47.2 
(1.73) 
Menopause 
1  397  39.0  43.0 
(1.63) 
1.35 
(.06) 
Long‐rank test, 
P=.0555 
1  59  29.0  40.3 
(4.56) 
1.285 
(.18) 
Long‐rank 
test, 
P=.17 
1  114  18.0  22.3 
(1.63) 
2.845 
(<.00) 
Long‐rank 
test, 
P=<.00 
  Missing  173        Missing  0        Missing  59       
  Total  671        Total  557        Total  671       
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Table 26 (Continued) 
  Observed value  Missing(1) vs. NonMissing(0)  
among Non‐systemic Missing 
Systemic Missing (1) vs. Complete Variables among 
Non‐SystemicMissing(0) 
0  551  40.0  46.4 
(1.63) 
Charlson_Index  1‐31 
Scores 
551  40.0  46.4 
(1.63) 
1.08 
(.06) 
N/A  N/A  N/A  N/A  N/A 
1  114  18.0  22.3 
(1.63) 
2.77 
(<.00) 
Long‐rank 
test, 
P=<.00 
  Missing  120        N/A  N/A  N/A  N/A  N/A  Missing  6       
  Total  671        N/A  N/A  N/A  N/A  N/A  Total  671       
0  301  45.0  50.4 
(2.16) 
0  529  39.0  45.7 
(1.67) 
0  529  39.0  45.7 
(1.67) 
Hypertension 
1  228  31.0  35.0 
(1.77) 
1.59 
(.00) 
Long‐rank test, 
P=.00 
1  28  64.0  56.4 
(4.27) 
.49 
(.02) 
Long‐rank 
test, 
P=.02 
1  114  18.0  22.3 
(1.63) 
2.68 
(<.00) 
Long‐rank 
test, 
P=<.00 
  Missing  142        Missing  0        Missing  28       
  Total  671        Total  557        Total  671       
0  270  36.0  42.7 
(2.14) 
N/A  N/A  N/A  N/A  N/A  0  557  40.0  46.5 
(1.625) 
ImpGths 
1  287  45.0  46.4 
(1.92) 
.78 
(.03) 
Long‐rank test, 
P=.03 
N/A  N/A  N/A  N/A  N/A  1  114  18.0  22.3 
(1.63) 
2.79 
(<.00) 
Long‐rank 
test, 
P=<.00 
  Missing  114        N/A  N/A  N/A  N/A  N/A  Missing  0       
  Total  671        N/A  N/A  N/A  N/A  N/A  Total  671       
0  557  40.0  46.5 
(1.625) 
ImpIncome  Dollars  557  40.0  46.5 
(1.625) 
1.00 
(.79) 
N/A  N/A  N/A  N/A  N/A 
1  114  18.0  22.3 
(1.63) 
2.79 
(<.00) 
Long‐rank 
test, 
P=<.00 
  Missing  114        N/A  N/A  N/A  N/A  N/A  Missing  0       
  Total  671        N/A  N/A  N/A  N/A  N/A  Total  671       
ImpCatIncome  1  71  34.0  48.2 
(5.44) 
1.00  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  2  156  45.0  44.6 
(2.60) 
.945 
(.78) 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  3  330  39.0  45.3 
(1.88) 
.96 
(.83) 
Long‐
rank 
test, 
P=.96 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
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Table 26 (Continued) 
  Observed value  Missing(1) vs. NonMissing(0)  
among Non‐systemic Missing 
Systemic Missing (1) vs. Complete Variables among 
Non‐SystemicMissing(0) 
  Missing  114        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Total  671        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
0  557  40.0  46.5 
(1.625) 
ImpStageIIBMI  Kg/m2  557  40.0  46.5 
(1.625) 
1.01 
(.51) 
N/A  N/A  N/A  N/A  N/A 
1  114  18.0  22.3 
(1.63) 
2.79 
(<.00) 
Long‐rank 
test, 
P=<.00 
  Missing  114        N/A  N/A  N/A  N/A  N/A  Missing  0       
  Total  671        N/A  N/A  N/A  N/A  N/A  Total  671       
0  31  58.0  42.3 
(4.84) 
1.00  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
1  118  32.0  37.6 
(2.64) 
1.70 
(.07) 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
ImpCatStageIIBMI 
2  408  45.0  48.4 
(1.95) 
1.22 
(.48) 
Long‐
rank 
test, 
P=.03 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Missing  114        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Total  671        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
0  31  58.0  42.3 
(4.84) 
1.00  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
1  118  32.0  37.6 
(2.64) 
1.71 
(.07) 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
2  257  46.0  51.0 
(2.46) 
1.1 
(.74) 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
ImpCat4StageIIBMI 
3  151  39.0  38.8 
(2.16) 
1.46 
(.20) 
Long‐
rank 
test, 
P=.01 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Missing  114        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Total  671        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
0  142  47.0  49.5 
(3.14) 
N/A  N/A  N/A  N/A  N/A  0  557  40.0  46.5 
(1.625) 
ImpMeno 
1  415  39.0  43.0 
(1.58) 
1.17 
(.26) 
Long‐rank test, 
P=.25 
N/A  N/A  N/A  N/A  N/A  1  114  18.0  22.3 
(1.63) 
2.79 
(<.00) 
Long‐rank 
test, 
P=<.00 
  Missing  114        N/A  N/A  N/A  N/A  N/A  Missing  0       
  Total  671        N/A  N/A  N/A  N/A  N/A  Total  671       
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Table 26 (Continued) 
  Observed value  Missing(1) vs. NonMissing(0)  
among Non‐systemic Missing 
Systemic Missing (1) vs. Complete Variables among 
Non‐SystemicMissing(0) 
ImpHypertension  0  320  47.0  51.2 
(2.08) 
N/A  N/A  N/A  N/A  N/A  0  557  40.0  46.5 
(1.625) 
  1  237  31.0  35.4 
(1.76) 
1.62 
(<.00) 
Long‐rank test, 
P=<.00 
N/A  N/A  N/A  N/A  N/A  1  114  18.0  22.3 
(1.63) 
2.79 
(<.00) 
Long‐rank 
test, 
P=<.00 
  Missing  114        N/A  N/A  N/A  N/A  N/A  Missing  0       
  Total  671        N/A  N/A  N/A  N/A  N/A  total  671       
0  557  40.0  46.5 
(1.625) 
ImpCharlson_Index  1‐31 
Scores 
557  40.0  46.5 
(1.625) 
1.085 
(.06) 
N/A  N/A  N/A  N/A  N/A 
1  114  18.0  22.3 
(1.63) 
2.79 
(<.00) 
Long‐rank 
test, 
P=<.00 
  Missing  114        N/A  N/A  N/A  N/A  N/A  Missing  0       
  Total  671        N/A  N/A  N/A  N/A  N/A  total  671       
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Table 27. Univariate Analyses by Cox regression with complete variables (Age, Black, ER, HER2, Metsite) 
    Observed value  Observed Value  
Among SystemicMissing 
Observed Value  
Among Non‐SystemicMissing 
Variable  Value  N  Median  Mean (SE)  HR (P‐value)  N  Median  Mean (SE)  HR (P‐value)  N  Median  Mean (SE)  HR (P‐value) 
Age  Year  671  33.0  41.6 
(1.39) 
1.01 (.03)  114  18.0  22.3 
(1.63) 
1.01 (.30)  557  40.0  46.5 
(1.625) 
1.01 (.00) 
  Total  671        114        557       
0  627  33.0  42.1 
(1.43) 
106  18.0  22.5 
(1.61) 
521  41.0  47.0 
(1.66) 
Black 
1  44  22.0  35.3 
(5.39) 
1.46 (.07) 
Long‐rank 
test, 
P=.07 
8  10.5  18.7 
(8.64) 
1.25 (.55) 
Long‐rank 
test, 
P=.55 
36  36.0  29.4 
(3.18) 
1.46 (.14) 
Long‐rank 
test, 
P=.14 
  Total  671        114        557       
Metsite  1‐7  664  33.0  41.9 
(1.40) 
1.345 
(<.00) 
107  18.0  22.1 
(1.60) 
1.225 
(.07) 
557  40.0  46.5 
(1.625) 
1.37 
(<.00) 
  Missing  7        7        0       
  Total  671        114        557       
ER  1  470  40.0  45.4 
(1.64) 
N/A  N/A  N/A  N/A  408  45.0  49.0 
(1.85) 
  2  196  22.0  32.1 
(2.17) 
1.685 (<.00) 
Long‐rank 
test, 
P=<.00 
N/A  N/A  N/A  N/A  149  26.0  37.6 
(2.78) 
1.54 (.00) 
Long‐rank 
test, 
P=.00 
  Missing  5        N/A  N/A  N/A  N/A  0       
  Total  671        N/A  N/A  N/A  N/A  557       
HER2  1  229  39.0  43.1 
(2.02) 
N/A  N/A  N/A  N/A  192  45.0  47.4 
(2.29) 
  2  422  33.0  40.5 
(1.74) 
1.21 (.08) 
Long‐rank 
test, 
P=.08 
N/A  N/A  N/A  N/A  365  38.0  43.9 
(1.975) 
1.28 (.05) 
Long‐rank 
test, 
P=.05 
  Missing  20        N/A  N/A  N/A  N/A  0       
  Total  671        N/A  N/A  N/A  N/A  557       
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Table 28. Univariate analyses by accelerated failure‐time model of missing variables (Gths, Income, Catincome, StageIIBMI, CatStageIIBMI, Cat4StageIIBMI, 
Menopause, Chalson_Index, Hypertension) and corresponding imputed variables (ImpGths, ImpIncome, ImpCatIncome, ImpStageIIBMI, ImpCatStageIIBMI, 
ImpCat4StageIIBMI, ImpMeno, impCharlson_index, impHypertension) for survival 
  Observed value  Missing(1) vs. NonMissing(0)  
among Non‐systemic Missing 
Systemic Missing (1) vs. Complete Variables among 
Non‐SystemicMissing(0) 
Variable  Value  N  Estimate*  Exponential  
estimate** 
P‐
value 
Value  N  Estimate*  Exponential  
estimate** 
P‐
value 
Value  N  Estimate*  Exponential  
estimate** 
P‐
value 
0  238  ref  1.00  0  486  ref  1.00  0  486  ref  1.00 Gths 
1  248  .24  1.27 
.02 
1  71  .08  1.08 
.58 
1  114  ‐.81  .44 
<.00 
  Missing  185        Missing  0        Missing  71       
  Total  671        Total  557        Total  671       
0  360  ref  1.00  0  360  ref  1.00 Income  Dollars  360  ‐.00  1.00  .53 
1  197  ‐.05  .95 
.58 
1  114  ‐.82  .44 
<.00 
  Missing  311        Missing  0        Missing  197       
  Total  671        Total  557        Total  671       
1  67  ref  1.00    N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
2  133  .06  1.06  .70  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
CatIncome 
3  160  .01  1.01  .95  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Missing  311        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Total  671        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
0  443  ref  1.00  0  443  ref  1.00 StageIIBMI  Kg/m2  443  ‐.01  .99  .45 
1  114  .33  1.39 
.01 
1  114  ‐.75  .47 
<.00 
  Missing  228        Missing  0        Missing  114       
  Total  671        Total  557        Total  671       
0  31  ref  1.00    N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
1  118  ‐.45  .64  .04  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
2  150  ‐.21  .81  .35  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
Cat4StageIIBMI 
3  144  ‐.32  .73  .15  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Missing  228        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Total  671        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
0  101  ref  1.00  0  498  ref  1.00  0  498  ref  1.00 Menopause 
1  397  ‐.25  .78 
.04 
1  59  ‐.20  .82 
.16 
1  114  ‐.84  .43 
<.00 
  Missing  173        Missing  0        Missing  59       
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Table 28. (Continued) 
  Observed value  Missing(1) vs. NonMissing(0)  
among Non‐systemic Missing 
Systemic Missing (1) vs. Complete Variables among 
Non‐SystemicMissing(0) 
  Total  671        Total  557        Total  671       
N/A  N/A  N/A  N/A  N/A  0  551  ref  1.00 Charlson_Index  1‐31 
Scores 
551  ‐.07  .93  .04 
N/A  N/A  N/A  N/A  N/A  1  114  ‐.82  .44 
<.00 
  Missing  120        N/A  N/A  N/A  N/A  N/A  Missing  6       
  Total  671        N/A  N/A  N/A  N/A  N/A  Total  671       
0  301  ref  1.00  0  529  ref  1.00  0  529  ref  1.00 Hypertension 
1  228  ‐.38  .68 
<.00 
1  28  .55  1.73 
.03 
1  114  ‐.80  .45 
<.00 
  Missing  142        Missing  0        Missing  28       
  Total  671        Total  557        Total  671       
0  270  ref  1.00  N/A  N/A  N/A  N/A  N/A  0  557  ref  1.00 ImpGths 
1  287  .21  1.23 
.03 
N/A  N/A  N/A  N/A  N/A  1  114  ‐.82  .44 
<.00 
  Missing  114        N/A  N/A  N/A  N/A  N/A  Missing  0       
  Total  671        N/A  N/A  N/A  N/A  N/A  Total  671       
N/A  N/A  N/A  N/A  N/A  0  557  ref  1.00 ImpIncome  Dollars  557  ‐.00  1.00  .72 
N/A  N/A  N/A  N/A  N/A  1  114  ‐.82  .44 
<.00 
  Missing  114        N/A  N/A  N/A  N/A  N/A  Missing  0       
  Total  671        N/A  N/A  N/A  N/A  N/A  Total  671       
1  71  ref  1.00    N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
2  156  .04  1.04  .79  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
ImpCatincome 
3  330  .03  1.03  .82  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Missing  114        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Total  671        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
N/A  N/A  N/A  N/A  N/A  0  557  ref  1.00 ImpStageIIBMI  Kg/m2  557  ‐.01  .99  .44 
N/A  N/A  N/A  N/A  N/A  1  114  ‐.82  .44 
<.00 
  Missing  114        N/A  N/A  N/A  N/A  N/A  Missing  0       
  Total  671        N/A  N/A  N/A  N/A  N/A  Total  671       
0  31  ref  1.00    N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
1  118  ‐.46  .63  .04  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
2  257  ‐.10  .90  .66  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
ImpCat4StageIIBMI 
3  151  ‐.34  .71  .14  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Missing  114        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
  Total  671        N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A 
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Table 28 (Continued) 
  Observed value  Missing(1) vs. NonMissing(0)  
among Non‐systemic Missing 
Systemic Missing (1) vs. Complete Variables among 
Non‐SystemicMissing(0) 
0  142  ref  1.00  N/A  N/A  N/A  N/A  N/A  0  557  ref  1.00 ImpMeno 
  1  415  ‐.13  .88 
.22 
N/A  N/A  N/A  N/A  N/A  1  114  ‐.82  .44 
<.00 
  Missing  114        N/A  N/A  N/A  N/A  N/A  Missing  0       
  Total  671        N/A  N/A  N/A  N/A  N/A  Total  671       
0  320  ref  1.00  N/A  N/A  N/A  N/A  N/A  0  557  ref  1.00 ImpHypertension 
1  237  ‐.39  .68 
<.00 
N/A  N/A  N/A  N/A  N/A  1  114  ‐.82  .44 
<.00 
  Missing  114        N/A  N/A  N/A  N/A  N/A  Missing  0       
  Total  671        N/A  N/A  N/A  N/A  N/A  total  671       
0  557  ref  1.00 ImpCharlson_Index  1‐31 
Scores 
557  ‐.07  0.93  .04  N/A  N/A  N/A  N/A  N/A 
1  114  ‐.82  .44 
<.00 
  Missing  114        N/A  N/A  N/A  N/A  N/A  Missing  0       
  Total  671        N/A  N/A  N/A  N/A  N/A  total  671       
 
  139
 
Table 29. Univariate Analyses by accelerated failure‐time model with complete variables (Age, Black, ER, HER2, Metsite) 
    Observed value  Observed Value 
Among SystemicMissing 
Observed Value 
Among Non‐SystemicMissing 
Variable  Value  N  Estimate*  Exponential 
Estimate** 
P‐value  N  Estimate*  Exponential 
Estimate** 
P‐value  N  Estimate*  Exponential 
Estimate** 
P‐value 
Age  Year  671  ‐.01  .99  .02  114  ‐.01  .99  .30  557  ‐.01  .99  .00 
  Total  671        114        557       
0  627  ref  1.00  106  ref  1.00  521  ref  1.00 Black 
1  44  ‐.33  .72 
.05 
8  ‐.05  .95 
.84 
36  ‐.32  .73 
.11 
  Total  671        114        557       
Metsite  1‐7  664  ‐.24  .79  <.00  107  ‐.15  .86  .04  557  ‐.25  .78  <.00 
  Missing  7        7        0       
  Total  671        114        557       
ER  1  470  ref  1.00  N/A  N/A  N/A  N/A  408  ref  1.00 
  2  196  ‐.40  .67 
<.00 
  N/A  N/A  N/A  N/A  149  ‐.32  .73 
.00 
 
  Missing  5        N/A  N/A  N/A  N/A  0       
  Total  671        N/A  N/A  N/A  N/A  557       
HER2  1  229  ref  1.00  N/A  N/A  N/A  N/A  192  ref  1.00 
  2  422  ‐.16  .85 
<.0555 
N/A  N/A  N/A  N/A  365  ‐.20  .82 
.04 
  Missing  20        N/A  N/A  N/A  N/A  0       
  Total  671        N/A  N/A  N/A  N/A  557       
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APPENDIX B 
SUPPLEMENTAL TABLES AND FIGURES FOR SPECIFIC AIM 2 
B.1 FREQUENCY DISTRIBUTIONS OF PREDICTOR VARIABLES 
BETWEEN PATIENTS WITH MISSING INFORMATION AND PATIENTS 
WITHOUT MISSING INFORMATION FOR TREATMENT 
Table 30. Frequency distributions of predictor variables between patients (n=4) with missing 
information and patient (n=553) with non-missing information for treatment 
Variable  553 patients  4 patients 
Age (Mean age in years)  56  47 
Race 
Non‐Black  517  4 
Black  36  0 
Education  
<=High School  270  0 
> High School  283  4 
Median Household Income (Mean of Median 
Household Income) 
$ 40906.1  $ 42299.9 
BMI 
Mean of BMI  28.03  27.86 
≤20 kg/m2  31  0 
20‐24.9 kg/m2  118  0 
25‐29.9 kg/m2  253  4 
≥30 kg/m2  151  0 
Menopausal status (P=0.053) 
Pre menopause  139  3 
Post menopause  414  1 
History of hypertension 
No  316  4 
Yes  237  0 
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Table 30 (Continued) 
Variable  553 patients  4 patients 
Charlson comorbidity score 
0  439  4 
1  15  0 
2  32  0 
3+  67  0 
Charlson Comorbidity Condition 
Myocardial infarct  6  0 
Congestive heart failure  13  0 
Peripheral vascular disease  2  0 
Cerebrovascular disease  8  0 
Dementia  1  0 
Chronic pulmonary disease  23  0 
Connective Tissue disease  4  0 
Ulcer disease  4  0 
Mild liver disease  24  0 
Diabetes  37  0 
Moderate or severe renal disease  2  0 
Diabetes with end organ damage  2  0 
Any Tumor  9  0 
Leukemia  1  0 
Lymphoma  3  0 
ER/PR status 
ER/PR positive  404  4 
ER/PR negative  149  0 
HER2 status 
HER2 positive  191  1 
HER2 negative  362  3 
Number of metastatic sites 
1  340  4 
2  137  0 
3+  76  0 
Metastatic location   
Brain  34  0 
Bone  298  3 
Liver  116  0 
Other  308  1 
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B.2 PATIENTS WITH MISSING INFORMATION FOR TREATMENT 
Table 31. Patients with missing information for treatment  
Treatment  Treatment delay  ID  Data analysis 
Any treatment  missing Æ 1st treatment  407,451,666  Excluded 
  missing  Æ obs. Æ 1st 
treatment 
502  Delayed treatment 
(at least) 
  obs. Æ missing Æ 1st 
treatment 
550  Delayed treatment 
(at least) 
  obs. Æ missing Æ obs Æ 
1st treatment 
223,372  Delayed treatment 
(at least) 
No any 
treatment 
obs. till study ending or 
death 
115,221,356,517,603  Delayed treatement 
  obs. Æ missing till study 
ending or death 
76,198, 214, 310,366,400  Delayed treatment 
(at least) 
  obs. Æ missing Æ obs 
Æmissing till study ending 
or death 
226  Delayed treatment 
(at least) 
  missing till study ending or 
death 
667  Excluded 
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B.3 LML FUNCTION AT MEAN OF TREATMENT DELAY  
 
Figure 16. Log minus log function at mean of treatment delay as a continuous variable 
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Figure 17. Log minus log function at mean of square root of treatment delay 
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B.4 COX REGRESSION ANALYSIS OF TREATMENT DELAY 
PERCENTILE FOR SURVIVAL MEASURED FROM METASTASIS AND 
FROM FIRST TREATMENT 
Table 32. Cox regression analysis of treatment delay percentile for survival from metastatic breast 
cancer diagnosis 
Survival measured from metastatic breast cancer diagnosis 
Univariate analysis    Multivariate analysis*  
Variable 
 
Patients No. (%)  Hazard ratio  95% CI  P‐value   Hazard ratio  95% CI  P‐value
Treatment delay 
Percentile 
553 (100.0)               
70 percentile  390 (70.5)  1.07  0.78‐1.45  0.680    1.05  0.77‐1.44  0.758 
70‐90 
percentile 
107 (19.4)  1.00  referent      1.00  referent   
90‐100 
percentile 
56 (10.1)  1.20  0.76‐1.87  0.435    1.02  0.62‐1.66  0.945 
 
Table 33. Cox regression analysis of treatment delay percentile for survival from first treatment 
Survival measured from first treatment 
Univariate analysis    Multivariate analysis**  
Variable 
 
Patients No. (%)  Hazard ratio  95% CI  P‐value   Hazard ratio  95% CI  P‐value
Treatment delay  539 (100.0)               
70 percentile  379 (70.3)  1.15  0.84‐1.57  0.378    1.11  0.80‐1.52  0.537 
70‐90 
percentile 
105 (19.5)  1.00  referent      1.00  referent   
90‐100 
percentile 
55 (10.2)  1.44  0.90‐2.31  0.130    1.36  0.81‐2.27  0.241 
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B.5 COX REGRESSION ANALYSIS OF TREATMENT DELAY (≤4 WEEK, 4–
12 WEEK, 12–24 WEEK, >24 WEEK) FOR SURVIVAL MEASURED FROM 
METASTASIS AND FROM FIRST TREATMENT 
Table 34. Cox  regression  analysis  between  treatment  delay  (≤4 week,  4–12 week,  12–24 week,  >24 
week) and survival  from metastatic breast cancer  in patients  (n = 553) with metastatic breast cancer 
identified at two sites of the UPMC, UPCI Breast Cancer Program 
Survival measured from metastatic breast cancer diagnosis 
Univariate analysis    Multivariate analysis*  
Variable 
 
Patients No. (%)  Hazard ratio  95% CI  P‐value    Hazard ratio  95% CI  P‐value 
Treatment delay  553 (100.0)      0.031†        0.065† 
≤4 week  390 (70.5)  1.11  0.83‐1.48  0.483    1.12  0.83‐1.52  0.450 
4–12 week  129 (23.3)  1.00  referent      1.00  referent   
12‐24 week  18 (3.3)  2.49  1.33‐4.65  0.004    2.13  1.12‐4.06  0.021 
>24 week  16 (2.9)  1.08  0.55‐2.12  0.813    0.71  0.35‐1.44  0.342 
Abbreviation: 95% CI, 95% Confidence Interval. 
* Cox regression was performed for examining the effect of treatment delay on survival, adjusted by covariates (BMI, history of 
hypertension, ER/PR status, HER2 status, number of metastatic sites, brain, bone and liver metastasis), selected to be significant with 
P‐value <0.05 by backward stepwise selection. 
† P‐value for omnibus test. 
 
Table 35. Cox  regression  analysis  between  treatment  delay  (≤4 week,  4–12 week,  12–24 week,  >24 
week) and survival from first treatment in patients* (n = 539) with metastatic breast cancer identified 
at two sites of the UPMC, UPCI Breast Cancer Program 
Survival measured from first treatment 
Univariate analysis    Multivariate analysis**  
Variable 
 
Patients No. (%)  Hazard ratio  95% CI  P‐value    Hazard ratio  95% CI  P‐value 
Treatment delay  539 (100.0)      0.021†        0.098† 
≤4 week  388 (71.9)  1.10  0.82‐1.47  0.537    1.06  0.78‐1.43  0.727 
4–12 week  125 (23.2)  1.00  referent      1.00  referent   
12‐24 week    16 (3.0)  2.74  1.39‐5.39  0.004    2.39  1.19‐4.77  0.014 
>24 week    10 (1.9)  1.41  0.61‐3.28  0.423    1.21  0.51‐2.87  0.669 
Abbreviation: 95% CI, 95% Confidence Interval. 
* Patients (n=14 among 553) censored their treatment interval until death or end of study were excluded from analysis. 
** Cox regression was performed for examining the effect of treatment delay on survival, adjusted by covariates (BMI, history of 
hypertension, ER/PR status, HER2 status, number of metastatic sites, and liver metastasis), selected to be significant with P‐value 
<0.05 by backward stepwise selection. 
† P‐value for omnibus test. 
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APPENDIX C 
SUPPLEMENTAL TABLES AND FIGURES FOR SPECIFIC AIM 3 
C.1 ASSESSMENT OF POTENTIAL MEDIATOR VARIABLE: BARON AND 
KENNY STEPS 
Panel A 
 C= total effect 
Panel B 
 C’=direct effect, C‐C’≈a*b =indirect effect  
 
Baron and Kenny steps 
– Step 1: testing c 
– Step 2: testing a 
– Step 3: testing b 
Assessed by equations: 
Y = ί1 + cX (step 1) 
M= ί2 + aX (step 2) 
Y = ί3 + c’X + bM (step 3) 
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Age  
(old > 51 years) 
 
(young ≤ 51 years) 
Survival
Comorbidity 
Charlson comorbidity score (CCS)                Hypertension‐augmented  
Hypertension                                                    Charlson comorbidity score (hCCS) 
HR: 1.38 (P=0.008)
OR of CCS (0 vs. 1): 2.76 (P<0.0001) 
OR of CCS (0 vs. 1 vs. 2): 2.73 (P<0.0001) 
OR of CCS (0 vs. 1 vs. 2 vs. 3+): 
 
OR of Hypertension: 5.08 (P<0.0001) 
 
OR of hCCS (0 vs. 1): 4.10 (P<0.0001) 
OR of hCCS (0 vs. 1 vs. 2): 4.30 (P<0.0001) 
OR of hCCS (0 vs. 1 vs. 2 vs. 3+): 
HR of CCS (continuous): 1.11 (P=0.296)
HR of CCS (0 vs. 1): 1.18 (P=0.257) 
HR of CCS (0 vs. 1 vs. 2):  
CCS1: 1.18 (P=0.335), CCS2: 1.19 (P=0.477) 
HR of CCS (0 vs. 1 vs. 2 vs. 3+): 
CCS1:, CCS2: CCS3: 
 
HR of Hypertension: 1.50 (P=0.002) 
 
HR of hCCS (continuous): 1.19 (P=0.012) 
HR of hCCS (0 vs. 1): 1.46 (P=0.003) 
HR of hCCS (0 vs. 1 vs. 2): 
hCCS1: 1.44 (P=0.007), hCCS2: 1.53 (P=0.025) 
HR of hCCS (0 vs. 1 vs. 2 vs. 3+): 
hCCS1:, hCCS2: hCCS3: 
Figure 18. Diagram for the association of comorbidity with age-survival relationship based on univariate analysis using Cox 
regression and logistic regression model 
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C.2 COVARIATES TO BE ADJUSTED IN MULTIVARIATE ANALYSIS 
 
Table 36. Covariates to be adjusted in multivariate analysis 
 no. variable value 
Patient ID 1 ID 553 patients 
1 Status event (0 censored, 1 dead) Outcome variable 
2 Msurv survival length in month 
Independent 
variable 
1 Age categorical variable (0, =< 51 years; 1, > 51 year) 
1 C2CCS Charlson Comorbidity Score, categorical variable (0, 0 score; 1, >0 score) 
2 ImpHypertension Hypertension (0, no of hypertension; 1, yes of hypertension) 
Mediator variable 
3 C2HCCS Hypertension augmented Charlson Comorbidity Score, categorical 
variable (0, 0 score; 1, >0 score) 
1 Black race (0, non-black; 1, black) 
2 ImpGths education (0, =< high school; 1, > high school) 
3 ImpER ER/PR status (0, positive; 1, negative) 
4 ImpHER2 HER2 status (0, positive; 1, negative) 
5 Metsite continuous variable (0,1,2, ect.) 
6 Metloc1 Metastatic location (Brain) at the initial metastasis diagnosis-Brain (0, no; 
1, yes) 
7 Metloc2 Metastatic location (Bone) at the initial metastasis diagnosis-Bone (0, no; 
1, yes) 
8 Metloc4 Metastatic location (Liver) at the initial metastasis diagnosis-Liver (0, no; 1, 
yes) 
Covariates 
9 Tr Treatment delay categorized into three groups (0,=<28 days; 1, 28<-84 
days; 2, >84 days) 
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Î covariate_h1=covariate_h2=covariate_h3; 
covariate_CCS1=covariates_CCS2=covariate_CC3; 
covariate_hCCS1=covariate_hCCS2=covariate_hCCS3. 
 
Î covariates_h=covariate_CCS=covariate_hCCS. 
Mediator: CCS
 
Mediator: Hypertension  Mediator: hCCS 
 
c  C’  cc c C’
b a  a  ba b
Covariate_h  
(=covariate_h1 for c = 
covariate_h2 for c’= 
covariate h3 for a*b)
Covariate_CCS 
(=covariate_CCS1 for c = 
covariate_CCS2 for c’= 
covariate CCS3 for a*b)
Covariate_hCCS  
(=covariate_hCCS1 for c = 
covariate_hCCS2 for c’= 
covariate hCCS3 for a*b)
Figure 19. Covariates to be adjusted in multivariate analysis of each step (c, c’, and a*b) of Baron Kenny 
approach for hypertension, CCS, and hCCS related to survival  
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C.3 FREQUENCY DISTRIBUTIONS OF COMORBIDITIES BY AGE 
 
Figure 20. Frequency distribution of hypertension by age in patients with metastatic breast cancer 
identified at two sites of the UPMC, UPCI Breast Cancer Program 
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Figure 21. Frequency distribution of CCS by age in patients with metastatic breast cancer identified at 
two sites of the UPMC, UPCI Breast Cancer Program 
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Figure 22. Frequency distribution of hCCS by age in patients with metastatic breast cancer identified at 
two sites of the UPMC, UPCI Breast Cancer Program 
  154
 
C.4 KAPLAN-MEIER’S CURVES OF SURVIVAL BY COMORBIDITIES  
 
 
 
Figure 23. Kaplan‐Meier’s curve of survival by history of hypertension in patients with metastatic 
breast cancer identified at two sites of the UPMC, UPCI Breast Cancer Program 
  155
 
 
 
Figure 24. Kaplan‐Meier’s curve of survival by Charlson Comorbidity Score (CCS) in patients with 
metastatic breast cancer identified at two sites of the UPMC, UPCI Breast Cancer Program 
  156
 
 
 
Figure 25. Kaplan‐Meier’s curve of survival by hypertension augmented Charlson Comorbidity Score 
(hCCS) in patients with metastatic breast cancer identified at two sites of the UPMC, UPCI Breast Cancer 
Program 
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C.5 DIAGRAMS FOR ASSOCIATIONS OF COMORBIDITIES WITH AGE-
SURVIVAL RELATIONSHIP  
 
Aim 3 Study Findings:
Mediator: Hypertension
Hypertension
OR* of Age: 4.66 
(P<0.0001)
HR* of Hypertension: 
1.45 (P=0.005)
Age 
(older aged > 51 vs. 
younger aged ≤ 51)
Survival
HR* of Age: 1.43 (P=0.005)
HR* of Age adjusted by 
Hypertension: 1.26 (P=0.086): 40%
* Multivariate regression was conducted.
 
Figure 26. Hypertension as a mediator of age-survival relationship 
 
Aim 3 Study Findings: 
Mediator: Charlson Comorbidity Score (CCS)
CCS
OR* of Age: 2.59 
(P=0.0002)
Age 
(older aged > 51 vs. 
younger aged ≤ 51)
Survival
HR* of Age: 1.43 (P=0.005)
HR* of Age adjusted by CCS: 1.37 
(P=0.016): 14%
* Multivariate regression was conducted.
HR* of CCS:
(1 vs. 0): 1.35 (P=0.088);
(2 vs. 0): 1.34 (P=0.266);
(3+ vs. 0): 0.88 (P=0.862)
 
Figure 27. CCS as a mediator of age-survival relationship 
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Aim 3 Study Findings: 
Mediator: Hypertension augmented Charlson
Comorbidity Score (hCCS)
hCCS
OR* of Age: 3.94 
(P<0.0001)
Age 
(older aged > 51 vs. 
younger aged ≤ 51)
Survival
HR* of Age: 1.43 (P=0.005)
HR* of Age adjusted by hCCS: 1.24 
(P=0.110): 44%
* Multivariate regression was conducted.
HR* of hCCS:
(1 vs. 0): 1.40 (P=0.015);
(2 vs. 0): 1.88 (P=0.004);
(3+ vs. 0): 1.42 (P=0.248)
 
Figure 28. HCCS as a mediator of age-survival relationship 
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Table 37. Proportion of indirect effect (c-c’) of comorbidity among total effect (c) for age-survival 
relationship (Accelerated failure time model vs. Cox regression model) 
Method  Accelerated 
failure time 
model 
Cox regression 
model 
Cox regression 
model 
(Total effect–
Direct effect) 
/Total effect 
Parameter  (c‐c’)/c  (HR(c)‐HR(c’)) 
/(HR(c)‐1) 
(c‐c’)/c 
Mediator  Hypertension  33%  40%  34% 
Mediator  C4CCS  12%  14%  12% 
Mediator  C4HCCS  37%  44%  39% 
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APPENDIX D 
METASTATIC BREAST CANCER (MBC) STUDY DATA COLLECTION AND 
MEDICAL RECORD ABSTRACTION PROCEDURE AND MISSING DATA 
 
D.1 MBC STUDY CODING SHEET  
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Table 38. MBC Study coding sheet 
CODING SHEET (MBC STUDY)             
Status               Update (OCT/10)      
0  Alive                    
1  Deceased                  
Age                      
   Subject's age at MetDX                
Race                      
1  Caucasian                  
2  African American                  
3  Asian‐ this includes China, Japan, Turkey, Iran, Iraq, etc.            
4  Hispanic                    
5  Other (ex., American Indian/Alaska Native)              
Sites                      
   Number of metastatic sites as of current update date            
LocMets                      
   Location of Metastatic sites                
MoMet                      
   Months from diagnosis to metastatic disease            
ER                      
1  ER and/or PR positive                
2  Neither ER nor PR positive                  
‐1  Unknown (both ER and PR unknown)                    
HER2                      
1  HER2 positive                  
2  Her2 negative                  
‐1  Unknown                    
Msurv                      
   Number of months from MetDX to current update date if alive or CTB date if deceased.      
Bcsurv                      
   Total months of breast cancer survival.  Only used for CTB subjects.  Leave blank in alive subjects.   
   Bcsurv = MoMet + Msurv.                
Tx1wait_Missing                    
1 
Patient have missing information for treatment during the time between the date of metastasis and the date of 
the first treatment of metastasis 
‐1 
Patient do not have missing information for treatment during the time between the date of metastasis and the 
date of the first treatment of metastasis 
Tx_  Overall treatment category                
‐1  No information of treatment on medical records            
1  Observation                  
2  Chemotherapy Alone                
3  Chemo + Herceptin                  
4  Herceptin Alone                  
5  Hormonal Therapy Alone                
6  Hormonal Therapy + Chemo                
7  Hormonal Therapy, Chemo + Herceptin              
8  Immunologic Therapy                
9  Hormonal Therapy + Herceptin                
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Table 38 (Continued)             
CODING SHEET (MBC STUDY)             
10  Vaccine + Chemo                  
11  Vaccine + Hormonal Therapy                
12  Vaccine Alone                  
13  Herceptin + Biologic Chemo (4,8)              
14  Herceptin, Biologic Chemo + Hormonal Therapy            
15  Trial: UPCI‐02‐106                  
16  Trial: AMG‐162                  
17  Clinical trial w/ Chemo (e.g., chemo vs. placebo)            
18  UPCI 06‐042                  
19  Biologic Chemo + Hormonal Therapy              
Mo                      
   monthly based period during the treatment              
PS  ECOG Pain Score:                  
1  If ECOG is 0 or 1                   
2  If ECOG is greater than 1                
Tx CHANGE  Was there a Tx Change?                
1  Yes                    
2  No                    
REASON  What prompted the Tx change?              
1  Radiographic Progression                
2  Toxicity                    
3  Clinical Progression                  
TX_Chemo  Chemotherapy Codes      TX_Horm  Hormonal Therapy Codes    
1  Adriamycin        1  Tamoxifen      
2  Cytoxan          2  Femera        
3  5‐FU          3  Megace        
4  Methotrexate        4  Arimidex        
5  Navelbine        5  Lupron        
6  Xeloda          6  Aromasin        
7  Taxol          7  Zoladex        
8  Taxotere          8  Raloxifine        
9  Mitoxantrone        9  Faslodex        
10  Gemzar          10  Fareston        
11  Carboplatinum        11  Fulvestrant      
12  Epirubicin          12  Femara/Lupron      
13  Doxil          13  Arimidex/Femera      
14  Veg F.          14  Arimidex/Lupron      
15  Theraptope        15  Aromasin/Faslodex      
16  Leukovorin        16  Faslodex/Tamoxifen      
17  Epitholone B        17  Arimadex/Faslodex      
18  Cisplatin          18  Lupron/Tamoxifen      
19  Carbo/Taxol        19  Faslodex/Lupron      
20  Taxotere/Xeloda        20  Aromasin/Lupron      
21  Carbo/Taxotere        21  Faslodex/Femara      
22  Adriamycin/Cytoxan        22  Lupron/Megace/Tamoxifen    
23  Gemzar/Taxotere        23  Megace/Tamoxifen      
24  Adriamycin/Cytoxan/Taxotere      24  same as 15      
25  TPA‐Alteplase        25  Arimidex/Aromasin      
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Table 38 (Continued)             
CODING SHEET (MBC STUDY)             
26  Cytoxan/Methotrexate/5‐FU      26  Arimidex/Megace      
27  Cytoxan/Epirubicin/5‐FU      27  Aromasin/Megace      
28  Epitholone/Xeloda        28  Lupron/Megace/Tamoxifen    
29  Adriamycin/Taxotere      29  Faslodex/Lupron/Megace    
30  Abraxane          30  Fareston/Zoladex      
31  Gemzar/Taxol        31  Femara/Zoladex      
32  Leukovorin/Mitoxantrone/5‐FU      32  Arimadex/Zoladex      
33  Cytoxan/Epirubicin        33  Megace/Zoladex      
34  Gemzar/Navalbene        34  Tamoxifen/Aromasin    
35  Epirubicin/Taxotere        35  Faslodex/Megace      
36  Adriamycin/Cisplatin/Cytoxan      36  Faslodex/Femara/Megace    
37  Carbo/Gemzar/Taxol      37  Tamoxifen/Zoladex      
38  Temodar          38  Arimidex/Tamoxifen      
39  Veg F/Xeloda        39  Femara/Lupron/Megace    
40  Carbo/Taxol/Taxotere      40  Femara/Megace      
41  Gemzar/Mitoxantrone      41  Aromasin/Zoladex      
42  Cisplatin/Gemzar        42  Faslodex/Femara/Lupron    
43  Leukovorin/5‐FU        43  Aromasin/Faslodex/Lupron    
44  Gemzar/Xeloda        44  Faslodex/Megace/Tamoxifen    
45  Carbo/Taxotere/Xeloda      45  Tamoxifen + Aromasin + Faslodex 
46  Navelbine/Taxotere        46  Tamoxifen + Arimadex + Lupron    
47  Gemzar/Abraxane        47  Aromasin + Zoladex + Faslodex    
48  Carbo/Gemzar/Taxotere      48  Zoladex + Faslodex      
49  Carbo/Gemzar        49  Tamoxifen + Femera      
50  Adriamycin/Cytoxan/5‐FU      50  Megace + Lupron      
51  Camptosar        51  Megace + Aromasin + Faslodex    
52  Carbo/Gemzar/Navelbine/Taxotere    52  Femera + Aromasin      
53  SB‐715992        53  Tamoxifen + Lupron + Faslodex    
54  Temodar          54  Tamoxifen + Femera + Faslodex 
55  Chemo vs. Placebo        55  Femera + Arimadex + Lupron    
56  Lapatinib vs. Placebo      56  Aromasin + Fareston      
57  Taxol & Xeloda        57  Arimadex + Lupron + Faslodex    
58  Carbo & Abraxane        58  Faslodex + Fareston      
59  Abraxane & Mitox        59  Arimadex + Aromasin + Faslodex 
60  Xeloda & Bevacizumab vs. placebo    60  Tamoxifen + Zoladex + Faslodex 
61  Lapatinib vs. Placebo and Xeloda    61  TAS‐108        
62  Lapatinib (Tykerb)        62  Arimidex + Zoladex + Faslodex    
63  Lapatinib/Abraxane                  
64  Triapine          Support  Supportive Care Codes (in abstracts) 
65  CPT‐11          1  Pamidronate (Aredia)    
66  Sutent (Sunitnib)        2  Local Radiation      
67  Lxabepilone (lxempra)      3  Gamma Knife      
68  Navelbine + Xeloda        4  Strontium        
69  Navelbine + Gemzar + Taxol      5  Sumarium      
70  Xeloda + Carbo + Abraxane + Lapatinib    6  Zometa (zoledronate)    
71  Navelbine + Lapatinib        7  RBC        
72  Xeloda + Mitoxantrone      8  Whole Brain XRT      
73  Xeloda+ Abraxane        9  Cyberknife      
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Table 38 (Continued)             
CODING SHEET (MBC STUDY)             
74  Navelbine + Gemzar        10  Erythropoietin, Procrit, Aranesp    
75  Xeloda + Carboplatinum      11  Neulasta, Neupogan    
76  Xeloda + Temodar + Lapatinib      12  Surgery        
77  5‐FU + Taxotere        13  Avastin vs. Placebo (Ribbon trials) 
78  Navelbine + Abraxane      14  Known Avastin       
79  Adriamycine + Xeloda + Taxotere    15  Denosumab vs. Placebo    
80  Navelbine + Doxil        16  Zometa vs. Placebo      
81  Xeloda + Temodar        17  Temodar         
82  Temodar + Lapatinib        18  Chlodronate vs placebo B‐34    
83  Cytoxan + Carboplatinum      19  AMG 479 study      
84  Navelbine + Temodar        20  Rituxan        
85  Xeloda + Lapatinib        21  Dasatinib vs. Placebo (UPCI # 08‐156) 
86  Navelbine + Xeloda + Lapatinib      22  Clodronate (UPCI # 06‐031)    
87  Navelbine + Xeloda + Doxil                
88  Navelbine + Xeloda + Taxotere + Carbo              
89  Cytoxan + Methotrexate                
90  Taxotere + Abraxane                  
91  Taxol + Sutent                  
92  Xeloda + Taxotere + Gemzar                
93  Ifex                    
94  Etoposide                    
95  Mitoxantrone+ lxempra + Ifex                
96  Mitoxantrone+ Ifex                  
97  Gemzar+ Lapatinib                  
98  ABT 888                    
99  Panobinostat                  
100  Doxil+ Abraxane                  
101  Cytoxan + Taxotere                  
102  5‐FU + Methotrexate                  
103  Xeloda + Sutent                  
104  Abraxane + Ixempra                  
105  Taxotere + Epirubicin + Melphalan              
106  Navelbine + Carboplatinum                
107  Gemzar+Adriamycin                  
108  Xeloda+ lxempra                  
109  Xeloda + Adriamycin                  
110  Doxil + Adriamycin                  
111  Gemzar + Xeloda + Lapatinib                
112  Iniparib (BSI‐201)                  
113  Carbo + Taxol + ABT 888                
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D.2 MBC STUDY CODING SHEET (CHEMO THERAPY) 
Table 39. Chemotherapy drugs classified by chemotherapy type 
ChemoWordIndex 
Word  Chemo Type 
Cyclopho
sphamid
e 
Platinum  5FU  Methotrexate 
Doxorubi
cin  Taxanes 
Gemcita
bine 
Vinorelbi
ne  Lapatinib
Epitholo
ne 
Mitoxant
rone  Sunitinib
Temozol
omide 
FolinicAc
id 
GrowthF
actor 
Irinoteca
n  Ispinesib
Unknow
n 
Cytoxan  1  X                                   
Carbo  2    X                                 
Carboplatinum  2    X                                 
Cisplatin  2    X                                 
Xeloda  3      X                               
Xeloda ==> deleted 
(same as 45) 
3      X                               
5‐FU   3      X                               
Methotrexate  4        X                             
Adriamycin  5          X                           
Doxil  5          X                           
Epirubicin  5          X                           
Adriamycine   5          X                           
Taxol  6            X                         
Taxotere  6            X                         
Abraxane  6            X                         
deleted (same as 30, 
Abraxane) 
6            X                         
Gemzar  7              X                       
Navelbine  8                X                     
Navalbene  8                X                     
Lapatinib (Tykerb)  9                  X                   
Lapatinib  9                  X                   
Epitholone  10                    X                 
Epitholone B  10                    X                 
Lxabepilone 
(lxempra) 
10                    X                 
Mitox  11                      X               
Mitoxantrone  11                      X               
Sutent  12                        X             
Temodar  13                          X           
Leukovorin  14                            X         
Veg F  15                              X       
Veg F.  15                              X       
CPT‐11  16                                X     
SB‐715992  17                                  X   
Lapatinib vs. Placebo 
and Xeloda 
                                     
Triapine                                       
Lapatinib vs. Placebo                                       
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D.3 MBC STUDY CODING SHEET (HORMONAL THERAPY) 
Table 40. Hormonal drugs classified by hormone type 
HormoneUniqueWords 
Word  GenericName HormoneType AromataseInhibitor SERM ERAntagonist GnRHAnalogue Progestin
Femera  letrozole  1 X         
Femara  letrozole  1 X         
Aromasin  eremestane  1 X         
Arimidex  anastrozole  1 X         
Arimadex  anastrozole  1 X         
Tamoxifen  tamoxifen  2   X       
Raloxifine  raloxifene  2   X       
Fareston  toremifene 
citrate 
2   X       
TAS‐108  TAS‐108  3     X     
Fulvestrant fulvestrant  3     X     
Faslodex  fulvestrant  3     X     
Zoladex  goserelin  4       X   
Lupron  leuprolide  4       X   
Megace  megestrol 
acetate 
5         X 
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D.4 MBC STUDY CODING SHEET (METASTATIC LOCATION) 
Table 41. Metastatic locations categorized into eight groups 
MetastaticSiteWordIndex 
Word  MetSiteType Brain Bone Lung Liver AdrenalGland SoftTissue Other LymphNode 
CSF  1  X               
Meningeal carcinomatosis  1  X               
Pituitary  1  X               
Brain  1  X               
CNS  1  X               
Leptomeningeal  1  X               
Leptomenigeal  1  X               
Dura  1  X               
Sternum  2    X             
Bone  2    X             
Scalp  2    X             
Bone marrow  2    X             
Orbital  2    X             
Pelvis  2    X             
Orbit  2    X             
Rib  2    X             
Thorax  3      X           
Lung  3      X           
Liver  4        X         
Adrenal gland  5          X       
Adrenal  5          X       
Neck  6            X     
Omentum  6            X     
Mediastinum  6            X     
Brachiplexy  6            X     
Brachial plexus  6            X     
Chest Wall  6            X     
Abd wall  6            X     
Abdominal  6            X     
Pleura  6            X     
Pleura Only  6            X     
Skin  6            X     
Pluera  6            X     
Peritoneum  6            X     
Sking  6            X     
Soft tissue  6            X     
Skeletal muscle  6            X     
Small bowel  7              X   
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Table 41 (Continued) 
MetastaticSiteWordIndex 
Word  MetSiteType Brain Bone Lung Liver AdrenalGland SoftTissue Other LymphNode 
Colon  7              X   
Malignant pericardial effusion 7              X   
Spleen  7              X   
Thymus  7              X   
Appendix  7              X   
Kidney  7              X   
Abdomen  7              X   
Endometrial  7              X   
Esophageal  7              X   
Fallopian tube  7              X   
Gall bladder  7              X   
Stomach  7              X   
Bladder  7              X   
Pericardium  7              X   
Bladder mucosa  7              X   
Gastric  7              X   
Pancreas  7              X   
Ovary  7              X   
Retinal  7              X   
Parotid  7              X   
Mesentary  7              X   
Uterus  7              X   
Renal  7              X   
Axillary  8                X 
Cervical  8                X 
Cervical node  8                X 
Axilla  8                X 
Cervical In  8                X 
Cervical L/N  8                X 
Meidastinal L/N  8                X 
Occipital L/N  8                X 
Thyroid  8                X 
Suprahilar  8                X 
Sq nodes  8                X 
Shoulder nodes  8                X 
SC nodes  8                X 
Retroperitoneum  8                X 
Retroperitoneal  8                X 
retroperital  8                X 
Prevascular  8                X 
Peritoneal L/N  8                X 
Peritoneal  8                X 
Pericardial/Periaortic nodes  8                X 
Mediatinal L/N  8                X 
Omental nodes  8                X 
Groin  8                X 
Mesenteric nodes  8                X 
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Table 41 (Continued) 
MetastaticSiteWordIndex 
Word  MetSiteType Brain Bone Lung Liver AdrenalGland SoftTissue Other LymphNode 
Mesenteric  8                X 
Medistinal L/N  8                X 
Mediastinal nodes  8                X 
Mediastinal node  8                X 
Mediastinal L/N  8                X 
Mediastinal  8                X 
Inguinal node  8                X 
Iliac L/N  8                X 
Hilar nodes  8                X 
Hilar L/N  8                X 
Hilar  8                X 
Groin Nodes  8                X 
Periaortic  8                X 
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D.5 PROTOCOL FOR MEDICAL ABSTRACTION PROCEDURE FOR 
SECONDAY REVIEW 
Table 42. Treatment delay variable abstraction from medical records 
Predictor Variable Variables Record Others 
DOM Date of metastatic 
breast cancer 
*Date of CT scan or biopsy, when metastatic breast 
cancer was diagnosed. 
*If more than two different sites have different dates of 
metastasis, choose earlier date for DOM. If the earliest 
date and month of multiple metastases is not available, 
then choose the second earlier date of metastasis for 
DOM. 
*If the exact date for a certain month is not for sure, 
choose the first day for a date of DOM (ex., June 1). 
*When date of CT or biopsy for metastases was prior to 
date of initial breast cancer diagnosis, choose date of 
initial breast cancer diagnosis (Rationale: DOM prior to 
date of initial cancer diagnosis does not make sense). 
*If there were no medical records to verify DOM (month 
& date), follow the abstraction sheet. 
Treatment delay 
DOFT Date of first 
treatment 
*Date of first treatment including treatment type 2 
through 19 
*Missing of DOFT (i.e., patients did not have treatment 
until death or study end point) is coded as -1. 
*If the exact date for a certain month is not for sure, 
choose the first day for a date of DOM (ex., June 1). 
*If the exact date for DOFT is not for sure, assuming that 
the date is surely not the first day but around certain dates 
(ex., June 20~ July 7), choose the first date of the next 
month (ex., July 1) (Rationale: Choose the late month 
with the first day). 
*If there was no medical records to verify DOFT (month 
& date), follow the abstraction sheet. 
Treatment 
Delay 
Treatment delay *Treatment delay = Obs day 
Missing 
Day 
Missing interval 
between DOM and 
DOFT 
*Tx1wait_loss to_fu was coded as 1. 
*Tx_ was coded as -1. 
*If there is no information on the chart, follow the 
information on the abstraction sheet. 
 
Obs Day Observation interval 
between DOM and 
DOFT 
*Tx_ was coded as 1. 
*If there is no information on the chart, follow the 
information on the abstraction sheet. 
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Table 43. Metastatic location variable abstraction from medical records 
Covariates Variables Coding and Record Others 
Metastatic 
sites 
MetSite >1  *Number of 
metastatic sites at 
metastatic breast 
cancer diagnosis 
1 Brain 
2 Bone 
3 Lung 
4 Liver 
5 Adrenal gland 
6 Soft tissue 
7 Other 
Metastatic 
location 
MetLoc 
8 Lymph node 
*Location of 
metastasis at 
metastatic breast 
cancer diagnosis 
*MetSite,MetLoc 
within one month 
of metastasis 
diagnosis is 
included. 
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Table 44. Independent variables abstraction from medical records 
Covariates Variables Coding and Record Others 
 0 No 
 1 Yes 
Marital status Marital Status 
-1 Unknown 
*Current marital status 
(Information within a week 
before and after the date of 
metastasis could be used) at 
metastatic breast cancer 
diagnosis (0 includes single, 
divorced, widow etc.) 
* Data based on New patient 
assessment form (Yellow sheet, 
1.3) or progress note 
* Nurse in clinic will give the 
information for missing data of 
marital status. 
 1 Private 
 2 Medicare 
 3 Medicaid 
 4 No insurance 
Insurance 
-1 Unknown 
*Data based on insurance 
record or progress note 
*Multiple insurances (e.g., 
1+2) are possible. Patients who 
were aged 65 and over will be 
coded as 2. 
 1 < High school 
 2 High school 
 3 > High school 
Education 
-1 Unknown 
Data based on New patient 
assessment form (Yellow sheet, 
6.7) 
SES 
Zip Code Zip code  *-1: Unknown 
*To link income data with 
census block group 
*Data based on New patient 
assessment form (Yellow 
sheet) or insurance record 
*Information within a week 
before and after the date of 
metastasis could be used 
BMI Stage I and BMI Stage II                                                                   -1:Unknown 
Stage I Height Height (meters)  
Stage I Weight Weight(kilograms)  
BMI Stage I 
:BMI at diagnosis 
of breast cancer Stage I BMI Weight/Height2  
*Use NHLBI(NIH) calculator 
*Data based on out patient flow 
sheet 
*Data before, after 1 month of 
diagnosis could be used. 
Stage II Height Height (meters)  
Stage II Weight Weight(kilograms)  
BMI Stage II 
:BMI at diagnosis 
of metastatic breast 
cancer 
Stage II BMI Weight/Height2  
*Use NHLBI(NIH) calculator 
*Data based on out patient flow 
sheet 
*Data before, after 1 month of 
metastasis could be used. 
Weight change 
between stage I 
and  stage II 
Weight Change Weight (stage I) – 
Weight (stage II) 
 Blank: Unknown, and when 
MoMet is 0 
 0 No 
 1 Yes 
Menopausal state Menopause 
-1 Unknown 
*Post menopause includes an 
artificial menopausal status 
(ex., total, radical 
hysterectomy). 
*When patients underwent 
Lupron, their menstrual status 
is at pre menopausal status. 
*Data based on Yellow sheet 
(2.2) or progress note or 
information from Dr. Peg for 
missing data 
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Table 44 (Continued) 
Covariates Variables Coding and Record Others 
Charlson_Index Score 0-31 
  
 
Charlson_ 
Descriptive 
Charlson_ 
Comorbidity lists  
 
*Data based on Yellow sheet 
(2.1, 2.5, 3), progress note, and 
correspondence with laboratory 
results 
*Use access file to calculate 
Charlson’s score adjusted for 
age. 
*Age-adjusted score are used 
(aim1, and aim2). 
*Do not enter “metastatic solid 
tumor” weighted as 6. 
 0 No 
 1 Yes 
Hypertension 
-1 Unknown 
Data based on  
Yellow sheet (2.1, 3), 
MedicationReconciliationForm 
(Red sheet); 
OutpatientFlowSheet; progress 
note, and correspondence 
AbstractionDate Date for Assessing comorbid conditions. -1: Unknown 
Comorbidity 
FirstvisitDate Date when the patient first visited at 
Magee corresponding to the date written in 
Yellow sheet. 
-1: Unknown 
Noofvisitfor7mo Frequency of patient-visits during 7 
months (before 6 months and after 1 
month of metastasis) if patient visited 
before the metastasis. 
-1: patient came on the same 
month when she was 
diagnosed with the 
metastasis or patient came 
after the metastasis or 
unknown. 
 
NoofComorbidity The number of comorbid conditions 
listed in Yellow sheet (2.1) 
-1: patient did not have 
Yellow sheet. 
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Table 45. Weighted index of Charlson comorbid conditions 
Assigned weights for diseases Conditions 
Myocardial infarct 
Congestive heart failure 
Peripheral vascular disease 
Cerebrovascular disease 
Dementia 
Chronic pulmonary disease 
Connective tissue disease 
Ulcer disease  
Mild liver disease 
1 
Diabetes 
Hemiplegia 
Moderate or severe renal disease 
Diabetes with end organ damage 
Any tumor 
Leukemia 
2 
Lymphoma 
3 Moderate or severe liver disease 
Metastatic solid tumor 6 
AIDS 
Î  See Appendix of Charlson M.E. et al, 198758 and Deyo R.A. et al, 1992105. 
Î Follow the Charlson’s index-criteria58 if there is a discrepancy between Charlson’s 
and Deyo’s criteria. 
  175
 
Specific criteria for selective charlson comorbid conditions 
 
Î Myocardial infarction does not include patients with coronary artery disease (CAD) without 
myocardial infarction (ICD-9-CM: 429.89). 
 
Î Congestive heart failure includes patients with medication. It dose not include more severe 
cases: patients who are on medication, but have had no symptomatic response and no evidence of 
improvement of physical signs. 58 These cases are not supposed to be cared in hospital because of 
illness-severity. Thus, all patients with medication for congestive heart failure in hospital are 
considered as having congestive heart failure scored 1.  
 
Î Dementia includes Alzheimer’s disease (ICD-9-CM: 294.1) even if Alzheimer’s disease was 
not counted as the Charlson comorbidity index components in Deyo R.A. et al, 1992. 
  
Î Chronic pulmonary disease includes mild, moderate, severe pulmonary disease: Bronchitis, 
Emphysema, Asthma, Bronchiectasis, Extrinsic allergic alveolitis, Chronic airway obstruction not 
elsewhere classified, Pneumoconioses, and Chronic respiratory condition due to fumes and vapors. 
Pulmonary embolism (ICD-9-CM: 415.1) and pulmonary hypertension (ICD-9-CM: 416.8) will 
not be included in Charlson_Index and Charlson_Descriptive variables. 
 
Î Connective tissue disease indicates rheumatologic disease. Among rheumatologic diseases, 
moderate to severe rheumatoid arthritis are coded when the patients got treatment of rheumatoid 
arthritis with the corresponding ICD-9-CM codes according to Deyo et al. 105 
 
Î Mild liver disease includes chronic hepatitis: 
Hepatitis exposure history in the yellow sheet (2.5) will be considered as chronic hepatitis if there 
is no further information such as hepatitis-antibody and antigen results regardless of their liver 
function tests and regardless of the date written on Yellow sheet. Few patients (less than 10% of 
patients with chronic hepatitis) get the antibody after chronic hepatitis, which are regarded to be 
cured. 
 
Î Diabetes with end organ damage (score 2) includes only severe diabetes. Moderate and mild 
diabetes are scored as 1 with patients having previous hospitalizations for ketoacidosis, 
hyperosmolar coma, or control and those with juvenile onset or brittle diabetics (moderate 
diabetes), and all other diabetes treated with insulin or oral hypoglycemia (mild diabetes), but not 
diet alone. 
 
Î Moderate or severe renal disease includes patients on dialysis, those who had a transplant, 
those with uremia (severe renal disease), and patients with serum creatinines of >3 mg% 
(moderate renal disease). Mild renal disease with serum creatinines of 2-3 mg% will not be 
included in Charlson_Index and Charlson_Descriptive variables even if Deyo R.A. et al counted 
the mild renal disease as the Charlson comorbidity index components. 
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D.6 REPRODUCIBILITY STUDY OF CHARTS ABSTRACTION 
PROCEDURE WITH CHARLSON COMORBIDITY AND HYPERTENSION 
Overview
1. Select a random sample of n=23 charts previously abstracted 
by Su.
2. Select a random sample of n=23 charts previously abstracted 
by medical resident.
3. Re‐abstract n=46 charts for the data elements comprising 
comorbidity index at the time of breast cancer metastasis. 
4. Arrange entry of results from both the initial and repeat 
chart abstractions into an electronic database.
5. Analyze for each data element of comorbidity index, with 
standard measures of inter / intra‐observer reliability.
 
Figure 29. Overview for the process of inter or intra observer reliability study 
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Data Arrangement
• 1st stage
• 2nd stage: combined original data with new data 
by using SAS 
666 (271 alive, 
395 deceased)
85 alive charts 
previously 
abstracted by 
medical resident
55 alive charts 
previously 
abstracted by Su
23 random samples 
from 85 charts for 
re-abstraction
23 random samples 
from 55 charts for 
re-abstraction
Original data New data
Resident23
Su23
 
Figure 30. Data arrangement of original and new data 
 
Inter‐Observer (Between‐Observer) Reliability:
Charlson_Index
• Weighted Kappa 
Coefficient: 0.8767
• P <.0001 with two 
sided test
• Discrepancy 
due to mild liver 
disease (ex., 
chronic hepatitis)
Frequency Charlson_Index_II (Repeated)
0 1 2 4 5 7 Total
Charlson_Index_I(O
riginal)
0 16 0 0 0 1 0 17
1 0 1 0 0 0 0 1
2 0 0 1 0 0 0 1
4 0 0 0 2 0 0 2
5 0 0 0 0 1 0 1
7 0 0 0 0 0 1 1
Total 16 1 1 2 2 1 23
 
Figure 31. Inter observer reliability study with Charlson index variable 
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Table: Weighted index of comorbidity
Assigned 
weighted for 
diseases
Conditions
1 Myocardial infact 1
Congestive heart failure 2
Peripheral vascular disease 3
Cerebro‐vascular disease 4
Dementia 5
Chronic pulmonary disease 6
Connective tissue disease 7
Ulcer disease 8
Mild liver disease 9
Diabetes 10
2 Hemiplegia 11
Moderate or severe renal disease 12
Diabetes with end organ damage 13
Any tumor 14
Leukemia 15
Lymphoma 16
3 Moderate or severe liver disease 17
6 Metastatic solid tumor 18
AIDS 19
Charlson_Descriptive Frequency
Codes for 
conditions
Original Repeated 
0 (no co‐
morbidity)
17 16
1 1 1
2 1 1
7 1 1
9 1 2
10 1 1
12 1 1
14 3 3
Total 26 26
Inter‐Observer (Between‐
Observer) Reliability :
Charlson_Descriptive
 
Figure 32. Inter observer reliability study with Charlson descriptive variable 
 
Inter‐Observer (Between‐Observer) Reliability:
Hypertension
• Kappa 
Coefficient: 
0.9263
• P <.0001 with two 
sided test
Frequency Hypertension_II (Repeated)
‐1 0 1 Total
Hypertension_I
(original)
‐1 2 0 0 2
0 0 11 0 11
1 1 0 9 10
Total 3 11 9 23
 
Figure 33. Inter observer reliability study with hypertension variable 
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Intra‐Observer (Within‐Observer) Reliability:
Charlson_Index
• Weighted Kappa 
Coefficient: 0.8832
• P <.0001 with two 
sided test
• Discrepancy 
due to Tumor (ex., 
skin cancer)
Frequency Charlson_Index_II (Repeated)
0 1 2 3 4 5 Total
Charlson_Index_I(O
riginal)
0 17 0 0 0 0 0 17
1 0 1 0 0 0 0 1
2 0 0 2 0 0 0 2
3 1 0 0 0 0 0 1
4 0 0 0 0 1 0 1
5 0 0 0 0 0 1 1
Total 18 1 2 0 1 1 23
 
Figure 34. Intra observer reliability study with Charlson index variable 
 
Intra‐Observer (Within‐
Observer) Reliability : 
Charlson_Descriptive
Table: Weighted index of comorbidity
Assigned 
weighted 
for diseases
Conditions
1 Myocardial infact 1
Congestive heart failure 2
Peripheral vascular disease 3
Cerebro‐vascular disease 4
Dementia 5
Chronic pulmonary disease 6
Connective tissue disease 7
Ulcer disease 8
Mild liver disease 9
Diabetes 10
2 Hemiplegia 11
Moderate or severe renal disease 12
Diabetes with end organ damage 13
Any tumor 14
Leukemia 15
Lymphoma 16
3 Moderate or severe liver disease 17
6 Metastatic solid tumor 18
AIDS 19
Charlson_Descriptive Frequency
Codes for 
conditions
Original Repeated
0 (no co‐
morbidity)
17 18
1 1 1
5 1 1
6 2 2
9 1 1
14 1 0
Total 23 23
 
Figure 35. Intra observer reliability study with Charlson descriptive variable 
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Intra‐Observer (Within‐Observer) Reliability:
Hypertension
• Kappa 
Coefficient: 
1.0000
• P <.0001 with 
two sided test
Frequency Hypertension_II (Repeated)
‐1 0 1 Total
Hypertension_I
(original)
‐1 2 0 0 2
0 0 15 0 15
1 0 0 6 6
Total 2 15 6 23
 
Figure 36. Intra observer reliability study with hypertension variable 
Inter and Intra‐Observer Reliability
of Charlson_Index and Hypertension
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Figure 37. Graph for kappa coefficients of inter and intra observer reliability study for 
Charlson index, and hypertension 
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D.7 MISSING DATA 
Table 46. Report of missing data 
Missing data report
Chart not available 
N=114
Chart available
N=557
N % N %
Abstracted by Su Yon Jung
Marital status 114 100% 223 40%
Insurance 114 100% 245 44%
Education 114 100% 71 13%
Zip code 114 100% 196 35%
BMI breast cancer diagnosis 114 100% 293 53%
Entry BMI 114 100% 114 20%
Weight change 114 100% 358 64%
Menopause 114 100% 59 11%
Charlson Index 114 100% 6 1%
Hypertension 114 100% 28 5%
Abstracted by study nurses
Number of metastatic sites 7 6% 0 0%
Metastatic locations 7 6% 0 0%
Age 0     0% 0 0%
Race 0      0% 0 0%
ER 5   4% 4  1% 
HER2 20 18% 41 7%
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Table 47. Assessment of relationship between missing and other missing variables; between missing and complete variables 
Missing variables  Complete Variables 
  Marital 
Status 
Insurance  Education  Zip 
code 
StageI 
BMI 
StageII 
BMI 
Weight‐ 
change 
Meno‐ 
pause 
Charlson_Ind
ex 
Hyper‐ 
tension 
HER2  ER  Metsite  Metlo
c 
Age  Race 
Operating‐ system  SPSS  SAS  SAS  SPSS  SPSS  SPSS  SPSS  SAS  SPSS  SAS  SAS  SAS  SPSS  SAS  SPSS  SAS 
Marital 
status 
N/A  P=<.00  P=<.00  P=.83  P=.46  P=.03  P=.40  P=<.00  P=.66  P=<.00  P=.01  P=.01  P=.48  P=.17  P=.26  P=.85 
Insurance  N/A  N/A  P=<.00  P=.03  P=.12  P=.23  P=.10  P=<.00  P=.00  P=<.00  P=.15  P=.02  P=.16  P=.30  P=.00  P=.94 
Education  N/A  N/A  N/A  P=.00  P=.11  P=.97  P=.73  P=<.00  P=.01  P=<.00  P=<.00  P=.03  P=.16  P=.03  P=.09  P=.05 
Obs values of Gths vs. Obs values of complete variables (Age, Black)  P=<.00  Black: 
P=.75 
P=.89* 
P=.10** 
P=.38* 
P=.06** 
P=.91* 
P=.04** 
P=.58* 
P=N/A** 
Zipcode  N/A  N/A  N/A  N/A 
SAS, 
P=<.00 
SAS, 
P=<.00 
SAS, 
P=<.00 
SPSS, 
P=.99 
SAS, P=<.00 
SPSS, 
P=.00 
SPSS, 
P=.00 
P=.00  P=.065  P=.02  P=.01  P=.70 
P=.99* 
P=.52** 
P=.40* 
P=.98** 
P=.67* 
P=.84** 
P=.59* 
P=N/A** 
Income  P=.23  SPSS, 
P=.82 
SPSS, 
P=.99 
N/A 
SAS, 
P=<.00 
SAS, 
P=<.00 
SAS, 
P=<.00 
SPSS, 
P=.54 
SAS, 
P=<.00 
SPSS, 
P=.42 
P=<.00  P=.00  P=.07  P=.02  P=.01  P=.70 
Black: 
P=.61 
Obs values of Income vs. Obs values of complete variables (Age, Black)  P=.18  Black: 
P=<.00 
P=.60* 
P=.31** 
P=.79* 
P=.65** 
P=.15* 
P=N/A** 
StageIBMI  N/A  N/A  N/A  N/A  N/A 
SAS, 
P=<.00 
SAS, 
P=<.00 
SPSS, 
P=.21 
SAS, 
P=<.00 
SPSS, 
P=.25 
SPSS, 
P=.61 
P=.41  P=.43  P=.15  P=.90  P=.80 
P=.85* 
P=.70** 
P=.65* 
P=.78** 
StageIIBMI  N/A  N/A  N/A  N/A  N/A  N/A 
SAS, 
P=<.00 
SPSS, 
P=.32 
SAS, P=<.00 
SPSS, 
P=.19 
SPSS, 
P=.87 
P=.00  P=.19  P=.04  P=.00  P=.51 
Obs values of StageIIBMI vs. Obs values of complete variables (Age, Black)  P=.04  Black: 
P=.05 
P=.98* 
P=N/A** 
Weight 
change 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  SPSS, 
P=.73 
SAS, P=<.00 
SPSS, 
P=.42 
SPSS, 
P=.43 
P=.08  P=.57  P=.36  P=.48  P=.91 
Menopause  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  P=.00  P=<.00  P=.03  P=.00  P=.30  P=.01  P=.00  P=.74 
Obs values of Menopause vs. Obs values of complete variables (Age, Black)  P=<.00  Black: 
P=.26 
Charlson_ 
Index 
N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  SPSS, 
P=.66 
SPSS, 
P=.085 
P=<.00  P=.28  P=.01
5 
P=.00  P=.72 
Hypertension  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  P=.02  P=.00  P=.07  P=.12  P=.00  P=.35 
HER2  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  N/A  P=<.00  P=.16  P=.03  P=.00  P=.72 
* Relationship of Missing vs. Present of right variables in terms of Present of 1st row variables. 
** Relationship of Missing vs. Present of 1st row variables in terms of Present of right variables. 
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Table 48. Analytic methods for the relationship between missing and other missing variable, or 
between missing and complete variable using SAS and SPSS 
Variable 
Type I 
Missing 
Data I 
Case Operating 
System 
How to compare Missing 
Data II 
Variable 
Type II 
Complete 
variable 
Case 1 SAS, 
Chisq test 
Each 
categories 
Missing-
freq 
Present-
freq 
Missing 
variable 
Category 
Variables 
Missing 
variable 
Case 2 SAS, 
Chisq test 
Missing-
freq 
Present-
freq 
Missing-
freq 
Present-
freq 
Missing 
variable 
Category 
Variable 
        
Missing 
variable 
Case 1 SPSS, 
Ttest 
Missing 
Present 
means Complete 
variable 
Missing 
variable 
Case 2 SPSS, 
Ttest 
Missing 
Present 
Present- 
means 
Missing 
variable 
Category 
Variables 
Complete 
variable 
Case 3 SAS, 
Chisq test 
Each 
categories 
Missing 
-freq 
Present 
-freq 
Missing 
variable 
Continuous 
Variables 
        
Complete 
variable 
Case 1 SPSS, 
Ttest 
Means Missing 
Present 
Missing 
variable 
Present-
means 
Missing 
Present 
SPSS, 
Ttest 
Missing 
Present 
Present-
means 
Continuous 
Variables 
Missing 
variable 
Case 2 
SAS, 
Chisq test 
Missing-
freq 
Present-
freq 
Missing-
freq 
Present-
freq 
Missing 
variable 
Continuous 
Variables 
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Figure 38. Number of co-morbidities listed on “Yellow Sheet”, by Year of Entry 
Co‐morbidities
Charlson Index Missing, n 0, n 1‐2, n >=3, n Total
Missing, n 1 0 1 4 6
0, n 31 54 168 185 438
>=1 18 10 26 59 113
>=1, % 36 16 13 24 20
0, % 62 84 86 75 79
Total 50 64 195 248 557
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Figure 39. Charlson co-morbidity Index by number of co-morbidities on “Yellow-Sheet” 
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Missing 1 1 0 4 6
0 0 113 99 226 438
>=1 0 25 22 66 113
>=1, proportion 0 0.180 0.182 0.223 0.203
Total 1 139 121 296 557
 
Figure 40. Charlson co-morbidity Index according to abstraction date 
Proportion of Charlson_Index>=1
by Abstractiondate on the Alive
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Figure 41. Charlson co-morbidity Index according to abstraction date by status (=0, Alive) 
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Figure 42. Charlson co-morbidity Index according to abstraction date by status (=1, Deceased) 
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Figure 43. Follow-up time by Systemic Missing 
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